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Nitroxyl (HNO), a potential heart failure therapeutic, is known to post-
translationally modify cysteine residues.  Among reactive nitrogen oxide species, the 
modification of cysteine residues to sulfinamides [RS(O)NH2] is unique to HNO.  Because 
this modification can alter protein structure and function, we have examined the reactivity 
of sulfinamides in several systems, including small organic molecules, peptides, and a 
protein.  At physiological pH and temperature, relevant reactions of sulfinamides involve 
reduction to free thiols in the presence of excess thiol and hydrolysis to form sulfinic acids 
[RS(O)OH].  In addition to utilizing ESI-MS and other spectroscopic methods to 
investigate sulfinamide reduction, we have applied 15N-edited 1H-NMR techniques to 
sulfinamide detection and used this method to explore sulfinamide hydrolysis.   
Since HNO-derived modifications may depend on local environment, we have also 
investigated the reactivity of HNO with cysteine derivatives and C-terminal cysteine-
containing peptides.  Apart from the lack of sulfinamide formation, these studies have 
revealed the presence of new products, a sulfohydroxamic acid derivative [RS(O)2NHOH] 
and a thiosulfonate [RS(O)2SR], presumably produced under our experimental conditions 
via the intermediacy of a cyclic structure that is hydrolyzed to give a sulfenic acid (RSOH). 
Apart from its role in thiol oxidation, HNO has been reported to have nitrosative 
properties, for example with tryptophan resulting in N-nitrosotryptophan formation.  We 
have examined the reactivity of HNO with tryptophan and small peptides containing either 
tryptophan or both a tryptophan and a cysteine residue. 
iii 
 
HNO has been shown to enhance cardiac sarcoplasmic reticulum Ca2+ cycling 
independent of the -adrenergic pathway.  In a collaborative project, the effects of HNO 
on the cardiac proteins, phospholamban (PLN) and sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA2a) were investigated. 
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Chapter 1 – Introduction 
1.1 Nitroxyl (HNO) 
HNO is the protonated, one-electron reduced form of nitric oxide (NO).  Its 
nomenclature is often ambiguous and includes nitroxyl, nitrosyl hydride, hydrogen 
oxonitrate, and azanone.1, 2 
Recent discoveries of important pharmacological properties have drawn significant 
attention to the biochemistry of HNO.  Among these are the therapeutic potential of HNO 
in heart failure, chronic alcoholism, cancer, and as a preconditioning agent in the treatment 
of myocardial ischemia-reperfusion.3-5  Also recent reviews highlight the potential uses of 
HNO in the treatments of other cardiovascular conditions such as angina, atherosclerosis, 
and acute hypertensive crisis.3, 4  Moreover, studies indicate that the physiological 
properties of HNO are different from those of NO.4, 6-8 
Although HNO has been known since late 19th century, its pKa has been re-evaluated 
and determined with confidence only approximately a decade ago.9, 10  The electronic 
ground state of HNO is singlet, whereas that of the deprotonated form, NO-, is triplet.11-13  
Due to the spin forbidden nature of the protonation/deprotonation of NO-/HNO, the 
equilibrium is slow, complicating the process.12  Experimental and theoretical studies have 
shown the pKa (
1HNO/3NO-) to be ca. 11.4,9, 10 indicating that HNO is the predominant 
species under physiological conditions. 
Despite several proposed pathways, endogeneous production of HNO has yet to be 
determined.4-6  These potential pathways include the decomposition of S-nitrosothiols, 
oxidation of L-arginine by nitric oxide synthase (NOS) in the absence of cofactor, and 
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oxidation of N-hydroxy-L-arginine or hydroxylamine.14-23  Thus, the potential role of HNO 
in signaling is currently unknown.  However, as mentioned in recent reviews, the impact 
of HNO is considered to be potent, very selective.4, 6 
Another important feature of HNO is its rapid dimerization reaction                                    
(k = 8 x 106 M-1s-1).  In this process, one HNO molecule reacts as a nucleophile and another 
acts as an electrophile to produce hyponitrous acid, which then undergoes spontaneous 
dehydration to generate nitrous oxide (N2O) and water (Scheme 1-1).
1, 24, 25  Consequently, 
storage of HNO is not possible and it is normally generated in situ by the decomposition 
of donor compounds. 
 
 
Scheme 1-1.  Dimerization of HNO. 
 
The most common HNO donor is Angeli’s salt (Na2N2O3; AS),
26, 27 which has a 
half-life of approximately 2.4 min at physiological pH and temperature, and decomposes 
to produce HNO and nitrite (NO2
-) (Scheme 1-2).  Throughout this work, we have 
employed AS, as well as other HNO donors, including 2-bromo-N-hydroxy-
benzenesulfonamide (2-BrPA),28 N-hydroxy-2-(methylsulfonyl)benzenesulfonamide (2-







Scheme 1-2.  Decomposition of Angeli’s salt (AS). 
 
1.2 Effects of HNO on Ca2+ Cycling 
One of the unique pharmacological properties of HNO is its effects on the 
cardiovascular system.6, 30  Cardiac excitation-contraction (EC) coupling is described as 
the process of converting the electrical excitation of the myocyte into the contraction of the 
heart (Figure 1-1).31  The second messenger, Ca2+, plays a crucial role in this process.31  
Contraction is initiated by the entrance of a small amount of Ca2+ to the cardiomyocyte 
through L-type Ca2+ channels.31  Triggered by this Ca2+ entry, Ca2+ is released from the 
sarco(endo)plasmic reticulum (SR) to the cytosol via specialized Ca2+-gated channels, 
ryanodine receptors (RyR2).31  The increase in the free intracellular Ca2+ concentration 
allows the binding of Ca2+ to myofilament proteins, which switches on the contractile 
machinery.31  The dissociation of Ca2+ from the myofilament proteins and consequently 
relaxation is achieved by the removal of the cytosolic Ca2+.31  Approximately 70% of the 
cytosolic Ca2+ is transported into the SR by the sarco(endo)plasmic reticulum Ca2+-ATPase 
(SERCA2a).31  The activity of SERCA2a is regulated by a small protein, phospholamban 
(PLN).32  The inhibitory effect of PLN on SERCA2a can be relieved by phosphorylation 
of PLN via -adrenergic pathway, which involves the activation of cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase A (PKA) upon -adrenergic 
stimulation.32  Moreover, many components of the EC machinery have cysteine residues, 
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which can be modified by reactive nitrogen or oxygen species (RNS or ROS) and act as 
redox switches.6, 33 
 
Figure 1-1.  Excitation-contraction coupling.  Adapted from Kho, C.; Lee, A.; Hajjar, R. 
J. (2012) Altered sarcoplasmic reticulum calcium cycling – targets for heart failure therapy, 
Nat. Rev. Cardiol. 9, 717-733. 
 
Impaired contractility and slowed relaxation are commonly observed features of 
congestive heart failure.34, 35  The downregulation of -adrenergic system has also been 
reported.6, 36  Recent studies by Paolocci and coworkers have shown that HNO augments 
contractility and accelerates relaxation in both normal and failing hearts.4, 6-8  Their findings 
suggest that HNO improves myocyte Ca2+ cycling independent of the -adrenergic 
pathway.6, 37  Importantly, the observed effects are not reproduced by NO donors.6 
As shown in Figure 1-2, HNO has been shown to interact directly and modify 
several proteins in the system.  HNO-induced stimulation of skeletal and cardiac Ca2+-
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release channels (RyR1 and RyR2) has been reported in isolated rodent myocytes and in 
receptors reconstituted in lipid bilayers.37, 38  Also, in a collaborative project, we have 
shown that HNO modifies PLN and affects the activity of the Ca2+-ATPase in a PLN-
dependent manner (Chapter 6).  Although the physiological relevance has not been 
investigated, a direct modification of SERCA2a by HNO has also been reported.39 
Figure 1-2.  Effects of HNO cardiomyocyte Ca2+ cycling.  Tocchetti, C. G., Stanley, B. A., 
Murray, C. I., Sivakumaran, V., Donzelli, S., Mancardi, D., Pagliaro, P., Gao, W. D., van 
Eyk, J., Kass, D. A., Wink, D. A., and Paolocci, N. (2011) Playing with cardiac "redox 




The effects of HNO on cardiac contractility have also been demonstrated by recent 
investigations conducted with the contractile machinery.40  These studies have indicated 
that HNO increases myofilament Ca2+ responsiveness and consequently enhances force 
generation by modifying the cardiac myofilament proteins, actin and tropomyosin, to form 
a heterodimer.40  In all cases, the HNO-derived effects were found to be readily reversible 
with thiol reducing agents.40 
1.3 Reactivity of HNO 
 HNO is a reactive intermediate which undergoes various reactions with itself, 
thiols, nitrogen oxides, metals, oxygen, amines, and indoles.2, 5, 11, 27, 41-43  Although HNO 
can act both as an electrophile and a nucleophile, recent reviews highlight the electrophilic 
nature of HNO towards soft bases such as thiols and phosphines.27, 41, 44  Moreover, it is 
reported to be less reactive towards hard bases such as oxygen-containing nucleophiles.41  
A distinct feature of HNO from other nitrogen oxides is its high thiophilicity.41  The 
reaction of HNO with thiols results in the formation of an initial N-hydroxysulfenamide 
(RSNHOH) intermediate.  This unstable species further reacts with either excess thiol to 
form a disulfide or rearranges to form a sulfinamide (RS(O)NH2) (Scheme 1-3).
45, 46  The 
reactivity of HNO with C-terminal cysteines is discussed in Chapter 4. 
 
 
Scheme 1-3.  The reaction of HNO with thiols 
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Indeed, the majority of HNO-induced biological effects are attributed to the 
reactivity of HNO with thiols.6, 41  For example, studies suggest that the alcohol deterrent, 
cyanamide, interacts with the active site cysteine residues of aldehyde dehydrogenase via 
the intermediacy of HNO.47  Similarly, HNO has been shown to affect glycolysis via 
modification of the thiol residues of the glycolytic enzyme, GAPDH, potentially interfering 
with the major energy pathway for most solid tumors.5, 48-50  Consistent with these 
investigations, recent reports indicate the inhibition of cancer proliferation in breast cancer 
and neuroblastoma in mouse tissue and culture following HNO treatment.5, 51, 52 
The rate constants for the reaction of HNO with several biomolecules have been 
experimentally determined by competition studies (Table 1-1).53  These findings support 
that the major biological targets of HNO involve thiols, thiol-containing proteins, and 
metalloenzymes.53  The second-order rate constant for the reaction of HNO with 
glutathione was determined to be 8 x 106 M-1s-1.53  Moreover, some thiol-containing 
proteins such as the cysteine protease, papain, are estimated to have higher rate constants 
(kpapain = 2 x10
7 M-1s-1).54 
The selectivity of HNO towards certain protein thiols has also been observed in 
cellular systems.48, 54  Investigations have shown that HNO can specifically react with 
GAPDH without being trapped by cellular GSH in yeast.48  Similarly, intracellular GSH 
levels were found to be unchanged upon inhibition of aldehyde dehydrogenase by HNO 
(generated from cyanamide) in cultured hepatocytes.47, 48, 55, 56  Likewise, another cysteine 
protease, cathepsin B, is inhibited by HNO in macrophages containing cellular glutathione 
and endogeneously produced NO.  Although the exact mechanisms for the observed 
8 
 
selectivity are yet to be determined, these reports emphasize further the potency of HNO 
as a thiol-modifying agent.54  
 
Table 1-1.  Rate constants of HNO with biomolecules.53 
Biomolecule  k (M-1s-1) 
Ferricytochrome c 4  104 
Oxygen 3  103 
Cu/Zn Superoxide Dismutase 1  106 
Mn Superoxide Dismutase 7  105 
Glutathione 2  106 
N-Acetyl-L-Cysteine 5  105 
Catalase 3  105 
Metmyoglobin 8  105 
Oxymyoglobin 1  107 
Horseradish Peroxidase 2  106 
Tempol 8  104 
  
As mentioned above, HNO has also been shown to react with metalloporphyrins 
and metalloenzymes such as iron heme proteins.2, 41, 57, 58  Initial studies have revealed the 
quenching of HNO by both methemoglobin and metmyoglobin.45, 59  Recent findings 
indicate that HNO can react with either ferric or ferrous forms of the enzymes (Scheme 1-
4).2, 41  Farmer and coworkers have characterized an HNO adduct of myoglobin (Mb), 
formed by trapping of HNO by deoxy Mb or reduction of ferrous-NO complex.60  Later 
studies with isolated metalloporphyrins have suggested that the strong influence of protein 
environment on the stability of Mb-HNO adduct.2  Nevertheless, several metalloporphyrin 
nitrosyl complexes are obtained from the reaction of Fe(III), Co(III), or Mn(III) porphyrins 
9 
 
with HNO.2  Similar to NO, HNO is also known to react with dioxygen complexes of 
ferrous heme proteins (Scheme 1-4).41 
 
 
Scheme 1-4.  Reaction of HNO with (a) ferrous, (b) ferric, and (c) dioxygen complex of 
ferrous myoglobin (Mb).   
 
Studies indicate that although HNO and NO cannot be distinguished by iron 
porphyrins due to the reductive nitrosylation reaction, both Mn and Co porphyrins can be 
employed to differentiate between the two nitrogen oxides.2  Based on these findings, 
Co(III) and Mn(III) porphyrins react with HNO, but not with NO, whereas Co(II) and 
Mn(II) porphyrins react with only NO.2 
As shown in Table 1-1, HNO reacts with O2 to form a currently uncharacterized 
HNO-O2 adduct.
61, 62  Due to its spin forbidden nature, this reaction is slow                                
(k = 3 x103 M-1s-1).53  Unlike the analogous reaction of NO- with O2, which proceeds rapidly 
to form peroxynitrite (ONOO-), the HNO-O2 adduct has been suggested to be distinct from 
ONOO-.61, 62 
Recent reports also point to the nitrosation of indoles by HNO in the presence of 
oxygen.42, 63  Although the mechanistic details have yet to be confirmed, treatment of the 
indolic compounds, melatonin, N-acetyl-L-tryptophan, and indole-3-acetic acid, with HNO 
generated from AS under aerobic conditions results in the formation of N-nitrosoindoles.42  
Moreover, the product profiles obtained following exposure to HNO and ONOO- have been 
demonstrated to be different.42   
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The nitrosative properties of HNO, produced from AS, have also been observed 
following in vivo studies.42  Using reductive denitrosation to generate NO and a 
chemiluminescence method for NO detection, the amount of N-nitroso species have been 
determined in various tissues.42  These reports indicate that the quantity of N-nitroso 
species are significantly higher in the heart tissue upon treatment with AS.42  Experiments 
with the NO donor, DEA/NO, resulted in lower amounts of N-nitroso species in heart tissue 
compared with AS, although similar amounts were obtained in blood upon treatment with 
AS or DEA/NO.42  These findings also confirm that the biological chemistry of HNO and 
NO are different, and the environment may affect their nitrosative properties.42  
1.4 Introduction to This Work 
 As mentioned previously, thiols play a crucial role in HNO biology.  To better 
understand the impact of HNO in biological systems, the fundamental reactivity of HNO 
and HNO-derived modifications require further investigation.  Although disulfides are 
well-studied in the literature, there are very few reports on sulfinamides.  Since sulfinamide 
formation is one of the major HNO-induced modifications, we have explored the reactivity 
of HNO-derived sulfinamides in small organic molecules, peptides, and proteins.  The 
reduction of sulfinamides to free thiols at physiological pH and temperature is discussed in 
Chapter 2.   
Although mass spectrometry has been shown to be a valuable tool for the detection 
of sulfinamides,46, 64 alternate detection methods are also needed to investigate the 
reactivity of sulfinamides.  The application of 15N-edited 1H NMR techniques to 
sulfinamide detection and the study of hydrolysis of HNO-derived sulfinamides using this 
NMR method are discussed in Chapter 3. 
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Investigation of HNO-derived modifications has revealed the presence of different 
end-products following exposure of C-terminal cysteines to HNO.  The reactivity of C-
terminal cysteines with HNO and the intermediacy of a sulfenic acid is explained in 
Chapter 4. 
As mentioned in the previous section, recent reports point to the presence of an 
HNO-derived N-nitrosotryptophan formation.42, 63  The reactivity of HNO with tryptophan 
and small peptides containing either tryptophan or both a tryptophan and a cysteine residue 
is discussed in Chapter 5. 
To gain more insight into the impact of HNO on the cardiovascular system, the 
effects of HNO on phospholamban (PLN) and its interaction with the sarco(endo)plasmic 
reticulum Ca2+-ATPase (SERCA2a) have been explored in a collaborative project.  
Additionally, brief investigations involving the reactivity of other nitrogen oxides with 
PLN and SERCA2a have been carried out.  These studies are reported in Chapter 6. 
 Miscellaneous studies conducted to understand the reactivity of HNO, as well as 
other nitrogen oxides in various systems, and the reactivity of the corresponding 
modifications are described in Chapter 7.   
Lastly, in a collaborative project, we have assisted the investigation of the effects 
of post-training caffeine administration on memory consolidation.  This double-blind 
study, including a memory test and an HPLC assay to analyze the caffeine and paraxanthine 
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Chapter 2 – Reactivity of HNO-Derived 
Sulfinamides 
2.1 Introduction 
Thiol residues are prone to several post-translational modifications under oxidative 
conditions.  These include the formation of disulfide bonds, sulfinamides, and sulfenic, 
sulfinic and sulfonic acids.1, 2  Nitroxyl (HNO), the protonated one-electron reduced form 
of nitric oxide (NO), has been shown to be a potential therapeutic agent for heart       
failure.3, 4  Moreover, recent reviews highlight the potential uses of HNO in the treatments 
of alcoholism, vascular dysfunction, and cancer.5, 6  One of the most significant features of 
HNO is its reactivity towards thiols.7, 8  This reactivity can result in the formation of a 
disulfide or a sulfinamide depending on the concentration of thiol (Scheme 2-1).  In the 
presence of excess thiol, the end products are disulfide and hydroxylamine, whereas at low 
thiol concentration the product is sulfinamide. 
 
Scheme 2-1.  The reaction of HNO with thiols 
Previous studies have shown that protein cysteine residues are targets of HNO.9, 10  
HNO-induced disulfide and/or sulfinamide modifications are observed in papain,11 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),12, 13 cathepsin B,14 yeast 
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transcription factor Ace1,15 ryanodine receptors (RyR),16 N-methyl-D-aspartate (NMDA) 
receptor,17 bovine serum albumin (BSA),18 aldehyde dehydrogenase (AlDH)19 and 
phospholamban (PLB).20  Traditionally, disulfide formation is considered to be reversible, 
whereas sulfinamide modification has been considered to be irreversible in peptides and 
proteins.8, 9, 11-15, 19, 20  To date, there have been no reports of sulfinamide reduction under 
physiologically relevant conditions. Also, recent studies with t-butanesulfinamide indicate 
that it is unreactive towards dithiothreitol (DTT).20  Moreover, we are aware of only one 
example of the reduction of a sulfinic acid in a biological system, which occurs by an ATP-
dependent process.21-23  
Although not investigated thoroughly, the possible reduction of sulfinamides by 
thiols has been suggested by some recent studies.  For example, free thiols have recently 
been observed upon treatment of peptide sulfinamides with DTT at elevated 
temperatures.24  Similarly, the reaction of N-phenylbenzenesulfinamide and thiophenol in 
ethanol produces aniline and diphenyl disulfide, via a direct thiolysis mechanism involving 
the initial protonation of the sulfinyl group followed by a series of nucleophilic 
displacement reactions, the first of which gives thiosulfinate and elimination of the amine 






Scheme 2-2.  Direct thiolysis mechanism of N-phenylbenzenesulfinamide  
A well-known process affecting proteins at physiological pH and temperature is the 
succinimide-mediated deamidation reaction.  In this non-enzymatic reaction, the side chain 
amide linkage in an asparagine residue is hydrolyzed to form a carboxylic acid.27-29  The 
mechanism is thought to involve an intramolecular cyclization in which the α-amino group 
of the carboxyl-side amino acid residue attacks the side chain carbonyl carbon of an 
asparaginyl residue forming a succinimide intermediate.27-29  This cyclic intermediate is 
then hydrolyzed to give the carboxylic acid, either in the L-normal or L-iso peptide 
(Scheme 2-3).  Consistent with the involvement of the cyclic succinimide intermediate, 
significant substituent effects on the C-terminal side of the asparagine residue have been 
observed.27  In addition, the effect of solvent dielectric constant on this reaction has been 
examined and indicates that the rate of deamidation is significantly reduced in solvents of 






Scheme 2-3.  Succinimide-mediated deamidation mechanism 
 
A sulfinamide (RS(O)NH2) to sulfinic acid (RS(O)OH) conversion has recently 
been proposed to occur via a mechanism analogous to the succinimide-mediated 
deamidation reaction, mainly under gel electrophoresis conditions.24  The mechanism 
involves the formation of a five-membered succinimide-like intermediate 1 (Scheme 2-4) 
with subsequent hydrolysis to yield the corresponding sulfinic acid-containing peptide.  
Considering the greater nucleophilicity of thiols over water, we hypothesized that the 
reduction of sulfinamides might be facilitated in peptides via a similar mechanism.  To test 
this hypothesis, we have studied the reactivity of sulfinamides in a small organic molecule, 
peptides, and a protein.  In addition, we have also examined the impact of solvent dielectric 




Scheme 2-4.  Mechanism of sulfinamide reduction via a cyclic intermediate 
 
2.2 Results  
2.2.1 Formation of Peptide Sulfinamides by Reaction with HNO  
We initially investigated the reaction of HNO with the cysteine-containing peptides 
VYPCGA and VYPCLA to determine the product distribution and to optimize conditions 
for sulfinamide formation.  Both sulfinamide and disulfide modifications are observed 
upon treatment with HNO, as has been reported in the literature.7, 8  At the concentrations 
employed, ESI-MS was responsive to the relative concentration of the sulfinamide.  As the 
ratio of HNO-donor to peptide was increased, we observe an increase in the relative amount 
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of sulfinamide along with a corresponding decrease in observed thiol (Figure 2-1a, c).  As 
expected, higher yields of disulfide are observed at lower HNO-donor to peptide ratios 
(Figure 2-1b, d).  For 0.1 mM peptide, sulfinamide formation was most efficient with        
0.3 - 1 mM AS.  A similar trend is observed upon incubation of GSH with an HNO-donor 
in ammonium bicarbonate buffer, also consistent with previous HPLC studies.31  (Due to 
the low molecular weight of GSH, desalting was inefficient and experiments were 
conducted in ammonium bicarbonate, an MS-compatible buffer.)  The higher sulfinamide 
yield observed with VYPCLA (97%) versus VYPCGA (66%) is presumably due to the 
presence of the adjacent Leu residue, which inhibits the formation of peptide disulfide due 




Figure 2-1.  Formation of peptide-derived sulfinamides and disulfides in phosphate buffer.  
The ratios of sulfinamide, disulfide, and thiol ion abundance to total ion count were 
analyzed for (a, b) VYPCGA (0.1 mM) and (c, d) VYPCLA (0.1 mM) following incubation 
with 0-1000 M AS in 10 mM phosphate buffer with 50 M DTPA (pH 7.4) at 37 °C for 
30 minutes (SEM ±5%, n≥3). 
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2.2.2 Sulfinamide Reduction 
To determine the extent of sulfinamide reduction back to the free thiol at 
physiological pH and temperature, the VYPCGA-derived sulfinamide (CG-S(O)NH2) was 
incubated with 50 mM DTT in phosphate buffer for a total of 26 h and aliquots were 
analyzed after 0, 1, 6 and 26 h.  As observed by ESI-MS (Figure 2-2a), the ratio of CG-
S(O)NH2 to the corresponding thiol-containing peptide (VYPCGA, CG-SH) decreases 
significantly after 26 h incubation.  Note that the disulfide-modified peptide, which can be 
observed in the absence of reducing agents, was not detected in the initial sample due its 
immediate reduction by DTT.  Thus, we attribute the increase in free thiol observed 
following incubation to reduction of the sulfinamide.  As can be seen in Figure 2-2a, no 
other significant changes are observed in the ESI-MS data.  After 1, 6 and 26 h incubation 
at 37 °C, 7, 30, 69% sulfinamide reduction was observed, respectively, with a 
corresponding increase in thiol (18, 34 and 66%, respectively).  As shown in Table 2-1, the 
ESI-MS-derived increase in thiol agrees very well with that determined by a standard 
DTNB assay.35  Upon 64 h incubation at 37 °C, the sulfinamide reduction was found to be 
86%.  In the absence of DTT, no increase in free thiol was observed upon incubation of 





Figure 2-2.  Reduction of the VYPCGA-derived sulfinamide (CG-S(O)NH2).  VYPCGA 
(0.1 mM) was treated with 0.3 mM AS to produce the corresponding sulfinamide.  The 
sample was incubated in phosphate buffer at 37 °C in the presence of 50 mM DTT.  (a) 
Representative ESI-MS spectra showing the reduction of CG-S(O)NH2 to the free thiol 
(CG-SH).  No disulfide was observed in the initial sample due to its immediate reduction 
by DTT.  (b) The ratios of CG-S(O)NH2 (◊) and CG-SH () ion abundance to total ion 
count observed by ESI-MS during the reduction of CG-S(O)NH2 in the presence of 50 mM 
DTT (SEM ±5%, n≥3). 
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Table 2-1.  Percent Increase in VYPCGA Free Thiol Upon DTT Treatment of VYPCGA-
derived Sulfinamide 
 
Time (h)a ESI-MSb DTNBc 
1 18 22 
6 34 36 
26 66 64 
 
aIncubation time in phosphate buffer at 37 °C in the presence of 50 mM DTT.   
bThe ratio of free thiol (CG-SH) ion abundance to total ion count was measured for each 
incubation time.  The percent increase reported was determined by normalization with 
respect to the initial (t = 0) sample (SEM ±5%, n≥3).   
cThe percent increase reported was determined by a standard DTNB assay normalized with 
respect to the initial (t = 0) sample (SEM ±5%, n≥3).   
 
Similar results were obtained with 50 mM BME, indicating that the reduction is not 
specific to DTT and should take place in the presence of thiol-based reducing agents in 
general (Figure 2-3 and Supporting Information).  Also, upon increasing BME 








Figure 2-3.  Reduction of the VYPCGA-derived sulfinamide (CG-S(O)NH2) in the 
presence of various reducing agents.  VYPCGA (0.1 mM) was treated with 1 mM AS to 
form the corresponding sulfinamide.  The samples were incubated with 50 mM DTT (), 
50 mM BME (☐), or 320 mM BME () in phosphate buffer at 37 °C.  The ratio of CG-
S(O)NH2 ion abundance to total ion count was determined for each incubation time.  The 
percent CG-S(O)NH2 was determined by normalizing the ion abundance ratios with respect 
to that detected in the initial peptide sample (SEM ±5%, n≥3). 
 
The rate of the protein deamidation reaction is known to be dependent on the nature 
of the amino acid located at the C-terminal side of the Asn residue.  To determine if a 
similar effect is observed in the reduction of peptide sulfinamides, we utilized the 
VYPCLA-derived sulfinamide (CL-S(O)NH2), which contains an adjacent Leu rather than 
Gly.  Again, as observed by ESI-MS (Figure 2-4), a significant amount of CL-S(O)NH2 
was reduced to the corresponding thiol-containing peptide (VYPCLA, CL-SH) in the 
presence of DTT.  Compared with CG-S(O)NH2, a small decrease in the extent of reduction 
upon 26 h incubation with DTT in phosphate buffer was observed (Figure 2-5).  CG-
S(O)NH2 and CL-S(O)NH2 were reduced by approximately 70 and 60% after 26 h, 
respectively, suggesting that sulfinamide reduction is not as sensitive to peptide sequence 
as the deamidation reaction.  The reactivities of VYPCGA-derived and GSH-derived 
sulfinamides were found to be comparable in ammonium bicarbonate buffer (Figure 2-5).  
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The difference in CG-S(O)NH2 reduction observed in phosphate (70%) versus bicarbonate 




Figure 2-4.  Representative ESI-MS spectra showing the reduction of VYPCLA-derived 
sulfinamide (CL-S(O)NH2) to the free thiol (CL-SH).  VYPCLA (0.1 mM) was treated 
with 0.3 mM AS to form the corresponding sulfinamide.  The sample was incubated in 
phosphate buffer at 37 °C in the presence of 50 mM DTT for 26 h.  No disulfide was 




Figure 2-5.  Reduction of the VYPCGA-derived (CG-S(O)NH2), VYPCLA-derived (CL-
S(O)NH2), and glutathione-derived (GS(O)NH2) sulfinamides in phosphate or bicarbonate 
buffer.  The samples were incubated with 50 mM DTT in sodium phosphate or ammonium 
bicarbonate buffer (as indicated) at 37 °C for 26 h.  The ratio of sulfinamide ion abundance 
to total ion count was determined in each case.  The percent sulfinamide was determined 
by normalizing the ion abundance ratios with respect to that detected in each initial peptide 
sample (SEM ±5%, n≥3). 
 
2.2.3 Sulfinamide Reduction in Peptides versus a Small Organic 
Molecule as a Function of Solvent Dielectric Constant  
To test the hypothesis that sulfinamide reduction is facilitated in the peptides, we 
conducted experiments with a small organic molecule, which cannot form a “succinimide-
like” intermediate 1 (Scheme 2-4).  For this purpose, we employed 2-
phenylethanesulfinamide (PE-S(O)NH2) and compared its reactivity to that of sulfinamides 
generated by HNO in the VYPCGA and VYPCLA peptides (CG-S(O)NH2 and CL-
S(O)NH2, respectively).  Also, to probe the reactivity of sulfinamides in hydrophobic 
environments, we examined the effect of solvent dielectric on these reductions in buffer, 
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ACN/buffer 50:50 (v/v), and dioxane/buffer 50:50 (v/v), which have dielectric constants 
of approximately 74, 55, and 34, respectively.30, 37, 38  
As shown in Figure 2-6a, DTT reduction of PE-S(O)NH2 is much more facile in 
buffer versus either ACN/buffer or dioxane/buffer, demonstrating that the direct thiolysis 
reaction rate is substantially inhibited in lower dielectric environments.  Relative to this 
PE-S(O)NH2 result, the reduction of both CG-S(O)NH2 and CL-S(O)NH2 is more efficient 
in ACN/buffer and dioxane/buffer (Figure 2-6b-c).  A similar behavior was also observed 
when the experiments were conducted at 55 oC in ACN/buffer (Supporting Information).  
These results indicate that the reduction of peptide sulfinamides involves a second 
mechanism, implicating the proposed cyclic intermediate 1 (Scheme 2-4) in addition to the 
direct thiolysis reaction.  Moreover, in dioxane/buffer, it appears that the reduction of CG-
S(O)NH2 is more efficient than that of CL-S(O)NH2.  This result suggests a substituent 
effect (Gly versus Leu) on this reaction that becomes more apparent in dioxane/buffer and 
may be further indication of the participation of a cyclic intermediate as has been observed 







Figure 2-6.  Reduction of (a) 2-phenylethanesulfinamide (PE-S(O)NH2), (b) the 
VYPCGA-derived sulfinamide (CG-S(O)NH2), and (c) the VYPCLA-derived sulfinamide 
(CL-S(O)NH2) as a function of solvent dielectric constant.  The samples were incubated 
with 50 mM DTT in buffer, ACN/buffer or dioxane/buffer at 37 °C for 26 h.  The relative 
amounts of PE-S(O)NH2 were quantified by HPLC (SEM ±5%, n≥3).  CG-S(O)NH2 and 
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S(O)NH2 ion abundance to total ion count in each case.  The percent sulfinamide was 
determined by normalizing each ion abundance ratio with respect to that detected in the 
initial peptide sample (SEM ±5%, n≥3). 
 
2.2.4 Deamidation of Asn-Containing Peptides  
The mass difference between a sulfinamide and its corresponding sulfinic acid is 1 
Da.  To confirm that sulfinamides and sulfinic acids can be distinguished by ESI-MS, initial 
experiments were performed with the previously studied peptides, VYPNGA and 
VYPNLA, which are known to undergo deamidation.27, 28, 30, 39  Upon incubation of these 
peptides at 100 °C for 1 h, VYPDGA, the corresponding deamidation product of 
VYPNGA, was detected in significant amounts, whereas no VYPDLA was observed 
(Supporting Information).  VYPDLA, however, was detected following extended 
incubation at 100 °C for 10 h.  These results correlate well with the reported half-lives of 
0.15 and 4.9 h for VYPNGA and VYPNLA, respectively.27  Thus, a 1 Da shift (i.e., the 
mass difference between an amide and a carboxylic acid) can be observed with our ESI-
MS system, making it a viable technique for the analysis of the sulfinamide to sulfinic acid 
reaction. 
2.2.5 Conversion of Sulfinamides to Sulfinic Acids  
The time frame for sulfinic acid formation was investigated by incubating CG-
S(O)NH2 in phosphate buffer at 37 °C.  As observed by ESI-MS (Figures 2-7 and 2-8), 
slow conversion of CG-S(O)NH2 to the corresponding VYPCGA-derived sulfinic acid 
(CG-S(O)OH) occurs in the absence of reducing agents.  No reaction was observed when 
the incubations were done at -20 °C.  Interestingly, the reaction was found to be even slower 
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in ammonium bicarbonate buffer at pH 7.4, again indicating the potential importance of 
buffer conditions.36  
To confirm the relative rates of sulfinamide reduction (to form thiol) versus 
hydrolysis (to form sulfinic acid), analogous experiments were conducted in the presence 
of DTT.  Under these conditions, no sulfinic acid is observed, suggesting that there is a 
competition between the two reactions.  Similar results were obtained upon conducting 
HPLC experiments with PE-S(O)NH2 in the presence or absence of DTT.  These results 





Figure 2-7.  Representative ESI-MS spectra showing the formation of the VYPCGA-
derived sulfinic acid (CG-S(O)OH) from the VYPCGA-derived sulfinamide (CG-
S(O)NH2).  VYPCGA (0.1 mM) was treated with 0.3 mM AS to form the corresponding 
sulfinamide.  The sample was incubated in phosphate buffer at 37 °C in the absence of 
reducing agents.  During data analysis, the intensity of the CG-S(O)NH2 M+1 isotope was 




Figure 2-8.  Hydrolysis of the VYPCGA-derived sulfinamide (CG-S(O)NH2) to the 
VYPCGA-derived sulfinic acid (CG-S(O)OH).  VYPCGA (0.1 mM) was treated with 0.3 
mM AS to form the corresponding sulfinamide and the samples were incubated in 
phosphate buffer at 37 °C.  CG-S(O)NH2 and CG-S(O)OH were analyzed by ESI-MS by 
examining the ratios of CG-S(O)NH2 (☐) and CG-S(O)OH (■) ion abundance to total ion 
count (SEM ±5%, n≥3).   
 
2.2.6 Detection of Ammonia  
The release of ammonia as a byproduct in the reduction of 2-phenylethanesulfinamide was 
confirmed by a fluorometric assay.40  When this sulfinamide is incubated in the presence 
of DTT, increasing concentrations of ammonia are detected corresponding to 53% and 
100% reduction after 6 and 26 h, respectively (Figure 2-9a); no ammonia is detected in the 
initial sample.  These results are consistent with the reduction results obtained for 2-
phenylethanesulfinamide by HPLC (54% after 6 h; 98% after 26 h).  Moreover, Figure 2-
9b shows that a small quantity of ammonia (corresponding to 27% sulfinamide hydrolysis 
after 26 h) is detected in the absence of DTT, which again corresponds well to the amount 






Figure 2-9.  Formation of ammonia detected by OPA fluorescence assay. A 2.5 mM 
solution of 2-phenylethanesulfinamide (PE-S(O)NH2) was incubated at 37 °C for 26 h (a) 
in the presence or (b) in the absence of 50 mM DTT and the amount of ammonia was 
detected in the initial (☐), 6 h-incubated () and 26 h-incubated () samples.  
 
2.2.7 Reduction of Sulfinamide Modification in Papain 
HNO targets several enzymes with active site thiol residues resulting in the loss of 
enzyme activity.8, 11-14  The cysteine protease, papain, which in its active form has a single 
free thiol,41, 42 is known to be inhibited by HNO.  The mechanism of inhibition has been 
proposed to be due to the formation of a sulfinamide.11 In addition, it has been observed 
that incubation of AS-treated papain with DTT for 1 h results in a small recovery in enzyme 
activity.11  To determine whether a sulfinamide modification in a protein can be reverted 
back to the free thiol, we investigated the reactivity of this modification in AS-treated 
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papain.  As seen in Figure 2-10, the inhibition of papain activity can be partially reversed 
upon incubation with thiol reducing agents over 10 h.  Moreover, 26 and 105 h incubation 
with GSH led to 18% and 44% activity recovery, respectively.  Longer incubations were 
not possible with DTT or BME due to the significant loss of papain activity observed in 
the control samples. 
 
 
Figure 2-10.  Reduction of the HNO-derived sulfinamide in papain.  Previously activated 
papain (0.2 mg/ml) was treated with 100 M AS.  The samples were incubated with 5 mM 
GSH (◊), 10 mM DTT (), 50 mM BME (☐), or 320 mM BME () in phosphate buffer 
at 37 °C.  Data is expressed as the percentage of the activity of the control samples (SEM 
±5%, n≥3).  No increase in papain activity was observed in the absence of reducing agents. 
 
To rule out the presence of an HNO-induced disulfide and its subsequent reduction, 
we investigated the time frame for the reduction of disulfide-modified papain.  Non-
activated papain was used for these experiments, since its single, active site cysteine is 
known to exist in a mixed disulfide form rather than the free sulfhydryl form.43  As 
expected, non-activated papain had no significant activity.  Upon incubation with 50 or 
320 mM BME at physiological pH and temperature, the enzyme was activated in less than 
10 min (Supporting Information).  These results support the hypothesis that the gain of 
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activity observed after much longer incubation times with AS-treated papain in the 
presence of reducing agents is due to the reduction of a sulfinamide. 
2.3 Discussion  
Sulfinamide formation is observed upon the reaction of HNO with thiols.  Many 
examples of sulfinamide-modified proteins have been reported, with several of them being 
enzymes containing critical cysteine residues.11-14, 44  Thiol modification has been shown 
to have dramatic effects on the activities of these enzymes.  Although the reduction of this 
sulfinamide modification has not been studied under physiologically relevant conditions, 
it has generally been assumed to be stable.8, 11-14, 20, 44  Our results, employing short peptides 
as model systems, indicate that the HNO-induced thiol to sulfinamide modification can be 
reduced in the presence of excess thiol, albeit quite slowly.  At physiological pH and 
temperature, about one third of the sulfinamide-modified peptide is reduced back to free 
thiol after 6 h.  This reduction does not seem to be strongly dependent on the peptide 
sequence in buffer, but a substituent effect is observed in lower dielectric constant solvents.  
Direct thiolysis (Scheme 2-2) and a mechanism analogous to the succinimide-
mediated deamidation mechanism (Scheme 2-4) are two plausible pathways.  The major 
difference between the two mechanisms is the involvement of a cyclic intermediate 1, the 
formation of which is facilitated by a peptide structure.  Intermediate 1 has been proposed 
in the hydrolysis of peptide sulfinamides to produce the corresponding sulfinic acids.24  We 
have observed that under physiological conditions only a small amount of our peptide 
sulfinamides are converted to the corresponding sulfinic acids after 26 h.  Due to the 
relatively longer half-life of sulfinic acid formation, the reduction of sulfinic acids to thiols 
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is not considered to be a probable pathway.45, 46  This is supported by the fact that no 
significant sulfinic acid formation is observed in the presence of DTT.    
Previously we have reported that t-butanesulfinamide is unreactive with DTT at 
room temperature over 12 h.20  Since t-butanesulfinamide is extremely sterically hindered, 
we tested the reactivity of a more relevant small organic molecule sulfinamide, 2-
phenylethanesulfinamide (PE-S(O)NH2).  Upon 26 h incubation in thiol-containing buffer 
at 37 °C, >90% reduction is observed, demonstrating that direct thiolysis (Scheme 2-2) is 
a viable mechanism at physiological pH and temperature.  It should also be noted that 
sulfinic acid formation is not detected upon incubating 2-phenylethanesulfinamide in the 
presence of DTT, indicating that direct thiolysis of this sulfinamide is more efficient than 
the corresponding hydrolysis reaction. 
To learn more about the reactivity of sulfinamides, we have also investigated the 
effect of solvent dielectric by employing different co-solvents.  Our results with PE-
S(O)NH2 indicate that the direct thiolysis reaction is significantly inhibited as the solvent 
dielectric constant decreases.  Moreover, we have shown that in lower dielectric 
environments peptide sulfinamides are more reactive towards reduction by DTT compared 
with PE-S(O)NH2.  A possible explanation for the observed difference in reactivity is that 
in the case of the peptide sulfinamides there is a contribution from cyclic intermediate 1, 
which becomes more significant upon inhibition of the direct thiolysis pathway.  This 
explanation is further supported by the observed sequence dependence (analogous to that 
for the asparagine deamidation reaction27) that is manifested only under low dielectric 
constant conditions.  Based on the overall results, it can also be inferred that the impact of 
solvent dielectric is larger on the direct thiolysis mechanism (Scheme 2-2) compared to the 
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mechanism involving cyclic intermediate 1 (Scheme 2-4), although both mechanisms are 
affected.  Our results are consistent with a recent computational study, where the energetics 
and feasibilities of several asparagine deamidation pathways were compared.47  These 
computational results indicate that direct hydrolysis is a competitive reaction with the 
imide-mediated deamidation reaction even in the absence of acid or base catalysis.47 
Considering that the half-life of proteins varies from less than 3 min to more than 
20 h in vivo,48-51 the time scales presented here are relevant to cellular proteins (e.g., 
GAPDH, t1/2=38.1 h).
52  Moreover, our results in lower solvent dielectric media indicate 
that sulfinamide reduction can take place in hydrophobic as well as hydrophilic regions of 
proteins.  This may also be particularly relevant to HNO-targeted proteins containing 
cysteines in their hydrophobic domains such as the regulatory protein of the sarcoplasmic 
reticulum Ca2+ pump, phospholamban.20  Since the irreversible inhibition of proteins with 
critical thiol residues has been hypothesized to have detrimental effects on lysosomal 
protein degradation, cell cycle, and energy metabolism at the glycolytic level,11, 14, 53 the 
reduction of a sulfinamide modification is relevant to the use of HNO as a therapeutic 
agent.  It should be noted that the peptides used in the present study do not have well-
defined secondary structure and that the presence of higher order structures may very likely 
affect reaction rates.   
Papain is a well-studied cysteine protease containing three disulfide bonds and a 
single active site cysteine residue,41, 42 which is prone to inhibition presumably due to 
HNO-induced sulfinamide formation.11  In a previous study, AS-treated papain was 
incubated with DTT for a short period of time (1 h) and some recovery in the activity was 
observed.11  Since sulfinamide reduction was previously thought to be unlikely, this 
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recovery was attributed to the reduction of a possible disulfide modification.  We have 
observed that the time frame for the reduction of disulfides (<10 min) and sulfinamides 
(several hours) are significantly different.  Although we have not yet directly characterized 
the modification, based on the results reported here, we suggest that the HNO-derived 
sulfinamide in papain can be reduced back to free thiol in the presence of reducing agents, 
indicating the feasibility of this reaction in a protein environment.    
2.4 Conclusions 
We have demonstrated that HNO-derived sulfinamides can be reverted back to free 
thiols under physiologically relevant conditions.  In the presence of reducing agents, this 
reaction is feasible in small organic molecules, peptides, and proteins.  Although both 
peptide and small organic molecule sulfinamides are susceptible to hydrolysis, this reaction 
is slower than reduction by thiols.  Our results suggest that the mechanism of peptide 
sulfinamide reduction involves a contribution from a cyclic intermediate, whose relative 
impact becomes more significant in environments of lower dielectric constant.  
Considering the broad spectrum of pharmacological effects attributed to HNO,5, 6, 53 these 
findings are relevant to the study of HNO-induced modifications in biological systems. 
2.5 Experimental Methods  
Reagents. Glutathione (GSH), papain, Nα-Benzoyl-L-arginine 4-nitroanilide 
hydrochloride (L-BAPNA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phthalaldehyde 
(OPA), β-mercaptoethanol (BME) and DTT were of the highest purity available and 
purchased from Sigma (St. Louis, MO).  2-Phenylethanethiol and 2-(bromoethyl)benzene 
were purchased from Acros.  HPLC grade acetonitrile (ACN) was purchased from Thermo 
Fisher Scientific (Rockford, IL).  The HNO-donors, Angeli’s salt (Na2N2O3, AS) and 2-
46 
 
bromo-N-hydroxybenzenesulfonamide (2-BrPA), were synthesized as previously 
described.54, 55  Milli Q water was used for all purifications and experiments. 
Peptide Synthesis and Purification. Synthetic peptides VYPCGA, VYPCLA, 
VYPNGA and VYPNLA were synthesized on a Symphony Quartet peptide synthesizer 
(Protein Technologies Inc., Tucson, AZ) following Fmoc solid-phase peptide synthesis 
methods.56  The crude product was dissolved in 0.1% trifluoroacetic acid (TFA) and 
purified by HPLC (Waters HPLC equipped with Delta 600 pump system and dual 
wavelength absorbance detector) on an Apollo C18 reverse-phase column using a linear 
gradient of 5-75% ACN with 0.1% TFA over 50 min at room temperature.  Peptide 
fractions were identified by electrospray ionization mass spectrometry (ESI-MS).  Pure 
fractions were pooled and lyophilized, and the purified product was quantified based on 
the absorbance at 280 nm (280= 1490 M
-1 cm-1).57  In all cases, the peptides were stored at 
-20 °C in lyophilized form until use.  
Synthesis of 2-Phenylethanesulfinamide.  The synthesis was carried out based on 
known methods for the synthesis of sulfinamides.58  Briefly, bis(2-phenylethyl) disulfide 
was generated from (2-bromoethyl)benzene using thiourea, MnO2 and Na2CO3 as 
described in the literature.59  The disulfide was reacted with 1.5 equivalents of N-
bromosuccinimide (NBS) in methanol to form the corresponding methyl sulfinate.  After 
stirring the reaction at room temperature for 3 h, the mixture was diluted with CH2Cl2, 
washed with saturated NaHSO3 solution, and extracted with a saturated solution of 
NaHCO3.  2-Phenylethanesulfinamide was formed by reacting methyl 2-
phenylethylsulfinate with 2 equivalents of butyllithium and 2 equivalents of 
bis(trimethylsilyl)amine in tetrahydrofuran at -78 °C.  (Caution:  Butyllithium is water-
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reactive, extremely flammable, and pyrophoric.)  The reaction was then stirred at room 
temperature for 2 h and quenched by adding a saturated solution of NH4Cl.  The mixture 
was extracted with ethyl acetate (EtOAc), dried with MgSO4, and the solvent was 
evaporated under vacuum.  The resulting sulfinamide was purified on a silica column by 
employing a hexane/EtOAc solvent system.  The solvent was evaporated under vacuum to 
obtain a white solid:  1H NMR (CDCl3) δ 7.27 (m, 5H), 4.10 (s, 2H), 3.06 (m, 4H); 
13C 
NMR (CDCl3) δ 138.8, 128.8, 128.5, 126.8, 58.7, 29.0; FAB-MS (3-NBA):  m/z calcd 
170.06396 [M+H], found 170.06470.  The structure of 2-phenylethanesulfinamide was also 
confirmed by X-ray crystallography (Supporting Information). 
Formation of Peptide Sulfinamides by Reaction with HNO.  Peptides were 
dissolved in 10 mM sodium phosphate buffer with 50 M of the metal chelator, 
diethylenetriamine pentaacetic acid (DTPA), at pH 7.4 (or in 10 mM ammonium 
bicarbonate buffer with 50 M DTPA at pH 7.4 where indicated) to have a final 
concentration of 100 M and used immediately.  Stock solutions of AS were prepared in 
0.01 M NaOH, kept in ice, and used within 15 min of preparation.  Stock solutions of 2-
BrPA were prepared in ACN and used within 15 min of preparation.  The peptides were 
incubated with various concentrations of AS or 2-BrPA (as indicated) at 37 °C for 30 min 
in a block heater.  The samples were flash-frozen and lyophilized overnight.  The 
lyophilized samples were stored at -20 °C and used within a day. 
In the case of ammonium bicarbonate buffer, the peptides were dissolved to have a 
final concentration of 250 M and incubated with 5 mM 2-BrPA as described above.  The 
samples were used immediately without prior lyophilization.  Under the conditions of our 
experiments, ammonium bicarbonate buffer remained stable over a period of 69 h, as 
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indicated by a pH increase of only 0.7 units over this time period.  For all experiments, the 
volume of 0.01 M NaOH or ACN introduced was less than 1% of the total sample volume. 
Peptide Incubations in Buffer.  Stock solutions of DTT (1 M) were freshly 
prepared in water and used within 15 min of preparation.  BME was used directly.  The 
sulfinamide-containing peptides were redissolved in water to have a final peptide 
concentration of 0.8 mM and buffer concentration of 82 mM sodium phosphate with 410 
M DTPA at pH 7.4. The samples were aliquoted and incubated in the presence or absence 
of reducing agents at 37 °C as indicated.  Individual aliquots were removed from the 
samples for analysis at certain time intervals.  The peptides were purified and desalted with 
C18 PepClean spin columns, and then diluted into 70% ACN with 0.1% TFA for immediate 
ESI-MS analysis. 
Peptide Incubations in ACN/Buffer or Dioxane/Buffer.  Stock solutions of the 
reducing agents were prepared as described above.  The sulfinamide-containing peptides 
were redissolved in ACN/water 50:50 (v/v) or dioxane/water 50:50 (v/v) to have a final 
peptide concentration of 0.8 mM and buffer concentration of 82 mM sodium phosphate 
with 410 M DTPA.  The samples were incubated in the presence of reducing agents at 37 
or 55 °C.  Individual aliquots were removed from the samples for analysis at certain time 
intervals.  The solvent was then removed under vacuum at room temperature in a Savant 
Speedvac apparatus.  The residue was dissolved in water and prepared for ESI-MS analysis 
as described above.  As a control, in all cases, a side-by-side experiment was conducted in 
sodium phosphate buffer and the sample was exposed to the same sample preparation steps 
as the sample in ACN/buffer or dioxane/buffer. 
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Incubation of Asn-Containing Peptides.  VYPNGA and VYPNLA were 
dissolved in 50 mM phosphate buffer at pH 7.4.  The samples were incubated at 100 °C 
and aliquots were taken for analysis at certain time intervals.  They were prepared for ESI-
MS analysis as described above. 
Incubation of 2-Phenylethanesulfinamide and HPLC Analysis.  Stock solutions 
of the reducing agents were prepared as described above.   2-Phenylethanesulfinamide was 
dissolved in 82 mM sodium phosphate buffer with 410 M DTPA at pH 7.4 to have a final 
sulfinamide concentration of 2.5 mM.  The samples were incubated in the presence or 
absence of reducing agents at 37 °C.  Individual aliquots were removed from the samples 
for analysis at certain time intervals and cooled in ice for 5 min.  They were then 
immediately analyzed by HPLC.  All the analyses were performed on an Apollo C18 
reverse-phase column connected to the HPLC system described above.  A linear gradient 
of 35-80% ACN with 0.1% TFA over 35 min was employed at room temperature.  The 
compounds were followed at 220 nm and peaks were assigned based on co-injection with 
authentic samples. 
For experiments performed in organic co-solvents, 2-phenylethanesulfinamide was 
dissolved in ACN/pH 7.4 phosphate buffer 50:50 (v/v) or dioxane/pH 7.4 phosphate buffer 
50:50 (v/v) to have a final sulfinamide concentration of 2.5 mM and buffer concentration 
of 82 mM sodium phosphate with 410 M DTPA.  The samples were incubated in the 
presence or absence of reducing agents at 37 or 55 °C and analyzed as described above.   
Mass Spectrometric Analyses.  ESI-MS analysis was carried out on a Thermo 
Finnigan LCQ Deca Ion Trap Mass Spectrometer fitted with an electrospray ionization 
source, operating in the positive ion mode with an accuracy of ca. 0.1 m/z.  In all 
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experiments, the samples were introduced to the instrument at a rate of 10 L/min using a 
syringe pump via a silica capillary line. The heated capillary temperature was 250 °C and 
the spray voltage was 5 kV. 
DTNB Assay for Quantitation of Free Thiol.  Stock solutions of DTT were 
prepared as described above.  The sulfinamide-containing peptides were redissolved in 
water to have a final peptide concentration of 0.8 mM and buffer concentration of 82 mM 
sodium phosphate with 410 M DTPA at pH 7.4.  The samples were incubated in the 
presence of reducing agents at 37 °C.  Individual aliquots were removed from the samples 
for analysis at certain time intervals.  The peptides were desalted with C18 PepClean spin 
columns to remove excess DTT.  The solvent was then removed under vacuum at room 
temperature and the residue was redissolved in 10 mM phosphate buffer with 50 M DTPA 
at pH 8.  The free sulfhydryl content was immediately determined by DTNB titration.35  In 
all cases, a peptide sample incubated without AS and exposed to the same sample 
preparation procedure was employed as a control.  The results were corrected for the 
amount of free thiol in the initial sample and normalized with respect to the indicated 
control sample.     
Detection of Ammonia.   2-Phenylethanesulfinamide was dissolved in 82 mM 
sodium phosphate buffer with 410 M DTPA at pH 7.4 to have a final sulfinamide 
concentration of 2.5 mM.  The samples were incubated in the presence or absence of DTT 
at 37 °C.   Individual aliquots were removed from the samples for analysis at certain time 
intervals and the concentration of ammonia was analyzed by a fluorometric assay using 
OPA.40  (NH4)2SO4 solutions were used as calibration standards.  For the standard solutions 
and incubations carried out in the absence of DTT, the reducing agent was added at the 
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time of the fluorometric assay (which requires DTT).  The fluorometric analyses were 
conducted on a Spex Fluorolog equipped with a 450 W Xe lamp. 
Activation of Papain.  A 0.5 mg/ml papain solution was prepared by dissolving 
the lyophilized enzyme in 82 mM sodium phosphate buffer with 410 M DTPA at pH 7.4.  
The papain sample was activated by treating it with 2 mM DTT for 1.5 h at room 
temperature to reconvert its single free cysteine to the sulfhydryl form.  The activated 
enzyme was stored at -20 °C.  Before analysis, it was thawed and desalted with Zeba spin 
desalting columns to remove excess DTT.  The papain solution was then diluted to 0.2 
mg/ml with sodium phosphate buffer.  To overcome batch to batch variation in the actual 
activity of the reduced papain preparation, all activity results are expressed as a percentage 
of the indicated control. 
Incubation of Papain Solutions and Activity Assay.  A solution of 0.2 mg/ml 
activated papain in 82 mM sodium phosphate buffer with 410 M DTPA at pH 7.4 was 
divided into two and the aliquots were incubated with 0 or 100 M AS at 37 °C for 30 min.  
Reducing agents were then added to both solutions to have the required concentration, as 
indicated.  The samples were incubated at 37 °C and aliquots were taken from each sample 
at certain time intervals, and immediately analyzed by a 20 min kinetic assay using L-
BAPNA as the substrate.11  In all cases, the sample incubated without AS served as the 
control sample to correct for the decrease in papain activity due to long incubations.  In 
some experiments, non-activated papain, whose single active site cysteine is in a mixed 
disulfide form,43 was utilized instead of the activated papain as indicated.  All the 




Analysis of the Data.  All analyses were carried out in triplicate.  Although the 
absolute amounts of the relevant thiol-containing species cannot be determined from any 
one of the reported ESI-MS experiments, the changes in the relative amounts of 
sulfinamide, sulfinic acid, thiol, and disulfide can be determined by calculating the 
percentage of each species in the total ion count (TIC).  Such analyses, where ratios of ion 
abundances are compared in different experiments, have been commonly employed as 
label-free quantification methods in proteomics.60  In addition, for comparison, absolute 
yields of thiol were determined by DTNB assay and were in good agreement with the ESI-
MS determined relative yields.  In all cases, error (SEM) was found to be ±5%. 
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2.7 Supporting Information 
X-Ray Crystallography of 2-phenylethanesulfinamide.  All reflection intensities were 
measured using a KM4/Xcalibur (detector: Sapphire3) with enhance graphite-
monochromated Mo Kα radiation (λ = 0.71073 Å) under the program CrysAlisPro (Version 
1.171.35.11 Oxford Diffraction Ltd., 2011). The program CrysAlisPro (Version 
1.171.35.11, Oxford Diffraction Ltd., 2011) was used to refine the cell dimensions. Data 
reduction was done using the program CrysAlisPro (Version 1.171.35.11, Oxford 
Diffraction Ltd., 2011). The structure was solved with the program SHELXS-97 
(Sheldrick, 2008) and was refined on F2 with SHELXL-97 (Sheldrick, 2008). Analytical 
numeric absorption corrections based on a multifaceted crystal model were applied using 
CrysAlisPro (Version 1.171.35.11, Oxford Diffraction Ltd., 2011). The temperature of the 
data collection was controlled using the system Cryojet (manufactured by Oxford 
Instruments). The H atoms (except for the H atoms attached to N1) were placed at 
calculated positions using the instructions AFIX 23 or AFIX 43 with isotropic 
displacement parameters having values 1.2 times Ueq of the attached C atoms.  The 
positions of the H atoms attached to N1 were found from Fourier difference maps.  The 
NH distances were restrained to 0.88(3).  Data were collected at 110 (2) K after the crystal 
had been flash-cooled from room temperature. The structure is ordered. 
 
Results: 
Fw = 169.24, colorless block, 0.41  0.30  0.13 mm3, monoclinic, P21/c (no. 14), a = 
13.9432(7), b = 5.24461(18), c = 11.9405(5) Å,  = 105.094(5), V = 843.04(6) Å3, Z = 4, 
Dx = 1.333 g cm
−3,  = 0.324 mm−1, abs. corr. range: 0.9040.969.  5149 Reflections were 
62 
 
measured up to a resolution of (sin /)max = 0.62 Å−1. 1708 Reflections were unique (Rint 
= 0.0260), of which 1505 were observed [I > 2(I)]. 106 Parameters were refined using 2 
restraints. R1/wR2 [I > 2(I)]: 0.0311/0.0837. R1/wR2 [all refl.]: 0.0360/0.0866. S = 1.067. 
Residual electron density found between −0.27 and 0.32 e Å−3. 
 
 








Figure 2-12.  Reduction of the VYPCGA-derived sulfinamide (CG-S(O)NH2).  The 
samples were incubated with (a) 50 mM  and (b) 320 mM BME in sodium phosphate buffer 
at 37 °C for 26 h.  The relative ratios of sulfinamide and thiol were determined by 














































Figure 2-13.  Sulfinamide reduction in peptides versus a small organic molecule in 
ACN/Buffer at 55 oC.  VYPCGA (0.1  mM) and VYPCLA (0.1 mM) were treated with 1 
mM AS to form the corresponding sulfinamides, CG-S(O)NH2 and CL-S(O)NH2, 
respectively.  The synthesis of 2-phenylethanesulfinamide (PE-S(O)NH2) was carried out 
as described in the experimental section.  The samples were incubated with 50 mM DTT.  
The amount of sulfinamide was normalized with respect to that detected in the initial 




Figure 2-14.  Effects of DTT and BME on 2-phenylethanesulfinamide in ACN/pH 7.4 
phosphate buffer 50:50 (v/v) at 55 °C.  Synthetic 2-phenylethane-sulfinamide (2.5 mM) 
was incubated in the presence of 50 mM DTT () or BME (☐).  The samples were 




































Figure 2-15.  (a) Representative ESI-MS spectra showing the deamidation of VYPNGA 
peptide upon 1 h boiling in buffer. (b) No change was observed upon boiling VYPNLA 
peptide for 1 h. 







Figure 2-16.  Disulfide reduction in papain.  Non-activated papain (0.2 mg/ml) was 
incubated with 50 or 320 mM BME in phosphate buffer at 37 °C.  Data is normalized with 
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Chapter 3 – NMR Detection and Study of the 
Hydrolysis of HNO-Derived Sulfinamides 
3.1 Introduction 
Cysteine residues are known to be targets of reactive nitrogen oxide species 
(RNOS).1-3  Nitroxyl (HNO), the protonated, one-electron reduced form of NO, has been 
shown to have potential uses in the treatments of heart failure, alcoholism, vascular 
dysfunction, and cancer.2, 4-6  HNO is very reactive with thiols, forming sulfinamides or 
disulfides depending on the concentration of thiol (Scheme 1).7, 8  Sulfinamide formation 
dominates at low thiol concentrations, whereas disulfide and hydroxylamine become the 
major end products in the presence of excess thiol.  
 
 
Scheme 3-1.  The reaction of HNO with thiols 
 
HNO-induced effects have been detected on several cysteine-containing    
proteins.9-23  In many of these proteins the observed effects are attributed to the formation 
of a sulfinamide.  Apart from these HNO studies, administration of sulfonamide antibiotics 
and arylamines has been shown to result in formation of N-substituted sulfinamides in 
proteins.24, 25  To understand the pharmacological effects of HNO more completely, the 
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reactivity of sulfinamides under biologically relevant conditions requires further 
investigation. 
At physiological pH and temperature, the major reactions of sulfinamides involve 
the reduction to free thiols in the presence of excess thiol and hydrolysis to form sulfinic 
acids.26, 27  There are very few studies on the hydrolysis of sulfinamides, the majority of 
which have been carried out under aqueous, acidic conditions.28-30  The mechanism is 
thought to involve a sulfurane intermediate (Scheme 2).30  Studies conducted with several 
N-substituted alkyl sulfinamides indicate that aliphatic secondary sulfinamides are 
relatively stable at basic pH, but hydrolysis can proceed readily at pH 3.17, 28  Also, tertiary 
sulfinamides have been found to be more reactive than secondary sulfinamides.28  Although 
the hydrolysis of HNO-derived sulfinamides has been observed,17, 26, 27 the reaction has not 
been studied in detail under physiological conditions.  In recent studies, sulfinic acid 
modifications of thiols were seen upon exposure of HNO-treated samples to proteomic 
analysis or upon storage.17, 26  Moreover, we recently reported the slow conversion of 









Scheme 3-2.  Hydrolysis of sulfinamides 
  
Isotope-edited 1H NMR techniques are generally used for investigating interactions 
in macromolecular complexes such as ligand-protein, protein-protein, or protein-nucleic 
acid interactions.31-33  In this method, one or more components of the complex are labeled 
with NMR active isotopes and the selective detection of protons bonded to the isotope-
labeled atom is achieved.31  Sulfamate groups on glycosaminoglycans and a DNA-peptide 
adduct were recently characterized using an analogous NMR method.34, 35  Herein, we are 
pleased to report the application of 15N-edited NMR spectroscopy to detect and study the 
hydrolysis of sulfinamides in several small organic molecules, peptides, and the cysteine 
protease, papain. 
3.2 Results and Discussion  
Since protein structure and function can be altered significantly due to post-
translational modifications of cysteine residues, the biological effects of HNO are often 
attributed to its reactivity with thiols.6, 27, 36-38  Sulfinamides are one of the major thiol 
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modifications observed upon exposure to HNO.7, 8  Although thiols are known to react with 
other RNOS, sulfinamide formation is considered to be unique to HNO.39  Despite being a 
well-established modification, very few studies on the reactivity of HNO-derived 
sulfinamides have been reported.   
To detect and study the reactivity of sulfinamides in a facile manner, we have 
applied 15N-edited NMR techniques, which are commonly used to study ligand-protein 
interactions.31-33  These techniques are based on distinguishing between protons bonded to 
isotope-labeled and unlabeled nuclei.31-33  Although direct 15N NMR detection is a well-
known technique, unfortunately it suffers from low sensitivity.40-42  To determine the 
potential applicability of direct 15N NMR spectroscopy to the study of sulfinamides, we 
explored its detection limit by employing 15N-labeled urea.  These preliminary studies have 
shown that although 1 M 15N-labeled urea can be observed in less than 30 min, the addition 
of relaxation agents42 and an extended number of scans are needed to observe 10-100 mM 
15N-labeled urea.  These results suggest that 15N NMR spectroscopy would not be 
convenient for the detection of HNO-derived sulfinamides, which are expected to be 
formed in much lower concentrations.  Apart from retaining the sensitivity of 1H NMR, the 
major advantage of 15N-edited NMR procedures is the ability to provide simpler and more 





3.2.1 Detection of Synthetic and HNO-Derived Small Organic 
Molecule Sulfinamides by 1H NMR 
We initially investigated the conditions necessary to detect sulfinamides by 1H 
NMR in order to identify characteristic chemical shifts for the sulfinamide functional 
group.  For this purpose, commercially available t-butanesulfinamide was employed.  
Although we attempted NMR analysis directly in buffer using water suppression 
techniques, the sulfinamide NH signal resonates too closely with the water signal, 
precluding its detection.  Among the NMR solvents employed (CDCl3, ACN-d3, DMSO-
d6, THF-d8), DMSO-d6 provided the best results in terms of sample solubility and the clean 
observation of sulfinamide chemical shifts (5.1-6.3 ppm) (Figure 3-1).  Also, the lack of 
exchangeable protons in DMSO-d6 avoided the possible exchange between the sulfinamide 
NH's and deuterated solvent, allowing for better detection and accurate quantification.  
Similar results were obtained with synthetic 2-phenylethanesulfinamide, confirming the 
characteristic chemical shift region for the sulfinamide functional group and the general 
applicability of the method to other sulfinamides (Figure 3-1).  Therefore, we carried out 
all reactions in phosphate buffer and then transferred the samples into DMSO-d6 (via 





Figure 3-1.  1H NMR spectra of (a) t-butanesulfinamide, (b) synthetic, and (c) HNO-
derived 2-phenylethanesulfinamide collected in DMSO-d6 at 30 
oC.  The HNO-derived 
sulfinamide was formed by treating 2-phenylethanethiol (0.1 mM) with AS (1 mM) in 10 
mM phosphate buffer with 50 M DTPA (pH 7.4) at 37 °C for 30 minutes.  An asterisk (*) 
indicates the sulfinamide NH signals. 
  
To determine if the above conditions can be applied to HNO-derived sulfinamides, 
we treated 2-phenylethanethiol with AS in buffer to form the corresponding 2-
phenylethanesulfinamide.  Similar to our previous ESI-MS results,27 using a thiol to HNO 
donor ratio of 1:5 or 1:10 provided sufficient amount of 2-phenylethanesulfinamide.  HPLC 
and ESI-MS analysis confirmed that the reaction of 2-phenylethanethiol with HNO 
produces the corresponding sulfinamide with a small amount of disulfide (Supporting 
Information).  The 1H NMR analysis was carried out following lyophilization of the 
sulfinamide from buffer and re-dissolving it in DMSO-d6.  As expected, the characteristic 
sulfinamide NH signal was observed at the same chemical shift for the synthetic and HNO-
derived 2-phenylethanesulfinamides (5.8 ppm) (Figure 3-1b,c). 
Since hydroxylamine is obtained as a byproduct in the case of HNO-induced 
disulfide formation (Scheme 3-1), we carried out control experiments with hydroxylamine 
exposed to the same sample preparation procedures or directly dissolved in the NMR 
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solvent.  These results did not show any peaks in the chemical shift region assigned to the 
sulfinamide NH's (data not shown). 
3.2.2 15N-Edited 1H 1D NMR to Detect 15N-Labeled Small 
Organic Molecule Sulfinamides  
As mentioned previously, the use of isotope-edited methods simplifies the NMR 
spectra of complex samples by allowing selective detection of protons bonded to the 
isotope-labeled atom.  The labeling of sulfinamides with 15N was achieved by incubating 
thiols with 15N-AS, which decomposes to produce 15N-labeled HNO (H15NO) and 
unlabeled NO2
-.  As seen in Figure 3a, treatment of -mercaptoethanol (BME) with H15NO 
resulted in the formation of the corresponding 15N-labeled sulfinamide (BME-S(O)15NH2)  
with a 1H-15N coupling constant (JNH) of 76 Hz.  Upon application of an isotope filter to 
select for 15N, only the sulfinamide 15NH signal is observed in the decoupled 15N-edited 







Figure 3-2.  Selected region of 1H NMR spectrum showing (a) sulfinamide 15NH signals 
following the treatment of β-mercaptoethanol (0.1 mM) with 15N-AS (1 mM) in 10 mM 
phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min and (b) the corresponding 
region of the 15N-edited 1H 1D-NMR decoupled spectrum acquired using the HSQC pulse 
sequence for selection.  The spectra were collected in DMSO-d6 at 30 
oC. 
 
3.2.3 Detection of HNO-Derived Sulfinamides in Peptides 
Given the results described above, the hexapeptide, VYPCLA, was employed to 
test our detection method on a more complex system.  In our previous work, the 
sulfinamide yield of this peptide was determined to be greater than 90% upon incubation 
with ten times excess AS.27  As seen in Figure 3-3a-e, the sulfinamide NH peaks (5.8-6.3 
ppm) are observed only after HNO treatment of the thiol-containing peptide.  Control 
experiments conducted with the unmodified peptide or following treatment with DEA/NO, 




Figure 3-3.  NMR spectra observed for VYPCLA (0.1 mM) (a) untreated or treated with 
(b) 1 mM AS, (c,d) 1 mM 15N-AS, and (e) 0.5 mM DEA/NO in 10 mM phosphate buffer 
with 50 µM DTPA (pH 7.4) at 37 oC for 30 min.  Spectra (a-c) and (e) are 1H NMR spectra 
and (d) is an 15N-edited 1H 1D-NMR spectrum which uses the HSQC pulse sequence for 
selection.  The spectra were collected in DMSO-d6 at 30 
oC.  An asterisk (*) indicates the 
sulfinamide NH and 15NH signals. 
 
Unlike the signals for small organic molecule sulfinamides, two different signals 
are observed for the VYPCLA-generated sulfinamide (Figure 3-3b-d).  This result can be 
explained based on the known chirality of the sulfur atom in sulfinamides.43, 44  Upon 
sulfinamide formation, the stereochemistry at sulfur can be either R or S.  In a small organic 
molecule sulfinamide, where the sulfur is the only chiral center, the resulting compound is 
racemic, and therefore, shows only one NMR signal.  However, in the case of an L-peptide, 
the resulting sample is composed of two diastereomers (more specifically epimers) with 
the L-peptide containing either an R or S sulfinamide, consistent with the observed two 
NMR signals.   
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We have also conducted 2D-ROESY and COSY experiments on the HNO-derived 
VYPCLA sulfinamide.  These data indicate the presence of two distinct sulfinamide species 
with a single NH2 signal at 5.97 and 6.07 ppm (Figure 4).  Moreover, the 5.97 ppm peak 
shows ROE cross peaks with the cysteine β- and -H's, whereas the downfield species 
shows ROE cross peaks only with the cysteine β-H's (Figure 3-4).  These results are 
consistent with the presence of two diastereomers.  Comparison of the cysteine β-H's also 
reveals a 0.2 ppm downfield shift between the unmodified and sulfinamide modified-
VYPCLA, further confirming that the HNO-derived modification is on the cysteine residue 




Figure 3-4.  Selected region of 2D-ROESY spectrum showing ROE cross peaks involving 
sulfinamide NH2 signals of VYPCLA (0.1 mM) treated with 1 mM AS in 10 mM phosphate 
buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min.  The spectra were collected in 





The presence of two peaks could potentially be due to restricted rotation of the 
sulfinamide group causing the -NH's to be magnetically non-equivalent.  However, the 
discrepancy between small organic molecule and peptide sulfinamides, as well as the low 
rotational barrier (~8.5 kcal/mole) suggested for the S-N bond, which would correspond to 
approximately -92 oC, make restricted rotation unlikely.45  Nevertheless, to eliminate this 
possibility, we performed NMR experiments, in which the same NMR sample was 
analyzed at temperatures from 30 to 70 oC (Supporting Information).  These data show that 
two sulfinamide peaks can be observed even at 70 oC, indicating that the two peaks are not 
due to restricted rotation around the S-N bond.  
As seen in Figure 3-5, results similar to those observed with VYPCLA are obtained 
upon treatment of glutathione with H15NO to produce the glutathione sulfinamide.  
Moreover, for both peptides, unequal amounts of the two diastereomers were obtained 
indicating that one diasteromer has lower energy and potentially the reaction is under 
kinetic control under these conditions.  The 1H-15N coupling was determined to be 76 Hz, 
as observed for all the peptide sulfinamides detected.   





Figure 3-5.  1H NMR spectrum of (a) unmodified GSH or (b) the glutathione sulfinamide 
formed by treating GSH (0.2 mM) with 1 mM 15N-AS in 2 mM phosphate buffer with 12.5 
µM DTPA (pH 6) at 37 oC for 30 min.  (c) 15N-edited 1H 1D-NMR spectrum of the 
glutathione sulfinamide acquired using the HSQC pulse sequence for selection.  The 
samples were analyzed in DMSO-d6 at 55 
oC.  An asterisk (*) indicates the sulfinamide 
15NH signals. 
 
3.2.4 Detection of an HNO-Derived Sulfinamide in Papain  
The 23.4 kDa cysteine protease, papain, is one of the several enzymes known to be 
inhibited by HNO.21  It has significant similarities with important mammalian proteases 
such as cathepsins and calpains.46  The active site of papain contains a catalytic triad, which 
involves Cys25, His159 and Asn175.47  In its active form, Cys25 exists as a thiolate and 
constitutes the only free thiol in the papain structure.47, 48  The catalytic mechanism of 
papain involves nucleophilic attack of the Cys25 thiolate to form an acylenzyme 
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intermediate followed by a deacylation step.47, 49  The roles of His159 include participation 
in a thiolate/imidazolium ion pair to maintain the thiolate anion and also participation as a 
general acid catalyst during acylation and as a general base catalyst during       
deacylation.47, 48 
Although the formation of a sulfinamide has been proposed for papain after HNO 
treatment, to the best of our knowledge, it has not been observed directly.  Therefore, we 
applied the 15N-edited 1H 1D NMR method to characterize the HNO-derived modification 
of papain.  Figure 3-6 demonstrates that although the sulfinamide -NH signal could not be 
unambiguosly detected by 1H NMR spectroscopy due to the interference of other signals 
and an inherently weak signal, it can be observed clearly in the 15N-edited NMR spectrum 
(at 5.8 ppm), demonstrating that this technique is a convenient method to study HNO-







Figure 3-6.  (a) 1H NMR spectrum of sulfinamide modified-papain formed by treating 
papain (0.2 mM) with 1 mM 15N-AS in 10 mM phosphate buffer with 50 µM DTPA (pH 
7.4) at 37 oC for 30 min.  (b) 15N-edited 1H NMR spectrum of sulfinamide modified-papain 
acquired using the HSQC pulse sequence for selection.  The spectra were collected in 
DMSO-d6 at 30 
oC.  The relatively small, broad peak observed at approximately 7.9 ppm 
in Figure 6b corresponds to the natural abundance 15NH of backbone NH's. 
 
Note that only one sulfinamide signal is detected, potentially due to the large peak 
width (>90 Hz) associated with this protein sulfinamide.  However, the preferential 
formation of one diastereomer in papain active site is certainly possible.  Indeed, steepest 
descent minimizations performed with the Rosetta modeling suite suggests that the R 
sulfinamide papain variant is slightly more stable than the S sulfinamide variant (-
308.05±0.08 Rosetta energy units vs. -307.1±0.2 REU, respectively). 
The formation of the sulfinamide modification in papain was also confirmed by 
ESI-MS (Supporting Information).  Moreover, the inhibition of activated papain by AS 
under the conditions described above was confirmed by papain activity assays.  As has 
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been observed previously,21 no significant papain activity could be detected after AS 
treatment, consistent with sulfinamide formation (Supporting Information). 
3.2.5 Reduction of Peptide Sulfinamides 
Previously we had used ESI-MS to demonstrate that approximately 60% of the 
VYPCLA sulfinamide can be reverted back to free thiol upon 26 h-incubation with excess 
thiol at physiological pH and temperature.  To determine if the 15N-edited 1H NMR method 
can be applied to study sulfinamide reactivity, we repeated the above experiment by 
incubating VYPCLA sulfinamide with BME and employing 15N-labeled benzamide as the 
internal standard during NMR analysis.  The NMR data, which indicates 57% sulfinamide 
reduction, is in very good agreement with the previous ESI-MS results (Supporting 
Information). 
3.2.6 Hydrolysis of Peptide Sulfinamides 
Sulfinamides are known to undergo hydrolysis to form sulfinic acids, especially 
under acidic conditions.17, 26, 28-30  We have previously observed the slow conversion of 
primary sulfinamides to their corresponding sulfinic acids27 and determined that have now 
explored this reactivity using the 15N-edited 1H NMR method.   
The extent of sulfinamide hydrolysis was investigated by incubating the HNO-
derived VYPCLA sulfinamide under physiological conditions and analyzing aliquots at 
different time intervals.  Following 28 h incubation, a 13% decrease in the sulfinamide 
peak was observed with respect to initial (Figure 3-7), confirming that slow hydrolysis of 
sulfinamides takes place under physiological conditions.26-28  Moreover, these findings are 
consistent with our previous ESI-MS results obtained for a similar hexapeptide 
(VYPCGA).27  Upon one week incubation under similar conditions, very slow sulfinamide 
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hydrolysis (50%) was observed (data not shown).  Almost complete hydrolysis (94%) was 
achieved upon boiling the sample for 5 days (Supporting Information).  The hydrolysis of 
glutathione sulfinamide was found to be 28% after 28 h incubation at physiological pH and 
temperature, indicating this peptide is more prone to hydrolysis compared with the 
VYPCLA sulfinamide.  Moreover, similar results were obtained when glutathione 
sulfinamide was formed using N-hydroxy-2-(methylsulfonyl)benzenesulfonamide (2-
MSPA) as HNO donor, which does not produce NO2
- as a byproduct, suggesting this 
reaction is independent of the presence of NO2
-. 
 
Figure 3-7.  Representative 15N-edited 1H NMR spectra showing the hydrolysis of HNO-
derived VYPCLA sulfinamide.  VYPCLA (0.1 mM) was treated with 1 mM 15N-AS in 10 
mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min to form the 
corresponding sulfinamide.  The sample was incubated in buffer at 37 oC for 28 h resulting 
in 13% decrease in sulfinamide peak with respect to initial.  15N-labeled benzamide was 
added as an internal standard before NMR analysis.  15N-edited 1H NMR spectra were 
acquired using the HSQC pulse sequence for selection.  The spectra were collected in 





We have explored the effect of pH on the hydrolysis of primary sulfinamides by 
incubating peptide sulfinamides at pH 5-9.  Upon 26 h incubation of the VYPCLA 
sulfinamide, we observed 33, 16, 13 and 14% sulfinamide hydrolysis at pH 5, 6, 7.4 and 9, 
respectively.  Similarly, 46 and 24% hydrolysis is detected upon incubation of the 
glutathione sulfinamide at pH 5 and 7.4 for 26 h, respectively.  These results indicate that 
sulfinamide hydrolysis is more facile at acidic pH values, presumably due to protonation 
of the sulfinamide (Scheme 3-2).  Potentiometric titration studies of the primary 
sulfinamide, t-butanesulfinamide, indicate that its pKa is ~3.9 (Supporting Information), 
consistent with the above results and the reported value of 3-3.5 for secondary 
sulfinamides.50 
3.2.7 Hydrolysis of Sulfinamide-Modified Papain and 
Comparison with Its Model Peptide 
Tertiary structure and local environment are known to have significant effects on 
reactivity.51-53  To determine the extent of sulfinamide hydrolysis in a protein environment, 
we investigated the reactivity of this modification in 15N-AS-treated papain.  Interestingly, 
54% of the sulfinamide was hydrolyzed after 28 h incubation under physiological 
conditions (Figure 3-8), which points to the reaction being significantly faster in the papain 
active site compared to the peptides tested (i.e., VYPCLA (13%) and GSH (28%)).  
Moreover, activity studies conducted with AS-treated papain has shown no significant 
change in papain activity after 28 h incubation, supporting the formation of a sulfinic acid 
(data not shown).   
The active site thiol is contained in the sequence GSCWA (residues 23-27) of 
papain.54  Since variations in the peptide sequence might cause changes in reactivity, a 
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model peptide (AGSCWA) of the papain active site was synthesized.  Upon analyzing the 
extent of hydrolysis in this H15NO-treated hexapeptide, no significant sulfinamide 
hydrolysis was observed after 28 h (Figure 3-8).  These results indicate that the hydrolysis 
reaction is significantly enhanced by the papain environment rather than as a result of the 
specific peptide sequence. 
 
 
Figure 3-8.  Hydrolysis of HNO-derived sulfinamides in papain, AGSCWA, VYPCLA, 
and glutathione (GSH).  Papain (0.2 mM), AGSCWA (0.1 mM), VYPCLA (0.1 mM) and 
GSH (0.2 mM) were treated with 1 mM 15N-AS in 10 mM phosphate buffer with 50 µM 
DTPA (pH 7.4) at 37 oC for 30 min to form the corresponding sulfinamides.  The samples 
were incubated in buffer at 37 oC for 28 h.  The amounts of sulfinamide were normalized 
with respect to that detected in the initial peptide samples (SEM ±5%, n=3). 
  
We used Rosetta to assist in formulating a hypothesis for the mechanism of 
sulfinamide hydrolysis within the papain active site environment.  The crystal structure of 
papain (PDB ID 9PAP), which contains a sulfonate modification on Cys25, was used as a 
template for generating PDB files for the wild type (WT), R sulfinamide, S sulfinamide, 









































variants were minimized and the resulting structures were examined.  In the case of all 
three variants, the oxygen atom bound to sulfur is placed in the oxyanion hole (Gln19) for 
the standard papain reaction (Figure 3-9).  This is similar to the orientation of the sulfonate 




Figure 3-9.  Active site of sulfinamide-modified papain involving (a) R and (b) S 
sulfinamide.  Models were generated using Rosetta software. 
 
The first step in sulfinamide hydrolysis is generally thought to be protonation of 
the sulfinamide oxygen.  In the S sulfinamide structure (Figure 3-9b), the sulfinamide NH2 
can hydrogen bond with His159; in the R sulfinamide structure (Figure 3-9a), the NH2 sits 
at the positively polarized end of an α helix and hydrogen bonds with the backbone of 
Trp26.  Only in the R sulfinamide structure is the catalytic His159 poised to function as a 
general base for deprotonation of water, just as it does in the standard papain reaction.  In 
our hydrolysis product model, Nδ1 of His159 is within hydrogen bonding distance of the 
second oxygen bound to sulfur.  It is also worth noting that the Rosetta score for the product 
(-311.7±4 REU) is lower than either the R or S sulfinamide (-308.05±0.08 and -307.1±0.2 
REU, respectively).  Thus, we propose the following mechanism, shown in Scheme 3-3.  
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The sulfinamide is activated by the partial positive character of the enzymatic oxyanion 
hole and the positive dipole of the α helix and the backbone amide of Trp26.  As in the 
papain enzymatic reaction, His159 deprotonates a water molecule for nucleophilic attack.  
After formation of the sulfurane, solvent-assisted proton transfer occurs, followed by loss 











Using the 15N-edited NMR method we have been able to detect primary 
sulfinamides in organic molecules, peptides, and proteins.  Moreover, analysis of the 
peptide sulfinamides indicates the generation of peptide diastereomers upon sulfinamide 
formation.  The capability to distinguish between stereoisomers makes this a beneficial 
method for sulfinamide detection.  Furthermore, this technique could also be used for the 
detection of N-substituted sulfinamides provided that there is a proton bonded to the labeled 
nucleus. 
We have extended our previous work27 on sulfinamide reactivity to investigate 
further sulfinamide hydrolysis at physiological pH and temperature.  Our results with 
peptide sulfinamides are consistent with our initial findings, indicating that despite being a 
slow reaction, hydrolysis is viable under physiological conditions.  Although the number 
of cases examined to date is limited, the hydrolysis of peptide sulfinamides seems to be 
affected minimally by peptide sequence (e.g. AGSCWA vs. VYPCLA vs. GSH), but 
substantially more by protein environment (e.g. papain); further investigations are 
required.  In addition, the hydrolysis reaction is facilitated at lower pH values similar to 
that observed for secondary sulfinamides and consistent with the generally accepted 
mechanism.17, 26, 28-30  Recent studies point to the potential signaling role of sulfinic acid 
formation in controlling protein function.55-57  Moreover, the reduction of sulfinic acids to 
thiols by an ATP-dependent process is well-established for the peroxiredoxin system.58-60  
The hydrolysis of HNO-derived sulfinamides to sulfinic acids might represent another 
pathway to sulfinic acid formation in proteins. 
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Papain, whose activity depends on a catalytic triad of Cys25, His159 and Asn175, 
is one of the most studied cysteine proteases.47  Our NMR experiments demonstrate 
sulfinamide formation upon HNO treatment, which correlates well with previous 
predictions that the observed inhibition of papain is due to the modification of its single 
free cysteine residue by HNO.21  Further analysis has shown that sulfinamide hydrolysis is 
significantly more efficient in the papain active site compared to small organic molecules27 
and related peptide systems.  These findings are also supported by computational studies, 
which indicate that hydrolysis can be enhanced in papain active site due to activation of 
the sulfinamide and facilitation of nucleophilic attack.       
3.4 Experimental Methods 
Reagents.  Glutathione (GSH), papain, Nα-Benzoyl-L-arginine 4-nitroanilide 
hydrochloride (L-BAPNA), β-mercaptoethanol (BME), t-butanesulfinamide (racemic), N-
ethylmaleimide (NEM), and dithiothreitol (DTT) were of the highest purity available and 
purchased from Sigma (St. Louis, MO).  2-Phenylethanethiol and 2-(bromoethyl)benzene 
were purchased from Acros.  HPLC grade acetonitrile (ACN) was purchased from Thermo 
Fisher Scientific (Rockford, IL).  Dimethyl sulfoxide-d6 (DMSO-d6), 
15N-labeled 
hydroxylamine hydrochloride and 15N-labeled benzamide were purchased from Cambridge 
Isotope Laboratories (Andover, MA).  The syntheses of 2-phenylethanesulfinamide, the 
HNO-donor, Angeli’s salt (Na2N2O3, AS), and the NO-donor (DEA/NO) were carried out 
as previously described.27, 61-63  The 15N-labeled HNO-donor, N-hydroxy-2-
(methylsulfonyl)benzenesulfonamide64 (15N-2-MSPA), was a generous gift from Cardioxyl 
Pharmaceuticals.  Milli Q water was used for all purifications and experiments. 
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Peptide Synthesis and Purification. Synthetic peptides VYPCLA and AGSCWA 
were synthesized on a Symphony Quartet peptide synthesizer (Protein Technologies Inc., 
Tucson, AZ) following Fmoc solid-phase peptide synthesis methods.65  The crude product 
was dissolved in 0.1% trifluoroacetic acid (TFA) and purified by HPLC (Waters HPLC 
equipped with Delta 600 pump system and dual wavelength absorbance detector) on an 
Apollo C18 reverse-phase column using a linear gradient of 5-75% ACN with 0.1% TFA 
over 50 min at room temperature.  Peptide fractions were identified by electrospray 
ionization mass spectrometry (ESI-MS).  Pure fractions were pooled and lyophilized, and 
the purified product was quantified based on the absorbance at 280 nm (280= 1490 M
-1 cm-
1).66  In all cases, peptides were stored at -80 °C in lyophilized form until use.  
Synthesis of 15N-labeled Angeli's salt (15N-AS).  Synthesis of 15N-labeled AS, 
which produces 15N-labeled HNO (H15NO) and unlabeled nitrite (NO2
-), was carried out 
based on a literature procedure by reacting 15NH2OH and isoamyl nitrate in basic 
methanol.67  The purity of 15N-AS was confirmed by comparison of the extinction 
coefficient at 248 nm in 0.01 M NaOH with the literature value (ε248 = 8300 M
-1cm-1).62  
Formation of Sulfinamides by Reaction with HNO.  Organic thiols or thiol-
containing peptides were dissolved in 10 mM sodium phosphate buffer with 50 M of the 
metal chelator, diethylenetriamine pentaacetic acid (DTPA), at pH 7.4 to have a final 
concentration of 0.1 or 0.2 mM and used immediately.  Stock solutions of AS or 15N-AS 
were prepared in 0.01 M NaOH, kept on ice, and used within 15 min of preparation.  Stock 
solutions of 15N-labeled 2-MSPA were prepared in ACN and used within 15 min of 
preparation.  The organic molecules or peptides were incubated with 1 mM AS or 15N-AS 
at 37 °C for 30 min in a block heater.  The samples were then aliquoted, flash-frozen and 
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lyophilized.  Following lyophilization, the samples were re-dissolved in DMSO-d6 for 
immediate NMR analysis. 
For experiments conducted at varied pH's, glutathione sulfinamide was formed by 
incubating GSH with 1 mM 15N-2-MSPA (rather than with AS) at 37 oC for 30 min in pH 
7.4 phosphate buffer due to higher sulfinamide yield obtained.  The samples were prepared 
for NMR analysis as described above. 
Incubations with DEA/NO.  The VYPCLA peptide was dissolved in 10 mM 
sodium phosphate buffer with 50 M DTPA, at pH 7.4 to have a final concentration of 0.1 
mM and used immediately.  Stock solutions of DEA/NO were prepared in 0.01 M NaOH, 
kept on ice and used within 15 min of preparation.  The peptide was incubated with 0.5 
mM DEA/NO at 37 °C for 30 min in a block heater.  (Note that DEA/NO was administered 
at half the concentration of HNO-donors used to account for two equivalents of NO 
production from one equivalent of DEA/NO.)  The samples were then prepared as 
described above for NMR analysis. 
Preparation of NMR Samples for Synthetic Sulfinamides.  Commercially 
available t-butanesulfinamide and synthetic 2-phenylethanesulfinamide were dissolved in 
DMSO-d6 to have a final concentration of 100 and 10 mM.  The samples were analyzed by 
NMR without any further treatment. 
HPLC Analyses of 2-Phenylethanesulfinamide.   All the analyses were 
performed on an Apollo C18 reverse-phase column connected to the HPLC system 
described above.  A linear gradient of 35-80% ACN with 0.1% TFA over 35 min was 
employed at room temperature.  The compounds were followed at 220 nm and peaks were 
assigned based on co-injection with authentic samples. 
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Activation of Papain.  A 0.2 mM papain solution was prepared by dissolving the 
lyophilized enzyme in 10 mM sodium phosphate buffer with 50 M DTPA at pH 7.4.  The 
papain sample was activated by treatment with 1 mM DTT for 30 min at room temperature 
to reconvert its single free cysteine to the sulfhydryl form.  The activated enzyme was then 
desalted with Zeba spin desalting columns to remove excess DTT.  
Generation of Sulfinamide-Modified Papain.  The activated papain in 10 mM 
sodium phosphate buffer with 50 M DTPA at pH 7.4 was immediately incubated with 1 
mM 15N-AS at 37 oC for 30 min to form the 15N-labeled sulfinamide as described above. 
Papain Activity Assay.  An aliquot from the 0.2 mM papain (with or without prior 
AS treatment) in 10 mM sodium phosphate buffer with 50 M DTPA at pH 7.4 was diluted 
into buffer to have a final papain concentration of 8.5 µM.  The activity of papain was 
analyzed by a 20 min spectrophotometric assay using L-BAPNA as the substrate.21 
ESI-MS Analyses of Papain.  An aliquot from the 0.2 mM papain (with or without 
prior AS treatment) in 10 mM sodium phosphate buffer with 50 M DTPA at pH 7.4 was 
lyophilized and purified by HPLC on a Viva C4 reverse-phase analytical column using a 
linear gradient of 5-95% ACN with 0.1% TFA over 80 min at room temperature.68  The 
samples were then analyzed on a Thermo Finnigan LCQ Deca Ion Trap Mass Spectrometer 
fitted with an electrospray ionization source, operating in the positive ion mode.  In all 
experiments, the samples were introduced to the instrument at a rate of 10 L/min using a 
syringe pump via a silica capillary line. The heated capillary temperature was 250 °C and 
the spray voltage was 5 kV.  Data analysis and deconvolution were carried out using 
Bioworks 3.2 software. 
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As a control, an aliquot from the papain sample was incubated with 2 mM NEM 
(with or without prior AS treatment) in buffer at 37 oC for 1.5 h.  The samples were purified 
and analyzed by ESI-MS as described above.  
Incubations of Peptides and Proteins in Buffer.  Aliquots of the sulfinamide-
containing samples (in 10 mM sodium phosphate buffer with 50 M DTPA, at pH 7.4) 
were incubated at 37 oC.  Individual aliquots were removed from the samples for analysis 
at certain time intervals, flash-frozen, lyophilized, and prepared for immediate NMR 
analysis as described above.  In all cases, 1 mM 15N-labeled benzamide was added to the 
NMR sample as an internal standard.  In some cases, VYPCLA sulfinamide was incubated 
in the presence of 50 mM BME (as indicated) and the samples were prepared as described 
above for NMR analysis. 
Incubations of Peptides at Varied pH.  Aliquots of the sulfinamide-containing 
samples (in 10 mM sodium phosphate buffer with 212 µM DTPA, at pH 7.4) were adjusted 
to the desired pH by adding 10% H3PO4 or 1 M NaOH while stirring.  The samples were 
incubated at 37 oC.  Individual aliquots were removed from the samples for analysis at 
certain time intervals, re-adjusted to pH 7.4, flash-frozen, lyophilized, and prepared for 
immediate NMR analysis as described above.  In all cases, 1 mM 15N-labeled benzamide 
was added to the NMR sample as an internal standard.    
Potentiometric Determination of t-Butanesulfinamide pKa.  The potentiometric 
titration was adapted from a literature procedure.69  Briefly, commercially available t-
butanesulfinamide was dissolved in 0.05 M KCl to have a concentration of 2 mM.  The 
solution was titrated with either 20 mM NaOH or 20 mM HCl prepared in 0.05 M KCl at 
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room temperature.  The changes in pH were determined using a general purpose 
combination pH probe with a built-in temperature sensor connected to a pH meter.  
NMR Analyses.  All 1H-NMR and 15N-edited 1H 1D-NMR analyses were carried 
out on a Bruker Avance 400 MHz FT-NMR spectrometer at 303 K.  In some cases, spectra 
were collected at temperatures from 303 K to 343 K (as indicated).  15N-edited 1H 1D-
NMR spectra were acquired using the HSQC pulse sequence for selection.  2D-ROESY 
and COSY spectra of the VYPCLA sulfinamide were obtained on a Bruker Avance 600 
MHz FT-NMR spectrometer.  All chemical shifts are reported in parts per million (ppm) 
relative to residual DMSO (2.49 ppm for 1H). 
Active Site Modeling.  The computational studies were conducted by Dr. Jason W. 
Labonte.  Briefly, a Python (v2.7) script was written using the PyRosetta v3.4.0 r53345 
libraries.70  Atom type parameters were added to the Rosetta database for the sp3-
hybridized NH2 group of sulfinamide.  Rosetta residue type parameter files were added for 
cysteine sulfinate and each cysteine sulfinamide stereoisomer.  Ideal bond lengths and 
angles were taken from PDB ID 1ACD and several references.71, 72  The Dunbrack rotamer 
library73 was used to select rotamers for each standard amino acid residue side chain.  Ten 
cycles of side-chain packing followed by steepest descent minimization were performed 
for each protein variant examined using the standard “score12” scoring function.  
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Figure 3-10.  HPLC traces of (a) 2-phenylethanesulfinamide (PE-S(O)NH2) formed via 
treatment of 2-phenylethanethiol (0.25 mM) with AS (1 mM) and (b) synthetic 2-
phenylethanesulfinamide.  The HNO-derived 2-phenylethanesulfinamide was confirmed 
by co-injection with the authentic sample as well as characterization by ESI-MS.  PE-SS-









Figure 3-11.  Selected region of 1H NMR spectrum showing VYPCLA (0.1 mM) (a) 
untreated and (b) treated with 1 mM AS in 10 mM phosphate buffer with 50 µM DTPA 
(pH 7.4) at 37 oC for 30 min.  The spectra were collected in DMSO-d6 at 30 
oC.  The 
chemical shifts were assigned based on the COSY spectra of the unmodified and 








Figure 3-12.  15N-edited 1H 1D-NMR spectra of the VYPCLA sulfinamide at various 
temperatures.  VYPCLA (0.1 mM) was treated with 1 mM 15N-AS in 10 mM phosphate 
buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min to form the corresponding 
sulfinamide.  The sample was analyzed in DMSO-d6 at (a) 30 








Figure 3-13.  Deconvoluted ESI-MS spectra of papain (0.2 mM) (a) untreated or treated 
with (b) 2 mM NEM at 37 oC for 1.5 h, (c) 1 mM AS at 37 oC for 30 min, and (d) 1 mM 
AS at 37 oC for 30 min followed by treatment with 2 mM NEM in 10 mM phosphate buffer 
with 50 µM DTPA.  The samples were analyzed by ESI-MS following HPLC purification 






Figure 3-14.  Previously activated papain (0.2 mM) was incubated in the absence (♦) or 
presence of 1 mM AS (◊) in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC 
for 30 min.  The samples were analyzed by following the absorbance at 405 nm 















































Figure 3-15.  15N-edited 1H NMR spectra of the reduction of HNO-derived VYPCLA 
sulfinamide.  VYPCLA (0.1 mM) was treated with 1 mM 15N-AS in 10 mM phosphate 
buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min to form the corresponding 
sulfinamide.  The sulfinamide-containing sample was incubated in the presence of 50 mM 
BME at 37 oC for 26 h in pH 7.4 buffer.  VYPCLA sulfinamide    (a) before and (b) after 
incubation with BME.  The spectra were collected in DMSO-d6 at 30 
oC.  15N-labeled 






Figure 3-16.  15N-edited 1H NMR spectra of the hydrolysis of HNO-derived VYPCLA 
sulfinamide.  VYPCLA (0.1 mM) was treated with 1 mM 15N-AS in 10 mM phosphate 
buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min to form the corresponding 
sulfinamide.  The sulfinamide-containing sample was boiled for one week in buffer.  
VYPCLA sulfinamide (a) before boiling and (b) after boiling.  The spectra were collected 
in DMSO-d6 at 30 





Figure 3-17.  Titration curve for t-butanesulfinamide (2 mM) treated with 0.02 M HCl or 






Chapter 4 – Reactivity of C-Terminal 
Cysteines with HNO 
4.1 Introduction 
Cysteine residues are known to form several oxidative modifications in the 
presence of reactive oxygen or nitrogen species.1-4  These post-translational modifications, 
including disulfide bonds, sulfinamides, and sulfenic, sulfinic, and sulfonic acids, can 
affect protein structure and function with potential biological impacts.1, 5, 6  Apart from the 
crucial roles of disulfide bonds, recent studies have emphasized the importance of sulfenic 
and sulfinic acids in redox catalysis and cell signaling.3, 7-9  Nitroxyl (HNO), the protonated, 
one-electron reduced form of NO, is a potential therapeutic for several conditions including 
heart failure, alcoholism, vascular dysfunction, and cancer.4, 10-12  Due to the highly 
thiophilic nature of HNO, the majority of its biological effects have been attributed to its 
reactivity with cysteines.4, 12, 13  As shown in Scheme 4-1, HNO reacts with thiols to form 
an N-hydroxysulfenamide intermediate.  This unstable species has been reported to form a 
sulfinamide or a disulfide depending on the concentration of thiol.14, 15  At low thiol 
concentrations, the N-hydroxysulfenamide rearranges to produce a sulfinamide, 
presumably via a reaction pathway, which involves the dehydration of the protonated N-
hydroxysulfenamide to form an alkyliminosulfonium intermediate (RS+=N) followed by 
reaction with water as suggested by computational studies.16  At high thiol concentrations, 





Scheme 4-1.  The reaction of HNO with thiols 
 
To gain insight into the pharmacological effects of HNO, we and others have 
investigated the production of HNO-derived thiol modifications and their consequences on 
protein function.16-34 Previous studies on sulfinamide reactivity indicate that reduction to 
free thiols in the presence of excess thiol and hydrolysis to form sulfinic acids constitute 
the major reactions of sulfinamides at physiological pH and temperature.21-23  We have also 
shown that sulfinamide hydrolysis can be facilitated in the active site of a cysteine protease, 
indicating that HNO-derived modifications can have different reactivities and consequently 
different biological impacts depending on their local environment.22  In addition, recent 
reviews have highlighted the importance of microenvironment on the reaction of HNO with 
thiols.35, 36 
With the aim of learning more about the factors that affect HNO-derived thiol 
modifications, we have further examined the reactivity of HNO with cysteine derivatives 
and cysteine-containing peptides.  These efforts have led to the observation that, regardless 
of the conditions employed, sulfinamide formation does not occur on a C-terminal cysteine 
under physiological conditions.  Mechanistic investigations have pointed to the 





Scheme 4-2.  The reaction of HNO with C-terminal cysteines 
 
4.2 Results and Discussion 
Thiols are considered to be one of the major targets of HNO in biological systems.12, 
13, 35, 37  Consistent with the complicated chemistry of sulfur, the nature and fate of HNO-
derived modifications seem to be affected by factors including thiol concentration and the 
identity of nearby residues.14, 15, 22, 23, 30, 35, 38  To gain more insight into the influence of local 
environment on HNO reactivity, we have explored how the position of the cysteine residue 
affects reactivity.  For this purpose, we have investigated the formation of HNO-derived 





4.2.1 Effect of C-Terminus on HNO-Derived Sulfinamides in 
Cysteine Derivatives 
Our previous studies have shown that several small organic molecule thiols and 
peptides containing internal cysteine residues can be modified to the corresponding 
sulfinamides by employing a thiol to HNO donor ratio of 1:5 or 1:10 under physiological 
conditions.23  We treated N-acetyl-L-cysteine (NAC) with the H15NO donor, 15N-2-MSPA, 
under the same conditions and analyzed the resulting products with our 15N-edited NMR 
sulfinamide detection method.22  This method involves the application of an isotope filter 
for 15N to achieve selective detection of protons attached to the 15N nuclei, providing 
simplified NMR spectra.22, 39  Surprisingly, no peaks were detected in the characteristic 
sulfinamide region (5.5 - 6.5 ppm) (Figure 4-1a), but a new peak was observed at 9.53 ppm.  
A similar spectrum was obtained upon treatment of NAC with 15N-AS (Supporting 
Information).  Although a previous study suggests the formation of N-
acetylcysteinesulfinamide from the reaction of NAC and HNO, the product was reported to 
be unstable and could not be structurally characterized.40 
 To determine if the carboxylic acid of the C-terminus affects sulfinamide formation, 
we treated N-acetyl-L-cysteine methyl ester (NAC-E), in which the free carboxylic acid is 
replaced with an ester, with H15NO.  As shown in Figure 4-1b, the corresponding 15N-
labeled sulfinamide signals are now observed.  Consistent with our previous studies, two 
characteristic sulfinamide peaks are detected at 5.89 and 5.94 ppm due to the formation of 
diastereomers.22  Similar results were obtained when HABA was used as the HNO donor 
(Supporting Information).  Control experiments carried out with NAC and NAC-E in the 
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presence of donor byproducts or hydroxylamine did not result in any 15N-edited peaks (data 
not shown), indicating that these observations (Figure 4-1) are due to HNO reactivity.  
 
 
Figure 4-1.  Selected region of 15N-edited 1H NMR spectrum (in DMSO-d6 at 30 
oC) 
showing 15NH signals following the treatment of (a) NAC (0.1 mM) and (b) NAC-E (0.1 
mM) with 15N-2-MSPA (1 mM) in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 
37 oC for 30 min.   
 
4.2.2 Effect of N-Terminus on HNO-Derived Sulfinamides in 
Cysteine Derivatives 
To determine if the free amino group of the N-terminus has a similar effect on the 
production of an HNO-derived sulfinamide, we conducted experiments with L-cysteine and 
L-cysteine ethyl ester, both possessing a free N-terminus.  Consistent with the above results, 
sulfinamide signals (5.76 and 5.90 ppm) were detected with the L-cysteine ethyl ester, but 
not with L-cysteine, indicating that the presence of a free N-terminus does not affect 
formation of the HNO-derived sulfinamide (Figure 4-2a,b).  Similarly, no sulfinamide was 
observed with D-penicillamine, which contains a free C-terminus, upon treatment with 15N-




Figure 4-2.  Selected region of 15N-edited 1H NMR spectrum (in DMSO-d6 at 30 
oC) 
showing 15NH signals following the treatment of (a) L-cysteine (0.1 mM) and (b) L-cysteine 
ethyl ester (0.1 mM) with 15N-2-MSPA (1 mM) in 10 mM phosphate buffer with 50 µM 
DTPA (pH 7.4) at 37 oC for 30 min. 
 
4.2.3 Effect of C-Terminus on HNO-Derived Sulfinamides in 
Peptides 
Given the above results, we next investigated the reactivity of HNO with cysteines 
in the dipeptide system, LC and CL.  No sulfinamide peaks were observed upon analysis of 
H15NO-treated LC by 15N-edited NMR spectroscopy (Supporting Information).  On the 
other hand, treatment of the N-terminal cysteine-containing peptide, CL, with 15N-AS 
produced the corresponding sulfinamide (Supporting Information).  Consistent with these 
observations, reaction of the hexapeptide AAAAAC with 2-MSPA also did not generate a 
sulfinamide (data not shown).  These results suggest that cysteine derivatives and C-
terminal cysteine-containing peptides react similarly with HNO, presumably due to the 




4.2.4 HNO-Derived Modifications of C-Terminal Cysteines 
Since sulfinamides are not observed with C-terminal cysteines, we explored the 
identity of HNO-induced modifications in these systems using the hexapeptide AFAAAC.  
To confirm the reactivity of HNO with this peptide and its methyl ester derivative, we 
initially applied our 15N-edited NMR method (Figure 4-3a,b).  As expected, characteristic 
sulfinamide signals at 5.90 and 5.95 ppm were detected only for the AFAAAC methyl ester 
(Figure 4-3b).  Similar to our results with H15NO-treated NAC (Figure 4-1a), a new peak at 
9.65 ppm was observed in the 15N-edited NMR spectrum of H15NO-treated AFAAAC 
(Figure 4-3a).  As indicated previously, the 15N-edited NMR method detects only protons 
bonded to a 15N nucleus.22, 39  To test if the 9.65 ppm peak was due to residual 15N-2-MSPA, 
we spiked the sample with the standard compound.  As seen in Figure 4-3a, an NMR signal 
for this compound appears at 9.00 ppm.  Additionally, no signal was detected upon exposure 
of 15N-2-MSPA to the same incubation and sample preparation conditions in the absence of 






Figure 4-3.  Selected region of 15N-edited 1H NMR spectrum (in DMSO-d6 at 30 
oC) 
showing 15NH signals following the treatment of (a) AFAAAC (0.1 mM) and (b) AFAAAC 
methyl ester (0.1 mM) with 15N-2-MSPA (1 mM) in 10 mM phosphate buffer with 50 µM 
DTPA (pH 7.4) at 37 oC for 30 min.  In (a) the peak at 9.00 ppm corresponds to the 15NH 
signal of 15N-2-MSPA, which was spiked into the sample. 
 
The reactivity of HNO with AFAAAC was further investigated by ESI-MS (Figure 
4-4a-c).  As shown in Figure 4b, a signal 32 Da heavier than the AFAAAC disulfide (m/z 
1135 vs. 1103), which could correspond to the peptide thiosulfonate (RS(O)2SR) (Scheme 
4-3), is observed as well as less intense signals assigned to sulfinic acid (RSO2H, m/z 585) 
and the AFAAAC disulfide (m/z 1103).  We hypothesize that the thiosulfonate is formed 
from a sulfenic acid-derived thiosulfinate (see below).  Moreover, another intense signal 63 
Da heavier than the unmodified peptide (m/z 616 vs 553) is also detected (Figure 4-4b).  
Two possibilities for this latter signal are a peptide sulfohydroxamic acid 2 or hydroxamic 
acid derivative 3, both of which have the same exact mass (Scheme 4-3).  Since the 
formation of either 2 or 3 requires the addition of a nitrogen-containing species, we 
conducted an analogous experiment with the 15N-labeled HNO donor, 15N-2-MSPA.  The 
+63 Da signal (m/z 616) is now replaced by a +64 Da signal (m/z 617) (Figure 4-4c).  
Notably, no other species were labeled with 15N.  Similar results were obtained with AS 
120 
 
(data not shown), further indicating that these observations are independent of the HNO 
donor used. 
 
Figure 4-4.  Selected region of ESI-MS spectrum showing AFAAAC (0.1 mM) (a) 
untreated or treated with (b) 2-MSPA (1 mM), and (c) 15N-2-MSPA in 10 mM phosphate 
buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min.  Spectra show the peaks for 
unmodified peptide (m/z 553.0 ± 0.1), sulfinic acid (m/z 585.0 ± 0.1, indicated by an 
asterisk (*)), sulfohydroxamic acid 2 or hydroxamic acid derivative 3 (m/z 616.0 ± 0.1), 
disulfide (m/z 1103.3 ± 0.1), dimeric adduct (m/z 1105.1 ± 0.1) (commonly observed by 
mass spectrometry), and thiosulfonate (m/z 1135.3 ± 0.1).  
 
Because the identity of the +63 Da peak could not be determined unambiguously 
from the ESI-MS data alone, we examined the AFAAAC peptide containing a hydroxamic 
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acid group at the C-terminal by 1H NMR spectroscopy.  In contrast to the HNO-treated 
AFAAAC sample, this peptide did not show any peaks at 9.65 ppm upon NMR analysis 
(data not shown), suggesting that the 9.65 ppm peak does not correspond to 3 and is likely 
due to sulfohydroxamic acid 2 (see Scheme 4-6 and text below for a detailed discussion). 
 
 
Scheme 4-3.  Thiosulfonate and sulfohydroxamic/hydroxamic acid species 
 
4.2.5 HNO-Derived Modifications of C-Terminal Cysteines 
under Anaerobic Conditions 
HNO is known to react with molecular oxygen to form an as of yet unidentified 
HNO-O2 adduct which can react as an oxidant.
41, 42  To understand whether the observed 
reactivity with C-terminal cysteines is due to HNO or the HNO-O2 adduct, we incubated 
the AFAAAC peptide with 2-MSPA under argon-saturated conditions.  As expected, control 
samples exposed to the same sample preparation procedures in the absence of 2-MSPA 
remained unchanged (Figure 4-5a).  For HNO-treated samples, identical products were 
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obtained under air or argon-saturated conditions (Figures 4-4b and 4-5b), indicating that the 
observed modifications are independent of oxygen.  
 
 
Figure 4-5.  Selected region of ESI-MS spectrum showing AFAAAC (0.1 mM) (a) 
untreated, or treated with (b) 2-MSPA (1 mM) in 10 mM phosphate buffer with 50 µM 
DTPA (pH 7.4) at 37 oC for 30 min under argon-saturated conditions.  Spectra show the 
peaks for unmodified peptide (m/z 553.0 ± 0.1), sulfinic acid (m/z 585.0 ± 0.1, indicated 
by an asterisk (*)), sulfohydroxamic derivative 2 (m/z 616.0 ± 0.1), disulfide (m/z 1103.3 
± 0.1), dimeric adduct (m/z 1105.1 ± 0.1) (commonly observed by mass spectrometry), and 
thiosulfonate (m/z 1135.3 ± 0.1). 
 
4.2.6 Formation of Thiosulfonate 
To gain further evidence for the production of a thiosulfonate, we also examined the 
HNO-treated AFAAAC samples by a standard DTNB assay.  As expected, no free thiol is 
detected following HNO treatment.  Subsequent incubation with excess DTT results in the 
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recovery of ca. 65% of the total thiol content (data not shown), suggesting the presence of 
reducible (65%) and not-readily reducible (35%) species. 
In addition, reaction of HNO-treated AFAAAC with thiophenol was examined by 
ESI-MS.  Consistent with the known reactivity of thiosulfonate with thiols (Scheme 4-4),43 
the m/z 1135 signal completely disappeared following a short (20 min) incubation with thiol 
at room temperature.  In addition to the peptide sulfinic acid and mixed disulfide (expected 
from thiol reduction of the thiosulfonate), the sulfohydroxamic acid 2 is still observed at 
m/z 616 under these conditions (Figure 4-6).  No significant changes were detected in the 
ESI-MS spectrum following a similar, short incubation in the absence of thiol.  Based on 
these results, the sulfohydroxamic acid 2 (and peptide sulfinic acid formed from the 
reduction of peptide thiosulfonate) may correspond to the non-reducible species observed 
in the above DTNB assay.  
 
 




Figure 4-6.  Selected region of ESI-MS spectrum showing AFAAAC (0.1 mM) treated 
with 2-MSPA (1 mM) in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 
30 min under argon-saturated conditions.  The samples were incubated for an additional 20 
min at RT (a) without or (b) with 5 mM thiophenol.  Spectra show peaks for the unmodified 
peptide (m/z 553.0 ± 0.1), sulfinic acid (m/z 585.0 ± 0.1, indicated by an asterisk (*)), 
sulfohydroxamic derivative 2 (m/z 616.0 ± 0.1), disulfide (m/z 1103.3 ± 0.1), mixed 
disulfide (m/z 661.0 ± 0.1), and thiosulfonate (m/z 1135.3 ± 0.1).  
 
 Cysteine thiosulfonate is known to be hydrolyzed to form the corresponding sulfinic 
acid and disulfide (Scheme 5).43  To test this reactivity, we incubated HNO-treated 
AFAAAC samples in buffer under physiological conditions for 22 h.  The peptide 
thiosulfonate signal at m/z 1135 disappeared completely and the signals for sulfinic acid and 




Scheme 4-5.  Hydrolysis of cysteine thiosulfonate 
 
 
Figure 4-7.  Selected region of ESI-MS spectrum showing AFAAAC (0.1 mM) treated 
with 2-MSPA (1 mM) in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 
30 min.  The samples were incubated at physiological pH and temperature for 22 h.  Spectra 
show the peaks for sulfinic acid (m/z 585.0 ± 0.1, indicated by an asterisk (*)), 
sulfohydroxamic derivative 2 (m/z 616.0 ± 0.1), disulfide (m/z 1103.3 ± 0.1), and 




4.2.7 Intermediacy of Sulfenic Acid 
The formation of thiosulfonate from the reaction of HNO with C-terminal cysteines 
could be explained by the intermediacy of a sulfenic acid (RSOH) (Scheme 4-6).  As 
mentioned previously, reaction of HNO with thiols results in the formation of an N-
hydroxysulfenamide intermediate (Scheme 4-1).  We hypothesize that in the case of a C-
terminal cysteine, this unstable species can react with the carboxylic acid group to form a 
cyclic intermediate 1 (Schemes 4-2 and 4-6), whose generation has been proposed for the 
bromine-dependent oxidation of cystine to cysteic acid.44  Subsequent hydrolysis of 1 would 
produce a sulfenic acid.45  In the absence of excess thiol or stabilizing factors such as sterics, 
aromaticity, hydrogen bonding or protein environment, sulfenic acids are known to dimerize 
rapidly to form thiosulfinates (Scheme 4-6).46-48  Recent studies indicate that at pH<10, the 
hydrolysis of cysteine thiosulfinates produces cysteine thiosulfonates.43  Moreover, cysteine 
thiosulfonates (RS(O)2SR) have been reported to be more stable at pH<7 and consequently 
become the predominant species at lower pH values.43  Presumably, once the peptide 
sulfenic acid is formed, under our experimental conditions it is converted to the 
corresponding thiosulfinate (RS(O)SR), which is subsequently hydrolyzed to the 
thiosulfonate.  The resulting peptide thiosulfonate (RS(O)2SR) is expected to be stabilized 





Scheme 4-6.  Formation of the observed products 
 
To explore other potential pathways for thiosulfonate formation, we conducted 
several control experiments involving oxidized derivatives of methanethiol or cysteine as 
model systems.  Incubation of cysteinesulfinic acid, methanesulfinic acid, or dimethyl 
disulfide under physiologically-relevant conditions did not generate the corresponding 
thiosulfonates (RS(O)2SR) (data not shown), indicating that simple oxidation is not the 
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origin of this species.  Similarly, no reaction was observed upon incubation of dimethyl 
disulfide with methanesulfinic acid or L-cystine with L-cysteinesulfinic acid (data not 
shown).  These results are consistent with the formation of thiosulfonate via the 
intermediacy of a sulfenic acid. 
Due to the reactive nature of sulfenic acids, they are generally detected by employing 
dimedone-based traps.49-52  Also, recent studies point to the use of benzoxaboroles as 
alternative sulfenic acid traps.53  The use of either class of sulfenic acid trap, however, was 
not feasible due to the reactivity of dimedone-based traps with HNO, as determined by 
headspace GC and 15N-edited NMR analyses, and the direct reactivity of benzoxaborole 
with HNO-donors (Supporting Information).  Moreover, cysteinethiosulfinate and methyl 
methanethiosulfonate were observed to react with dimedone, consistent with recent reports 
(Supporting Information).54 
4.2.8 Formation of Sulfohydroxamic Acid 
As seen in Schemes 4-1 and 4-2, hydroxylamine (NH2OH) is expected to be released 
upon reaction of HNO with excess thiol.  Since hydroxylamine might play a role in the 
generation of sulfohydroxamic acid 2, we looked into its reactivity in buffer with 
methanesulfinate (CH3SO2
-) and methyl methanethiosulfonate (CH3S(O)2SCH3) by 
1H 
NMR.  Although a reaction was observed between hydroxylamine and methyl 
methanethiosulfonate, the product does not correspond to methanesulfohydroxamic acid 
(CH3S(O)2NHOH) (Supporting Information), suggesting that the formation of 2 proceeds 
via a different pathway.  No products were formed upon incubation of methanesulfinate 
with hydroxylamine (data not shown). 
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Previous kinetic studies indicate that sulfinates (RSO2
-) can trap HNO, producing 
sulfohydroxamic acids.55, 56  To test the feasibility of this reaction under the conditions of 
our experiments, we incubated methanesulfinate with the HNO-donors, 2-MSPA and AS 
(Figure 4-8a-b and Supporting Information, respectively).  In both cases, the product was 
determined to be methanesulfohydroxamic acid (CH3S(O)2NHOH) via comparison with an 
independently prepared authentic standard.  Moreover, the corresponding 15NH peak, 
similar to the peak (ca. 9.6 ppm) detected with HNO-treated C-terminal cysteines (Figures 
4-1 and 4-3), is observed upon treatment of methanesulfinate with 15N-2-MSPA (Supporting 
Information).  The downfield shift observed for the NAC (or peptide) sulfohydroxamic acid 
(ca. 9.6 ppm) compared with methanesulfohydroxamic acid (ca. 9 ppm) is presumably due 
to hydrogen-bonding between the sulfohydroxamic acid 15NH and C-terminal carboxylate.  
Indeed, such an interaction is suggested by computational studies (Supporting 
Information).57-59  Since sulfinates are formed upon reduction or hydrolysis of thiosulfonates 
(Schemes 4-4 and 4-5), these results represent a potential pathway to sulfohydroxamic acid 
2 (Scheme 4-6).  Consistent with these results, treatment of methyl methanethiosulfonate 
with either 2-MSPA or AS under the same conditions resulted in the formation of 





Figure 4-8.  Selected region of 1H NMR spectrum showing methanesulfinate (1 mM) 
incubated in 250 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min  (a) 
with or (b) without 2-MSPA (10 mM).  The peak at 2.18 ppm corresponds to 
methanesulfinate.  An asterisk indicates the product (methanesulfohydroxamic acid, 3.06 
ppm) formed due to the reaction of methanesulfinate and HNO.  The small peak at 2.71 ppm 
corresponds to methanesulfonate (commonly observed due to oxidation of 




We have demonstrated that the C-terminal carboxylate influences the nature of 
HNO-derived modifications of C-terminal cysteines.  Unlike the standard end-products 
(sulfinamide and disulfide), the major products are now a thiosulfonate and a 
sulfohydroxamic acid derivative under the conditions of our experiments.  Moreover, the 
formation of these new products takes place independent of oxygen, presumably via the 
intermediacy of a cyclic structure followed by formation of a sulfenic acid (Schemes 4-2 
and 4-6).  To the best of our knowledge, this is the first report of HNO-derived thiol 
modifications involving a sulfenic acid intermediate.  Introduction of a C-terminal ester 
replaces this reactivity with the well-known sulfinamide generation, emphasizing the 
importance of local environment on HNO-induced modifications.  Further investigations 
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are required to determine if similar effects are also produced by adjacent side chain 
carboxylates (e.g., aspartate or glutamate).   
Proteomics studies conducted with cultured mammalian cells suggest that less than 
10% of total protein cysteines are involved in disulfide bond formation, indicating the high 
availability of cysteine residues for modification.60  Although the in vivo relevance of our 
results is yet to be determined, a simple database search reveals several important human 
proteins possessing C-terminal cysteine residues and unmodified carboxylates such as 
guanosine monophosphate reductase-2 (GMPR2), dihydropyrimidine dehydrogenase 
(DPD), elongin C, and sterol 27-hydroxylase (see Supporting Information for a more 
complete list).  Considering the central role of sulfenic acids in cell signaling and redox 
regulation, which may modulate transcription factors, channel activity, and also affect 
phosphorylation, SUMOylation and ubiquitination levels in cells,7, 61, 62 these findings may 
point to new biological and pharmacological properties of HNO. 
4.4 Experimental Methods 
Reagents.  L-cysteine, N-acetyl-L-cysteine (NAC), N-acetylcysteine methyl ester 
(NAC-E), L-cysteine ethyl ester, D-penicillamine, L-cystine, L-cysteinesulfinic acid 
monohydrate, sodium methanesulfonate, S-methyl methanethiosulfonate, 5,5'-dithiobis(2-
nitrobenzoic acid) (DTNB), dithiothreitol (DTT) were of the highest purity available and 
purchased from Sigma (St. Louis, MO).  Dimethyl disulfide, sodium methanesulfinate and 
dimedone were purchased from Acros.  2-(Hydroxymethyl)benzeneboronic acid hemiester 
was purchased from Alfa Aesar (Ward Hill, MA).  Peracetic acid (35%) was purchased 
from FMC Corporation (Philadelphia, PA).  HPLC and MS grade acetonitrile (ACN) were 
purchased from Thermo Fisher Scientific (Rockford, IL).  Dimethyl sulfoxide-d6 (DMSO-
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d6), D2O and 
15N-labeled hydroxylamine hydrochloride were purchased from Cambridge 
Isotope Laboratories (Andover, MA).  The syntheses of HNO donors, Angeli’s salt 
(Na2N2O3, AS),
63 15N-labeled Angeli’s salt (15N-AS),64 and 5-(N-hydroxylamine)-5-
(acetyl-O-methoxyoxime)-N,N-dimethylbarbituric acid (HABA)65 were carried                  
out as previously described.  The HNO donor, N-hydroxy-2-(methylsulfonyl)-
benzenesulfonamide (2-MSPA),66 the 15N-labeled HNO donor, 15N-hydroxy-2-
(methylsulfonyl)benzenesulfonamide (15N-2-MSPA),66 and the donor byproduct, 2-
(methylsulfonyl)benzenesulfinic acid (2-MSSA) were a generous gift from Cardioxyl 
Pharmaceuticals.  Methanesulfohydroxamic acid (CH3S(O)2NHOH) was synthesized 
following a literature procedure.67, 68  The synthesis of cysteine thiosulfinate was carried 
out following a literature procedure and the purity of the product was confirmed by 
electrospray ionization mass spectrometry (ESI-MS).69, 70  Milli Q water was used for all 
purifications and experiments. 
Peptide Synthesis and Purification.  Synthetic peptides AFAAAC, AAAAAC, CL 
and LC were synthesized on a Symphony Quartet peptide synthesizer (Protein 
Technologies Inc., Tucson, AZ) following Fmoc solid-phase peptide synthesis methods.71  
The crude product was dissolved in 0.1% trifluoroacetic acid (TFA) and purified by HPLC 
(Waters HPLC equipped with Delta 600 pump system and dual wavelength absorbance 
detector) on an Apollo C18 reverse-phase column using a linear gradient of 5-75% ACN 
with 0.1% TFA over 50 min at room temperature.  Synthesis of AFAAAC hydroxamic acid 
was carried out by employing hydroxylamine Wang resin and the crude product was 
purified by HPLC in the absence of TFA.  In all cases, peptide fractions were identified by 
ESI-MS.  Pure fractions were pooled and lyophilized, and the purified product was 
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quantified based on the absorbance at 257 nm (257 = 195 M
-1 cm-1) or a DTNB assay.72, 73  
Peptides were stored at -80 °C in lyophilized form until use. 
AFAAAC methyl ester was synthesized following literature procedures.74  Briefly, 
AFAAAC was dissolved in 0.1 M acetyl chloride in methanol to have a final concentration 
of 2 mM and stirred at room temperature for 25 h.  The solvent was then removed under 
vacuum at room temperature in a Savant Speedvac apparatus and the peptide was stored at 
-80 °C until use.  The complete conversion of the peptide C-terminal carboxylic acid to the 
corresponding methyl ester was confirmed by ESI-MS. 
Incubation of Thiols with HNO.  The incubations were carried out as previously 
described.22, 23  Cysteine derivatives or cysteine-containing peptides were dissolved in 10 
mM sodium phosphate buffer with 50 M of the metal chelator, diethylenetriamine 
pentaacetic acid (DTPA), at pH 7.4 to have a final concentration of 0.1 mM and used 
immediately.  Stock solutions of AS or 15N-AS were prepared in 0.01 M NaOH, kept on 
ice, and used within 15 min of preparation.  Stock solutions of 2-MSPA, 15N-2-MSPA, or 
HABA were prepared in ACN and used within 15 min of preparation.  Stock solutions of 
the donor byproducts, NO2
- and 2-MSSA were dissolved in 0.01 M NaOH and ACN/H2O 
(1:1, v/v), respectively.  The cysteine derivatives or cysteine-containing peptides were 
incubated with 1 mM AS, 15N-AS, 2-MSPA, 15N-2-MSPA, or HABA (as indicated) at 37 
°C for 30 min in a block heater.  In all cases, the final volume of ACN did not exceed 1% 
of the total.  As controls, incubations were also carried out with donor byproducts NO2
- and 
2-MSSA under the same conditions.  The samples were then prepared for either ESI-MS 
or NMR analysis. 
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For immediate ESI-MS analysis, the peptides were purified and desalted with C18 
PepClean spin columns, and then diluted into 70% ACN with 0.1% TFA as described 
previously.23  For NMR analysis, the samples were flash-frozen and lyophilized.  Following 
lyophilization, the samples were re-dissolved in DMSO-d6 for NMR analysis as described 
previously.22  
Incubation of Thiols with HNO under Anaerobic Conditions.  Cysteine-
containing peptides were dissolved in pH 7.4 phosphate buffer as described above.  The 
peptide solutions were purged with argon for 30 min prior to incubation with HNO-donors.  
A 0.1 M stock solution of 2-MSPA was prepared in ACN and purged with argon for 10 
min.  The argon-purged 2-MSPA solution was introduced via an air-tight syringe to have a 
final concentration of 1 mM and the samples were incubated at 37 oC for 30 min under 
continuous argon purging.  Following incubation, the samples were purged for an 
additional 30 min at room temperature, opened to air and prepared for immediate ESI-MS 
analysis as described above.  Also, control samples were prepared under the same 
conditions in the absence of 2-MSPA.  
Incubation of Methyl Methanethiosulfonate with Hydroxylamine.  Stock 
solutions of methanesulfinate (CH3SO2
-), methyl methanethiosulfonate (CH3S(O)2SCH3), 
and hydroxylamine were prepared in pH 7.4 phosphate buffer and used within 15 min of 
preparation.  Each oxidized sulfur compound was diluted into 250 mM phosphate buffer 
with 50 µM DTPA containing 10% D2O to have a final concentration of 1 mM.  The 
samples were incubated at 37 oC for 30 min in the presence or absence of 1 mM 




Incubation of Methanesulfinate with HNO-Donors.  Stock solutions of 
methanesulfinate, AS and 2-MSPA, and 15N-2-MSPA were prepared as described above.  
Methanesulfinate was diluted into 250 mM phosphate buffer with 50 µM DTPA containing 
10% D2O to have a final concentration of 1 mM.  The samples were incubated at 37 
oC for 
30 min in the presence or absence of 10 mM AS or 2-MSPA (as indicated).  The samples 
were then immediately analyzed by 1H NMR spectroscopy. 
In some cases, methanesulfinate was diluted into 10 mM phosphate buffer with 50 
µM DTPA to have a final concentration of 0.1 mM and the samples were incubated at 37 
oC for 30 min in the presence of 15N-2-MSPA (as indicated).  The samples were then flash-
frozen and lyophilized.  Following lyophilization, the samples were re-dissolved in DMSO-
d6 for NMR analysis as described above.    
Incubation of HNO-Donors with Dimedone and Benzoxaborole.  Stock solution 
of 15N-2-MSPA was prepared as described above.  Stock solutions of dimedone were 
prepared in DMSO.  Dimedone was diluted into 10 mM phosphate buffer with 50 µM 
DTPA at pH 7.4 to have a final concentration of 0.5 mM.  The sample was then incubated 
with 15N-2-MSPA (1 mM) at 37 oC for 30 min.  Following lyophilization, the samples were 
analyzed by NMR spectroscopy.    
Stock solution of AS and 2-MSPA were prepared as described above.  HNO-donors 
(9 mM) were incubated with benzoxaborole (2-(hydroxymethyl)benzeneboronic acid 
hemiester) (9 mM) in 250 mM phosphate buffer with 50 µM DTPA at pH 7.4 containing 
10% D2O at 37 
oC for 30 min.  As a control, benzoxaborole (9 mM) was incubated in the 
absence of HNO-donors.  The samples were immediately analyzed by 11B NMR 
spectroscopy.   
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DTNB Assay for Quantification of Free Thiol.  Stock solutions of DTT (1 M) 
were freshly prepared in water and used within 15 min of preparation.  AFAAAC was 
incubated with the HNO-donor, 2-MSPA, or its byproduct as described above.  The samples 
were then incubated with 10 mM DTT at 25 oC for 20 min.  Aliquots were taken from each 
sample at various stages and the peptides were desalted with C18 PepClean spin columns 
to remove excess DTT.  The solvent was then removed under vacuum at room temperature 
and the residue was re-dissolved in 10 mM phosphate buffer with 50 M DTPA at pH 8.  
The free sulfhydryl content was immediately determined by DTNB titration.73  The results 
were normalized with respect to the amount of free thiol in the initial sample.  Control 
samples treated with donor byproduct were also analyzed under the same conditions.   
NMR Analyses.  All NMR analyses were conducted on a Bruker Avance-400 FT-
NMR spectrometer operating at 400 and 128 MHz for 1H and 11B, respectively.  1H NMR 
and 15N-edited 1H 1D-NMR analyses were carried out in DMSO-d6 at 303 K.  In some 
cases, 1H NMR spectra were collected in pH 7.4 phosphate buffer with 10% D2O at 298 K 
(as indicated).  Solvent was suppressed by using 1 s pre-saturation pulse.  15N-edited 1H 
1D-NMR spectra were acquired using the heteronuclear single quantum correlation 
(HSQC) pulse sequence for selection.  Chemical shifts are reported in parts per million 
(ppm) relative to residual DMSO (2.49 ppm for 1H) or residual H2O (4.7 ppm for 
1H).  All 
11B NMR experiments were carried out in pH 7.4 phosphate buffer with 10% D2O at 295 
K.  Samples were analyzed in quartz NMR tubes and chemical shifts were referenced to 
Et2O•BF3 (41.6 ppm for 
11B) in CDCl3. 
Computational Analyses.  Calculations were performed using Spartan’14.75  
Following a conformation search on N-acetylcysteine sulfohydroxamic acid using 
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molecular mechanics, the geometry minimum in DMSO was determined by density 
functional theory (DFT) at the B3LYP/6-31G* level with the SM8 solvation model76. 
Mass Spectrometric Analyses.  ESI-MS analysis was carried out on a Thermo 
Finnigan LCQ Deca Ion Trap Mass Spectrometer fitted with an electrospray ionization 
source, operating in the positive ion mode with an accuracy of ca. 0.1 m/z.  In all 
experiments, samples were introduced to the instrument at a rate of 10 µL/min using a 
syringe pump via a silica capillary line.  The heated capillary temperature was 250 °C and 
the spray voltage was 5 kV. 
Nitrous Oxide Quantification by Headspace Gas Chromatography (GC).  To 
determine the reactivity of dimedone with HNO, its dimerization product, nitrous oxide 
(N2O), was analyzed by gas chromatography.  Experiments were performed on a Varian 
CP-3800 instrument equipped with a 1041 manual injector, electron capture detector, and a 
Restek ShinCarbon ST 80/100 molecular sieve packed column.  Grade 5.0 nitrogen was 
used as both the carrier (8 mL/min) and the make-up (22 mL/min) gas.  The injector oven 
and the detector oven were kept at 200 °C and 300 °C, respectively.  All N2O analyses were 
performed with the column oven held constant at 150 °C.  Stock solutions of AS, 2-MSPA, 
and dimedone were prepared as described above.  HNO-donors were diluted into argon-
saturated, pH 7.4 phosphate buffer with 50 µM DTPA to have a final concentration of 0.1 
mM.  The samples were incubated for 3 h at 37 oC in the presence or absence of dimedone 
(0.5 mM) to ensure complete decomposition and equilibration of N2O with the headspace.  
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4.6 Supporting Information 
 
Figure 4-9.  Selected region of 15N-edited 1H NMR spectrum (in DMSO-d6 at 30 
oC) 
showing 15NH signals following the treatment of NAC (0.1 mM) with 15N-AS (1 mM) in 




Figure 4-10.  Selected region of 1H NMR spectrum (in DMSO-d6 at 30 
oC) following the 
treatment of (a) NAC (0.1 mM) and (b) NAC-E (0.1 mM) with HABA (1 mM) in 10 mM 
phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min.  An asterisk indicates the 





Figure 4-11.  Selected region of 15N-edited 1H NMR spectrum (in DMSO-d6 at 30 
oC) 
showing 15NH signals following the treatment of (a) LC (0.1 mM) and (b) CL (0.1 mM) 
with 15N-AS (1 mM) in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 
30 min.  The additional sulfinamide peaks were formed due to the presence of a small 









Figure 4-12.  Selected region of headspace GC chromatogram showing nitrous oxide (the 
dimerization product of HNO) detected upon incubation of HNO-donors (a) 2-MSPA (0.1 
mM) and (b) AS (0.1 mM) in the absence (dashed line) or in the presence of dimedone (0.5 
mM) (solid line) in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 
min under argon-saturated conditions.  The samples were analyzed 2.5 h after the 







Figure 4-13.  Selected region of 11B NMR spectrum (buffer/D2O (90:10) at 25 
oC) showing 
11B signals of benzoxaborole (9 mM) (a) untreated or treated with (b) AS (9 mM), and (c) 






Figure 4-14.  Selected region of 1H NMR spectrum showing cysteine thiosulfinate (1 mM) 
incubated in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at room temperature for 
30 min (a) with or (b) without dimedone (5 mM).  The peaks at 0.90 and 2.04 ppm 
correspond to dimedone.  An asterisk indicates the product formed due to the reaction of 





Figure 4-15.  Selected region of 1H NMR spectrum showing methyl methanethiosulfonate 
(1 mM) incubated in 10 mM phosphate buffer with 50 µM DTPA (pH 7.4) at room 
temperature for 30 min (a) with or (b) without dimedone (5 mM).  The peaks at 0.90 and 
2.04 ppm correspond to dimedone.  An asterisk indicates the product formed due to the 
reaction of methyl methanethiosulfonate and dimedone.  The spectra were collected in 




Figure 4-16.  Selected region of 1H NMR spectrum showing methyl methanethiosulfonate 
incubated in 250 mM phosphate buffer with 50 µM DTPA (pH 7.4) at room temperature for 
30 min  (a) with or (b) without hydroxylamine.  The peaks at 3.36 and 2.61 ppm correspond 
to methyl methanethanethiosulfonate.  An asterisk indicates the product formed due to the 
reaction of methyl methanethiosulfonate and hydroxylamine.  The spectra were collected in 





Figure 4-17.  Selected region of 1H NMR spectrum showing methanesulfinate incubated in 
250 mM phosphate buffer with 50 µM DTPA (pH 7.4) at 37 oC for 30 min (a) with or (b) 
without Angeli’s salt (AS).  The peaks at 2.18 ppm corresponds to methanesulfinate.  An 
asterisk indicates the product formed due to the reaction of methanesulfinate and HNO.  The 
small peak at 2.71 ppm corresponds to methanesulfonate (commonly observed due to 




Figure 4-18.  Selected region of (a) 1H NMR and (b) 15N-edited 1H 1D-NMR spectrum 
showing 15NH signals of methanesulfohydroxamic acid formed by treating 
methanesulfinate (0.1 mM) with 15N-2-MSPA (1 mM) in 10 mM phosphate buffer with 50 
M DTPA (pH 7.4) at 37 oC for 30 min.  (c) 1H NMR spectrum showing NH signal of 
standard methanesulfohydroxamic acid.  The spectra were collected in DMSO-d6 at 30 




Figure 4-19.  Minimized geometry of the NAC sulfohydroxamic acid (in DMSO) 
determined by DFT (B3LYP/6-31G* with the SM8 solvation model) calculations showing 
the expected hydrogen bonds.  
Cartesian Coordinates (Angstroms) 
   Atom                     X                      Y                        Z  
 
 1   N  N           1.6410817        -0.1966512        -0.0476324 
 2   C  CA         0.6412091         0.4862651        -0.8368662 
 3   C  C            0.0821551         1.7128707        -0.1034166 
 4   O  O          -0.1435467         1.7740196         1.0929205 
 5   H  H           1.3709170        -1.0498755         0.4295358 
 6   H  HA        1.1052174         0.8639202        -1.7530937 
 7   C  CB       -0.4790085        -0.4635550        -1.3004796 
 8   S   SG       -1.3913631        -1.4019737        -0.0194647 
 9   H  1HB    -1.2340987          0.0733097        -1.8782897 
10  H  2HB    -0.0562486         -1.2481264        -1.9364213 
11  O  O1       -0.4265083         -2.0450127         0.8911381 
12  O  O2       -2.4063607         -2.1935068        -0.7190537 
13  N  N1       -2.2431244         -0.2917155         0.9863717 
14  H  H1       -1.5580665          0.3484629         1.4050244 
15  O  O3       -3.0640705          0.5553538         0.1724186 
16  H  H2       -3.9280208          0.1091791         0.2041968 
17  O  O4       -0.1846099          2.7204921        -0.9586481 
18  H  H3       -0.5955974          3.4390132        -0.4399152 
19  C  C1         2.8210567          0.4201349         0.2484061 
20  O  O5        3.0769038          1.5522214        -0.1745440 
21  C  C2        3.7899318         -0.3947576         1.0740018 
22  H  H6        3.2841394         -1.0811049         1.7598057 
23  H  H5        4.4251999         -0.9915765         0.4092132 
24  H  H4        4.4346871          0.2772401         1.6435470 
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Table 4-1.  Some C-terminal cysteine-containing proteins with free carboxylate 
Proteins 
Acid-sensing ion channel 2 
Actin filament-binding protein frabin 
Werner helicase-interacting protein 1 
B-cell lymphoma 6 protein 
Cbp/p300-interacting transactivator 1 
Complement component C1q receptor 
CST complex subunit CTC1 
Dihydropyrimidine dehydrogenase 
Glutathione S-transferase omega-2 
GMP reductase 2 
Interferon-induced, double-stranded RNA-activated protein kinase 
L-xylulose reductase 
Macrophage colony-stimulating factor 1 receptor 
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 
Nuclear receptor coactivator 3 
Period circadian protein homolog 3 
Protein lin-54 homolog 
Differentiation-related gene 1 protein 
Solute carrier organic anion transporter family member 1B1 
Double-stranded RNA-binding protein Staufen homolog 1 
Sterol 26-hydroxylase, mitochondrial 
Structural maintenance of chromosomes protein 4 
Syntaxin-5 (isoform 3) 
Elongin-C 




Chapter 5 – Study of HNO Reactivity with 
Tryptophan 
5.1 Introduction 
HNO (nitroxyl) is the protonated, one-electron reduced form of NO, with its own 
important biological and pharmacological properties.1-3  It has received significant 
attention due to its positive inotropic/lusitropic effects in normal and failing hearts, making 
it a potential heart failure therapeutic.4, 5  Moreover, we and others have shown that HNO 
targets several proteins involved in Ca2+ cycling.6-9  Recent reviews also highlight the 
possible benefits of HNO in conditions such as vascular dysfunction, cancer, and 
alcoholism.2, 3  Thiols constitute one of the major biological targets of HNO.3, 10, 11  
Although HNO and NO are redox siblings, the thiol reactivity of HNO differs significantly 
from that of NO and normally results in the formation of a disulfide or a sulfinamide 
depending on the concentration of thiol (Scheme 5-1).10, 11  Additionally, recent reports 
point to the nitrosative role of HNO in generating N-nitrosoindole species (Scheme 5-2).12, 
13  Although HNO-derived N-nitrosotryptophan (TrpNO) formation might be important in 
HNO pharmacology, information about this reactivity is scarce.  
  
 





Scheme 5-2.  Reaction of HNO with tryptophan13 
 
5.2 Results and Discussion 
To gain more insight into HNO reactivity, we have investigated TrpNO formation 
in the presence of a nearby cysteine residue.  For this purpose, we used the synthetic peptide 
AGSCWA, which involves the active site sequence of the cysteine protease, papain, as 
well as several of its variants (CGSAWA, ACSAWA, AGCAWA, AGSAWC, GSAWCA, 
and AGSAWA).  The small molecule N-acetyl-L-tryptophan was also employed for 
comparison. 
As seen in Figure 5-1, treatment of the non-cysteine-containing peptide, 
AGSAWA, with different HNO-donors (Angeli’s salt (AS) or N-hydroxy-2-
(methylsulfonyl)benzenesulfonamide (2-MSPA)) at physiological pH and temperature 
results in the formation of the corresponding TrpNO-containing peptides (m/z 591) (Figure 
5-1a-c).  Due to the reported instability of TrpNO species to mass spectrometry 
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conditions,14 electrospray ionization mass spectrometry (ESI-MS) data could be obtained 
only at relatively low temperatures (110 oC).  Upon treatment of the sample with the HNO-
donor byproducts (nitrite or 2-(methylsulfonyl)benzenesulfinic acid (2-MSSA)) no TrpNO 
species are detected.  Also, the use of a 15N-labeled HNO-donor, 15N-2-MSPA, provides 
the corresponding Trp15NO-containing peptide (m/z 592) (Figure 5-1d).  Similarly, the 
characteristic TrpNO peak was observed by UV-visible spectroscopy at 335 nm upon 
incubation of N-acetyl-L-tryptophan with the HNO donor, 2-bromo-N-
hydroxybenzenesulfonamide (2-BrPA)15 under the same conditions (data not shown).  
These results are consistent with previous reports suggesting the formation of HNO-
derived TrpNO,12, 13 and demonstrate that this modification is not specific to AS, but also 





Figure 5-1.  Selected region of ESI-MS spectra showing AGSAWA (0.3 mM) (a) untreated 
or treated with (b) 1 mM AS, (c) 1 mM 2-MSPA, and (d) 1 mM 15N-2-MSPA in 10 mM 
phosphate buffer with 50 M DTPA (pH 7.4) at 37 oC for 30 min.   
 
To assess the feasibility of an HNO-derived tryptophan modification in the vicinity 
of a free thiol, we treated the peptides containing both a tryptophan and a cysteine residue 
with different ratios of HNO-donor in 10 mM phosphate buffer with 50 M metal chelator 
at pH 7.4 (Figure 5-2).  The amount of thiol in the unmodified peptide samples was found 
to be similar based on a standard 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) assay (data 
not shown).16  Following a 30 min-incubation with AS at physiological pH and 




TrpNO is observed in all peptides upon treatment of 10-fold excess or equimolar 
amount of HNO-donor.  As expected, the percent yield of TrpNO is significantly higher in 
the presence of excess HNO-donor (ca. 24% vs ca. 3%) (Figure 5-2 and Supporting 
Information).  Side-by-side control experiments conducted with the AS byproduct, nitrite, 
did not produce any TrpNO peaks in either case (data not shown).  Comparisons with N-
acetyl-L-tryptophan and AGSAWA indicate that although similar TrpNO yields are 
obtained for the samples in the presence of excess AS, the TrpNO yields are lower in 
cysteine-containing peptides upon treatment with an equimolar amount of AS (Figure 5-
2).  These results suggest that the reaction of HNO with tryptophan is approximately 1-2 
orders of magnitude slower than the corresponding reaction with cysteine.  It should also 
be noted that no significant TrpNO modification was observed under anaerobic conditions, 
consistent with previous reports (data not shown).13   
 
 
Figure 5-2.  Percent yield of N-nitrosotryptophan (TrpNO) observed upon incubation of 
N-acetyl-L-tryptophan (Ac-Trp) or synthetic peptides with 10-fold excess ((□), 
[tryptophan]=0.1 mM, [AS]=1 mM) or equimolar ((■), [tryptophan]=0.3 mM, [AS]=0.3 
mM) amounts of HNO-donor in 10 mM phosphate buffer with 50 M DTPA (pH 7.4) at 
37 oC for 30 min.  The percent yield of TrpNO was determined by UV-visible spectroscopy 
with respect to the amount of tryptophan in the control samples (SEM ± 6%, n≥2).  
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Since HNO is known to be very thiophilic (Scheme 5-1), the extent of HNO-derived 
cysteine modifications in the above samples was determined by a DTNB assay.  As seen 
in Figure 5-3, treatment of the cysteine and tryptophan-containing peptides with equimolar 
amounts of AS results in the complete depletion of thiols, indicating that all cysteine 
residues are modified to the corresponding sulfinamide or disulfide species.  Consistent 
with these results, no free thiol is detected following incubation of the peptides with excess 
HNO-donor (data not shown).  Importantly, comparable quantities of free thiol are 
observed in the untreated and nitrite-treated samples, suggesting that the depletion in thiol 
is due to HNO treatment (Figure 5-3).  Overall, these results reveal that cysteine is more 
reactive towards HNO than tryptophan. 
 
 
Figure 5-3.  Standard DTNB analyses of peptides (0.3 mM) initially (□), or following 
treatment with nitrite ((▨), 0.3 mM) and AS ((■), 0.3 mM) in 10 mM phosphate buffer 
with 50 M DTPA (pH 7.4) at 37 oC for 30 min.  The amounts of free thiol were normalized 
with respect to that detected in the initial peptide samples. 
 
Since cysteines were found to be completely modified upon HNO treatment, all the 
TrpNO-containing peptides are also expected to carry an HNO-derived cysteine 
modification.  To gain more insight about the products formed, we first analyzed the 
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peptide samples with our 15N-edited nuclear magnetic resonance (NMR) method for 
sulfinamide detection.18  In this method, application of an isotope filter for 15N allows the 
selective detection of protons attached to the 15N nuclei and provides simplified NMR 
spectra.18, 19  Consistent with the expected reactivity of HNO, the corresponding 
sulfinamides are observed for all cysteine-containing peptides upon treatment with 10-fold 
excess H15NO-donor (Supporting Information),10, 11, 20 except for AGSAWC, which has a 
C-terminal cysteine and possesses an atypical reactivity, which we have recently examined 
in detail.21  With the use of an internal standard, 15N-labeled benzamide, the approximate 
relative yields of sulfinamides were estimated; they follow the order 
AGSCWA≈GSAWCA>ACSAWA>AGCAWA>CGSAWA. 
To investigate the presence of doubly modified-peptides, we examined HNO-
treated AGSCWA and CGSAWA by ESI-MS.  These results indicate that HNO-induced 
TrpNO modification is observed on both sulfinamide and disulfide-containing peptides 
(Figure 5-4 and Supporting Information).  Further studies are required to determine if 
TrpNO formation has a preference for either one of these thiol modifications.  Treatment 




Figure 5-4.  Selected region of ESI-MS spectra showing CGSAWA (0.1 mM) treated with 
(a) nitrite (1 mM) and (b) AS (1 mM) in 10 mM phosphate buffer with 50 M DTPA (pH 
7.4) at 37 oC for 30 min.  The peaks were assigned to the unmodified peptide (m/z 593.9 ± 
0.1), peptide sulfinamide (m/z 624.9 ± 0.1), peptide sulfinamide carrying a TrpNO 
modification (m/z 653.7 ± 0.1), peptide disulfide (m/z 1185.4 ± 0.1), and peptide disulfide 
carrying a TrpNO modification (m/z 1214.1 ± 0.1). 
     
Since TrpNO is known to undergo denitrosation upon incubation with thiols,22-24 
we have also examined the aerobic denitrosation of TrpNO-containing peptides in the 
presence of excess L-cysteine (5 mM).  The observed rates for TrpNO disappearance under 
pseudo-first-order conditions were determined by UV-visible spectroscopy.  Similar results 
(kobs ≈ 8.4 x 10
-4 s-1) were obtained for all TrpNO-containing peptides, indicating the 
presence of a nearby HNO-derived cysteine modification does not have a significant effect 
on denitrosation under these conditions (Table 5-1 and Supporting Information).  
Comparison with kobs for N-acetyl-N-nitroso-tryptophan (ca. 1.2 x 10
-3 s-1), which is in 
agreement with the reported values for glutathione and other nucleophiles,23, 25 
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demonstrates that the observed rates of denitrosation are slightly slower for peptide 
samples examined (Table 5-1), potentially due to steric hindrance.23  Under aerobic 
conditions, the kinetic behavior of HNO-derived N-acetyl-N-nitrosotryptophan is the same 
as the synthetic standard (data not shown), with the observed rates reaching a limiting value 
in the presence of ca. 1 mM L-cysteine, consistent with the literature.22, 23, 25, 26 
 
Table 5-1.  Observed rates for denitrosation of HNO-derived N-nitrosotryptophan species 




kobs x 104 (s-1)
b kobs x 104 (s-1)
c  
Ac-Trp 12 ± 0.1 5.3 
AGSAWA 7.9 ± 0.1 4.8 
CGSAWA 9.2 ± 0.1 6.7 
ACSAWA 9.3 ± 0.2 N/A 
AGCAWA 8.0 ± 0.4 N/A 
AGSCWA 8.1 ± 0.5 5.0 
AGSAWC 8.9 ± 0.6 4.8 
GSAWCA 7.7 ± 0.3 4.5 
aThe HNO-derived N-nitrosotryptophan samples were treated with excess L-cysteine (5 
mM) at physiological pH and temperature.  The observed rates are reported as mean ± SEM 
(n = 2). 
bData were collected under aerobic conditions.   
cData were collected under argon-saturated conditions.  The observed rates are reported as 
single values. 
 
Consistent with the suggested role of oxygen,23 the observed rates for denitrosation 
of all TrpNO-containing peptides were slower (ca. 5.2 x 10-4 s-1) upon treatment with 5 
mM cysteine under anaerobic conditions (Table 5-1).  It should also be noted that, the 
observed rates for denitrosation in the absence of L-cysteine were increased slightly under 
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argon-saturated conditions (ca. 3.3 x 10-4 s-1 vs. ca. 1.7 x 10-4 s-1).  By monitoring the 
observed rates of denitrosation of HNO-derived N-acetyl-N-nitrosotryptophan as a 
function of L-cysteine concentration (0-10 mM), the second-order rate constant for the 
reaction of N-acetyl-N-nitrosotryptophan with L-cysteine (kcys) can be estimated from the 
pseudo-first-order equation kobs = ko + kcys[cysteine], where ko is the rate of N-acetyl-N-
nitrosotryptophan decay in the absence of L-cysteine.  This analysis (Figure 5-5) gives 
kcys=5.8 x 10
-2 M-1 s-1 under argon-saturated conditions. 
 
 
Figure 5-5.  Observed rates of denitrosation of HNO-derived N-acetyl-N-
nitrosotryptophan as a function of L-cysteine concentration in 10 mM phosphate buffer 




In summary, the observation of TrpNO formation with different HNO-donors 
confirms that this modification of tryptophan is due to HNO reactivity.  We have examined 
HNO reactivity with tryptophan in peptides in the presence or absence of a nearby cysteine 
residue.  Our results confirm the highly reactive nature of cysteine towards HNO compared 
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with that of tryptophan.  Consequently, in the presence of cysteine, excess HNO is required 
for significant amounts of TrpNO formation. 
5.4 Experimental Methods 
Reagents.  N-acetyltryptophan was of the highest purity available and purchased 
from Advanced Chemtech.  L-cysteine and 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) 
were of the highest purity available and purchased from Sigma (St. Louis, MO).   HPLC 
grade acetonitrile (ACN) was purchased from Thermo Fisher Scientific (Rockford, IL).  
Dimethyl sulfoxide-d6 (DMSO-d6) and 
15N-labeled hydroxylamine hydrochloride were 
purchased from Cambridge Isotope Laboratories (Andover, MA).  The syntheses of HNO 
donors, Angeli’s salt (Na2N2O3, AS),
27 15N-labeled Angeli’s salt (15N-AS),28 and 2-bromo-
N-hydroxybenzenesulfonamide (2-BrPA),15 were carried out as previously described.  The 
HNO donor, N-hydroxy-2-(methylsulfonyl)benzenesulfonamide (2-MSPA), the 15N-
labeled HNO donor, 15N-hydroxy-2-(methylsulfonyl)benzenesulfonamide (15N-2-MSPA), 
and the donor byproduct, 2-(methylsulfonyl)benzenesulfinic acid (2-MSSA), were 
generous gifts from Cardioxyl Pharmaceuticals.  As a standard, N-acetyl-N-
nitrosotryptophan was independently synthesized and characterized following a literature 
procedure.22  Milli Q water was used for all purifications and experiments. 
 Peptide Synthesis and Purification. Synthetic peptides AGSAWA, CGSAWC, 
ACSAWA, AGCAWA, AGSCWA, AGSAWC and GSAWCA were synthesized on a 
Symphony Quartet peptide synthesizer (Protein Technologies Inc., Tucson, AZ) following 
Fmoc solid-phase peptide synthesis methods.29  The crude product was dissolved in 0.1% 
trifluoroacetic acid (TFA) and purified by HPLC (Waters HPLC equipped with Delta 600 
pump system and dual wavelength absorbance detector) on an Apollo C18 reverse-phase 
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column using a linear gradient of 5-75% ACN with 0.1% TFA over 50 min at room 
temperature.  Peptide fractions were identified by electrospray ionization mass 
spectrometry (ESI-MS).  Pure fractions were pooled and lyophilized, and the purified 
product was quantified based on the absorbance at 280 nm (280= 5500 M
-1 cm-1).30  In all 
cases, peptides were stored at -80 °C in lyophilized form until use.   
Incubation of Indoles with HNO.  N-acetyl-tryptophan and tryptophan-containing 
peptides were dissolved in 10 mM sodium phosphate buffer with 50 M of the metal 
chelator, diethylenetriamine pentaacetic acid (DTPA), at pH 7.4 to have a final 
concentration of 0.1 or 0.3 mM (as indicated) and used immediately.  Stock solutions of 
AS or 15N-AS were prepared in 0.01 M NaOH, kept on ice, and used within 15 min of 
preparation.  Stock solutions of 2-MSPA or 15N-2-MSPA were prepared in ACN and used 
within 15 min of preparation.  Stock solutions of the donor byproducts, NO2
- and 2-MSSA 
were dissolved in 0.01 M NaOH and ACN/H2O (1:1, v/v), respectively.  N-acetyl-
tryptophan or tryptophan-containing peptides were incubated with 0.3 or 1 mM AS, 15N-
AS, 2-MSPA, or 15N-2-MSPA (as indicated) at 37 °C for 30 min in a block heater.  In all 
cases, the final volume of ACN did not exceed 1% of the total volume.  As controls, 
incubations were also carried out with donor byproducts NO2
- and 2-MSSA under the same 
conditions.  The samples were then analyzed based on the absorbance at 335 (ε335 = 6100 
M-1 cm-1)17 or prepared for ESI-MS analysis.  For immediate ESI-MS analysis, the peptides 
were purified and desalted with C18 PepClean spin columns, and then diluted into 70% 
ACN with 0.1% TFA as described previously.20 
 In some cases, the samples were purged with argon for 30 min prior to incubation 
with HNO-donors.  A 0.1 M stock solution of AS was purged with argon for 5 min.  The 
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argon-purged AS solution was introduced via an air-tight syringe to have a final 
concentration of 1 mM and the samples were incubated at 37 oC for 30 min under 
continuous argon purging.  Following incubation, the samples were opened to air and 
analyzed by UV-visible spectroscopy.  Also, control samples were prepared with NO2
- 
under the same conditions.  
 DTNB Assay for Quantification of Free Thiol.  Tryptophan-containing peptides 
were dissolved in 10 mM sodium phosphate buffer with 50 M DTPA at pH 7.4 to have a 
final concentration of 0.3 mM and incubated with 0.3 mM AS as described above.  Aliquots 
were taken at various time intervals and the free sulfhydryl content was immediately 
determined by DTNB titration.16  The results were corrected for the amount of free thiol in 
the initial sample and normalized with respect to the initial.  As a control, the samples were 
also incubated with NO2
- under the same conditions and analyzed. 
 Incubation of N-Nitrosotryptophan-Containing Samples with L-Cysteine.  N-
acetyl-tryptophan and tryptophan-containing peptides (0.1 mM) were incubated with AS 
(1 mM) to form the corresponding TrpNO-containing species as described above.  The 
samples were then incubated in the presence or absence of L-cysteine (5 mM) in pH 7.4 
phosphate buffer at 37 oC and the reaction was followed by UV-visible spectroscopy at 335 
nm in kinetics mode for 1 h.  In all cases, spectra were recorded at 180 s intervals. 
 In some cases, following the generation of TrpNO-containing species with HNO, 
the samples were purged with argon for 5 min, and the spectrophotometric analyses were 
carried out under argon upon addition of excess L-cysteine (as indicated).  To determine 
the second-order rate constant, HNO-derived N-acetyl-N-nitrosotryptophan was incubated 
with varying concentrations (0-10 mM) of L-cysteine under argon-saturated conditions.  In 
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all cases, the kinetic traces fit to a single-exponential decay.  The second-order rate constant 
was determined by plotting the observed rates against the concentration of excess L-
cysteine. 
Mass Spectrometric Analyses.  ESI-MS analysis was carried out on a Thermo 
Finnigan LCQ Deca Ion Trap Mass Spectrometer fitted with an electrospray ionization 
source, operating in the positive ion mode with an accuracy of ca. 0.1 m/z.  In all 
experiments, samples were introduced to the instrument at a rate of 10 µL/min using a 
syringe pump via a silica capillary line. The heated capillary temperature was 110 °C and 
the spray voltage was 5 kV. 
NMR Analyses.  All 1H-NMR and 15N-edited 1H 1D-NMR analyses were carried 
out on a Bruker Avance 400 MHz FT-NMR spectrometer.  1H NMR and 15N-edited 1H 1D-
NMR analyses were carried out in DMSO-d6 at 303 K.  
15N-edited 1H 1D-NMR spectra 
were acquired using the HSQC pulse sequence for selection.  Chemical shifts are reported 
in parts per million (ppm) relative to residual DMSO (2.49 ppm for 1H). 
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5.6 Supporting Information 
 
Figure 5-6.  Selected region of UV-visible spectra showing AGSCWA (0.1 mM) treated 
with AS (1 mM) (-) and nitrite (1 mM) (--) in 10 mM phosphate buffer with 50 M DTPA 










Figure 5-7.  Selected region of 15N-edited NMR spectrum showing AGSCWA (0.1 mM) 
treated with AS (1 mM) in 10 mM phosphate buffer with 50 M DTPA (pH 7.4) at 37 oC 






Figure 5-8.  Selected region of ESI-MS spectra showing AGSCWA (0.1 mM) treated with 
(a) nitrite (1 mM) and (b) AS (1 mM) in 10 mM phosphate buffer with 50 M DTPA (pH 
7.4) at 37 oC for 30 min.  The peaks were assigned to the unmodified peptide (m/z 594.1 ± 
0.1), peptide sulfinamide (m/z 625.0 ± 0.1), and peptide disulfide (m/z 1185.5 ± 0.1).  The 
peak labeled with asterisk (*) was assigned to the peptide sulfinamide carrying a TrpNO 








Figure 5-9.  Representative kinetic trace at 335 nm showing the denitrosation of HNO-
derived AGSCWA N-nitrosotryptophan in the presence of excess L-cysteine (5 mM) in 




Chapter 6 – Effects of HNO on 
Phospholamban and Its Interaction with 
Sarco(endo)plasmic Reticulum Ca2+-ATPase 
6.1 Introduction 
Congestive heart failure is an abnormality, which frequently involves reduced 
cardiac contractility and slowed muscle relaxation.1, 2  A common component of treatment 
of heart failure often involves the use of vasodilators such as NO donors which serve 
mainly to enhance relaxation.3  Recently, HNO donors have been shown to augment 
contractility and accelerate relaxation in both normal and failing hearts.4-7 
Several studies have suggested that the biological effects and reactivity of HNO are 
distinct from those of NO.5, 6, 8, 9  In the case of cardiac function, NO acts via a cGMP signal 
transduction pathway by means of activating soluble guanylate cyclase, which results in 
increased cGMP levels.10  On the other hand, it has been determined that HNO acts 
independent of both cGMP and cAMP pathways.6, 11 
Cardiac function is regulated by varying the cytosolic calcium ion concentration in 
heart muscle cells (Figure 6-1).  The trigger for cardiac muscle contraction is a large (ca. 1 
M) cytosolic concentration of Ca2+ and the signal for contraction is a roughly 90% drop 
in the Ca2+ concentration.  These concentration fluctuations are achieved in part by the 
release and capture of Ca2+ ions by the sarco(endo)plasmic reticulum (SR).  In humans, 
greater than 70% of cytosolic Ca2+ is pumped into the SR by SR Ca2+-ATPase (SERCA2a). 
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The lumenal Ca2+ is released back into the cytosol by Ca2+-release channels (Ryanodine 
Receptors; RyRs).12 
 
Figure 6-1.  Cardiac Signaling Pathways.  Adapted from MacLennan, D. H., and Kranias, 
E. G. (2003) Phospholamban:  A crucial regulator of cardiac contractility, Nature Rev. Mol. 
Cell Biol. 4, 566-577. 
 
The SERCA pump is located in the SR within muscle cells and has three major 
isoforms, SERCA1-3.13  It plays a key role in smooth, cardiac, and skeletal muscle 
relaxation.13  SERCA2a is the predominant isoform found in cardiac muscle.12  It is a 110 
kDa integral membrane protein with three cytoplasmic domains (N, A and P) and one 
transmembrane domain (M).14  SERCA2a pumps two Ca2+ into the SR per ATP 
hydrolyzed.13 
Phospholamban (PLN) is a 52 amino acid transmembrane protein that is located in 
the SR.  PLN is associated with SERCA2a, and depending on its phosphorylation state, 
regulates the activity of SERCA2a.12, 15, 16  In the dephosphorylated state, PLN functionally 
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couples with SERCA2a resulting in the inhibition of SERCA2a activity and the reduction 
of both cardiac relaxation rates and contractility.17  This inhibition is relieved by 
phosphorylation of PLN.12 
PLN is phosphorylated by protein kinase A (PKA), which is part of the -
adrenergic pathway (Figure 6-1).  The signal-transduction is initiated by the release of 
adrenaline and other -agonists into the blood.12  The binding of a -agonist to the -
adrenergic receptor results in the stimulation of cyclic adenosine monophosphate (cAMP) 
formation by adenylate cyclase.  The increase in the cytosolic levels of cAMP affects the 
activity of PKA, which carries out the phosphorylation of PLN.17 
Sequence analysis of PLN has shown that the 6.1 kDa protein is organized in three 
domains:  cytosolic domain Ia (residues 1-20), cytosolic domain Ib (21-30) and domain II 
(31-52), which traverses the membrane.18  Domain Ia is a cytosolic helical region 
containing Ser 16, the site of phosphorylation by PKA.19  Despite this cytosolic 
phosphorylation, studies have shown that the inhibition of SERCA2a is due to the 
interaction of the transmembrane region of PLN and SERCA2a.20  Thus, it is suggested 
that the interaction between PLN cytosolic domain Ia and SERCA2a is not inhibitory, but 
phosphorylation in this domain results in a conformational change that disrupts the 
inhibitory transmembrane interaction.  
In the SR membrane or in sodium dodecyl sulfate (SDS) gels, PLN exists as an 
equilibrium mixture of a homopentamer and a monomer.21, 22  Based on site-directed 
mutagenesis studies, it has been concluded that PLN-PLN and PLN-SERCA2a interactions 
are on opposite faces of the PLN transmembrane helix and that the PLN homopentamer is 
stabilized by hydrophobic interactions.  Since mutations favoring PLN monomer result in 
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superinhibition of SERCA2a, it is suggested that the PLN monomer is the inhibitory 
species.23 
Previous work by Paolocci et al. has demonstrated that HNO enhances cardiac 
sarcoplasmic reticulum Ca2+ cycling without affecting the overall Ca2+ reserve in the 
system.11  Based on their Ca2+ uptake experiments, the authors conclude that HNO 
stimulates Ca2+ uptake by a mechanism that could involve direct targeting of SERCA2a or 
the relief of phospholamban inhibition by HNO.  Furthermore, they have shown that HNO 
improves Ca2+ release by stimulating RyR2 in isolated rodent myocytes and reconstituted 
in lipid bilayers.11 
To gain more insight into the mechanisms underlying the improvement of Ca2+ 
cycling by HNO, we have investigated the effects of HNO on the PLN/SERCA2a system 
in collaboration with Dr. Nazareno Paolocci (Division of Cardiology, Johns Hopkins 
Medical Institutions, and Department of Clinical Medicine, University of Perugia), Dr. 
James E. Mahaney (Department of Biochemistry, Virginia Polytechnic Institute and State 
University, and Edward Via Virginia College of Osteopathic Medicine), and the late Dr. 
Jeffrey P. Froehlich (Division of Cardiology, Johns Hopkins Medical Institutions, and 








6.2 Effects of HNO on Phospholamban 
Previous work has demonstrated that HNO activates SERCA2a in isolated murine 
cardiomyocytes.11  Moreover, this effect was also observed in isolated murine heart SR 
vesicles, indicating that it is independent of -adrenergic pathway.4, 11  Activity studies 
were conducted with SERCA2a expressed in the presence or absence of PLN in High Five 
(HF) insect cell microsomes to study SERCA2a stimulation by HNO.   
Recent work with expressed Ca2+ pump proteins suggests that activation of the 
cardiac SR Ca2+ pump following the relief of PLN inhibition involves changes in the kinetic 
behavior of the Ca2+-ATPase consistent with SERCA2a oligomerization.24  These changes 
include stabilization of the ADP-sensitive phosphoenzyme, E1P, and allosteric activation 
of dephosphorylation by ATP, resulting in increased turnover of the ADP-insensitive 
phosphoenzyme, E2P.  Expression of SERCA2a without PLN in HF insect cells activates 
E2P turnover.24 
Treatment of co-expressed SERCA2a and PLN with 0.25 mM of the HNO donor, 
Angeli’s salt (AS), resulted in acceleration of SERCA2a dephosphorylation.  Moreover, 
this activation of SERCA2a was observed only in the presence of PLN, indicating that 
HNO-induced effects are PLN-dependent.  Similarly, HNO stimulated SERCA2a activity 
in intact wild-type, but not in PLN knock-out SR vesicles.  Consistent with these 
observations, inotropic action of HNO was significantly diminished in PLN knock-out 
myocytes and whole hearts.  These findings point to the importance of PLN in HNO-





6.2.1 Formation of HNO-Derived PLN Dimer 
Based on the known reactivity of HNO, the observed effect of HNO on Ca2+ uptake 
may be due to the modification of PLN thiol residues.  PLN has three cysteine residues 
(36, 41 and 46) all in its transmembrane region.23  According to the proposed helical wheel 
model of PLN pentamer, C36 and C41 are in close proximity in adjacent PLN helices 
(Figure 6-2).25 
 
Figure 6-2.  Helical wheel model of PLN pentamer.  Adapted from Karim, C. B., Stamm, 
J. D., Jones, L. R., and Thomas, D. D. (1998) Cysteine reactivity and oligomeric structures 
of phospholamban and its mutants, Biochemistry 37, 12074-12081. 
                           
Previous research in the Toscano group had produced promising results,26 which 
encouraged us to investigate the effects of HNO on PLN further.  First of all, the aqueous 
(pH 7.4) reactions of HNO (generated via AS) with cysteine, serine, tyrosine, and lysine 
were examined and only cysteine was found to be consumed.  Also SDS-PAGE 
experiments combined with western blotting and immunodetection techniques were 
utilized to observe the effects of HNO on PLN-PLN interactions.   
Treatment of PLN microsomes with 5 mM and above concentrations of AS resulted 
in the formation of a new band, which is attributed to the PLN dimer.  As can be seen in 
185 
 
Figure 6-3, the amount of PLN dimer increases with increasing AS concentration.  
Moreover, boiling the AS-treated samples to convert the pentamer into monomer resulted 
in an increase in the amount of observed dimer, which may point to the generation of dimer 
within the PLN pentamer.  Analogous experiments with the 0-10 mM of the NO donor, 




Figure 6-3.  (a) Effect of HNO generated from AS on PLN dimer formation in HF insect 
cell microsomes with a short (30 s) exposure time.  (b) Visualization of the PLN dimer 
with a prolonged (30 min) exposure time. 
   
To understand if PLN dimer formation can be correlated to the HNO-induced 
activation of SERCA2a in the presence of PLN, we have also employed lower 
concentrations of AS, which were used in the activity studies.  As expected, PLN dimer 
was detected following 0-1 mM AS treatment under the same conditions (Figure 6-3).  
Notably, formation of PLN dimers and tetramers were also observed in intact 
cardiomyocytes and hearts extracts upon treatment with AS. 
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We have also investigated PLN dimer formation using a different HNO-donor, N-
hydroxy-2-bromobenzenesulfonamide (2-BrPA).  Treatment of PLN microsomes with 0-
10 mM AS, resulted in the expected dimer formation (Figure 6-4), suggesting that these 
findings are not specific to AS and can be observed with other HNO-donors.  It should be 
also noted that, in some cases, a small amount of dimer was present in the PLN samples 
before any treatment. 
 
 
Figure 6-4.  Effect of HNO generated from 2-BrPA on PLN dimer formation in HF 
insect cell microsomes with a short (30 s) exposure time.  Lanes (from right) correspond 
to treatments with 10% DMSO, 2-BrPA, decomposed 2-BrPA, and the sulfinic acid, 
decomposition byproduct of 2-BrPA, respectively. 
 
 
As mentioned previously, HNO is known to react with O2 to produce an 
uncharacterized HNO-O2 adduct, which has oxidative properties.
28, 29  To understand if O2 
plays a role in PLN dimer formation, we treated PLN microsomes with AS or 2-BrPA 
under argon.  These results demonstrate that PLN dimer is formed due to HNO reactivity, 
independent of O2 (Figure 6-5).  Moreover, similar yields of the PLN dimer were obtained 
upon treatment with AS under air or argon.  Comparison of the corresponding yields for 2-
BrPA-treated samples have shown that the yields of the PLN dimer were higher in argon-
saturated samples (Figure 6-6), presumably due to slight oxidation of 2-BrPA in the 
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absence of metal chelator, which results in its decomposition via a non-HNO-producing 
pathway, consequently lowering the yield of HNO.30  
 
  
Figure 6-5.  Microsomes containing expressed PLN were diluted to 1 mg/ml (in 0.1 M 
PBS containing 100 M EDTA) and then purged either with argon or compressed air in 
septum-sealed vials.  Aliquots of AS stock solution were added via syringe to the samples 
such that the final concentration of AS was 0, 5 or 10 mM.  After incubating at 37 oC for 
30 min, the samples were again purged with argon or compressed air to remove any gaseous 
reactive nitrogen oxide species that may have formed.  Loading buffer was then added and 





Figure 6-6.  Microsomes containing expressed PLN were diluted to 1 mg/ml (in 0.1 M 
PBS containing 100 M EDTA) and then purged with argon in septum-sealed vials.  
Aliquots of 2-BrPA stock solution were added via syringe to the samples such that the final 
concentration of 2-BrPA was 0, 5 or 10 mM.  After incubating at 37 oC for 30 min, the 
samples were again purged with argon or compressed air to remove any gaseous reactive 
nitrogen oxide species that may have formed.  Loading buffer was then added and the 
samples were subjected to SDS-PAGE analysis.
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To test the involvement of cysteine residues in the formation of the HNO-derived 
PLN dimer, we have employed the null-cysteine mutant of PLN (C36,41,46A-PLN).  
Administration of 0, 1, 5 and 10 mM AS did not result in any dimer formation (Figure 6-
7).  However, these results are difficult to interpret due to the absence of pentamers in these 
species.  Notably, no SERCA2a stimulation was observed upon treatment of microsomes 
containing co-expressed SERCA2a and null-cysteine PLN.  Moreover, cysteine blocking 
experiments using N-ethylmaleimide (NEM)31 has provided further support for the 
involvement of thiol residues in the HNO-induced PLN dimer formation.  When PLN was 
pre-treated with NEM prior to incubation with AS under argon, no PLN dimer was 
observed (Figure 6-8).  These findings are consistent with previous experiments in the 
Toscano group conducted under aerobic conditions.26  Although NEM can scavenge HNO 
to some extent, significant quenching of HNO is not expected under these conditions (see 
Chapter 7.1.1).  Overall, our results indicate the importance of cysteine residues in HNO-
derived modification of PLN. 
 
 
Figure 6-7.  Insect cell microsomes containing expressed null-cysteine PLN were diluted 
to 1 mg/ml (in 0.05 M PBS at pH 7.4) and incubated with varying concentrations of AS for 
30 min at 37 oC.  After the addition of loading buffer, the samples in the indicated lanes 






Figure 6-8.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml (in 
0.1 M PBS containing 100 M EDTA at pH 7.4) and treated with varying concentrations 
of NEM at room temperature for 1 h.  The samples were then purged with argon in septum-
sealed vials.  Aliquots of AS stock solution were added via syringe to the samples such that 
the final concentration of AS was 0, 10 or 50 mM.  After incubating at 37 oC for 30 min, 
the samples were again purged with argon to remove any gaseous reactive nitrogen oxide 
species that may have formed.  Loading buffer was then added and the samples were boiled 
for 10 min prior to SDS-PAGE analysis.
 
  
As mentioned previously, HNO generally reacts with thiols to form a disulfide or a 
sulfinamide (Scheme 2-1).  To gain more insight into the nature of HNO-induced effects 
on PLN, we have investigated its reversibility.  Prior studies in the Toscano group have 
revealed that the HNO-induced PLN dimer can be completely reduced by tris(2-
carboxyethyl)phosphine (TCEP).26  Moreover, we have shown that the dimer is reduced 
upon treatment with the thiol-based reducing agent, dithiothreitol (DTT), in a 
concentration-dependent manner (Figure 6-9).  Although less efficient, reduction of the 
dimer by -mercaptoethanol (BME) was also observed.  Our results indicate that PLN 
monomer can be recovered following 30 min incubation with reducing agents.  
Remarkably, these results were reproduced in cardiomyocytes and heart extracts.  
Similarly, exposure of HNO-treated SERCA2a and PLN-containing microsomes to DTT 




Figure 6-9.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml (in 
0.05 M PBS at pH 7.4) and treated with 0.25 mM AS at 37 oC for 30 min.  The samples 
were then incubated in the presence or absence of indicated amount of DTT at room 
temperature for 1 h. Following the incubation, loading buffer was added and the samples 
were subjected to SDS-PAGE analysis.
 
Despite the lack of reactivity observed following treatment of t-butanesulfinamide 
with DTT or TCEP at room temperature for 12 h, presumably due to steric reasons, our 
detailed studies on the reduction of sulfinamides at physiological pH and temperature have 
revealed that small organic molecule, peptide, and protein sulfinamides can be reduced 
back to free thiols in the presence of excess thiol (Chapter 2).  Similar experiments 
conducted with a model sulfinamide, 2-phenylethanesulfinamide, have demonstrated the 
reduction of the corresponding sulfinamide with TCEP.  Although the time frames of 
sulfinamide and disulfide reductions are significantly different (Chapter 2), our studies 
have also shown that the reactivity of HNO-derived modifications are dependent on protein 
environment (Chapter 3).  Moreover, mutation of key leucine and isoleucine residues in 
PLN transmembrane domain have been shown to destabilize the PLN pentameric structure, 
thus reducing the PLN pentamer/monomer ratio and increasing inhibition of SERCA2a.32-
34  Therefore, the presence of a potential sulfinamide modification, which could either 
disturb the functional coupling between PLN and SERCA2a directly, or by stabilizing PLN 
dimer, could not be eliminated.    
Based on these findings, the potential modifications on PLN are an intermolecular 
disulfide, an intramolecular disulfide, and/or a sulfinamide (Figure 6-10).  Although the 
cysteine residues in PLN do not seem to be positioned to facilitate an intramolecular 
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disulfide linkage, recent reports highlight the existence of forbidden disulfide bonds 
between i and i+5 residues in -helices of various proteins.35  Consequently, an HNO-
derived intramolecular disulfide modification involving PLN Cys36-Cys41 or Cys41-
Cys46 might be a plausible option.  Moreover, formation of an intramolecular disulfide 
bond could distort the conformation of PLN, thus perturbing its functional coupling with 




Figure 6-10.  Potential HNO-induced modifications on PLN:  inter- or intramolecular 
disulfide, and/or sulfinamide formation. 
 
Our current data seem to indicate that HNO promotes intermolecular disulfide bond 
formation between PLN monomers, presumably formed within the PLN pentamer.  The 
presence of an intermolecular disulfide linkage would result in the formation of PLN 
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oligomers at the expense of PLN monomers, decreasing the amount of inhibitory PLN 
species.  Moreover, recent studies have shown that a missense mutation (R9C) in PLN’s 
cytoplasmic region increases the stability of the PLN pentamer, precluding its interaction 
with SERCA2a.36 
6.2.2 Synthesis and Reconstitution of wt-PLN and Its Single 
Cysteine Variants  
To obtain high purity PLN samples in large quantities, we synthesized wild-type 
PLN and its single cysteine variants (C36,41A-PLN, C36,41A-PLN, and C41,46A-PLN) 
using our department's automated peptide synthesis system following a reported literature 
procedure,37, 38 which involves a modified Fmoc-based solid-phase method (Figure 6-11).  
In this procedure, the major challenges in PLN synthesis (hydrophobicity and length) were 
overcome by employing coupling reactions extended to 6 h as well as using a 
pseudoproline dipeptide (Leu7-Thr8) and a polyethylene glycol-polystyrene resin.  The 











The synthesized protein was purified by HPLC, lyophilized, characterized by 
MALDI-TOF MS (Figure 6-12) and reconstituted into phospholipids (DOPC/DOPE 4:1) 
according to a published procedure (Figure 6-13).37, 39  PLN was determined to be α-helical 
in the non-ionic detergent C12E8, and in phospholipids by circular dichroism spectroscopy 
(Figure 6-13).  The reconstituted PLN was identical to the native PLN on SDS-PAGE, 
forming both monomer and pentamer (Figure 6-13).   
 
 
Figure 6-12.  (a) HPLC spectrum of synthetic PLN (crude).  (b) Silver stained gel showing 
synthetic PLN.  (c) Selected region of MALDI-MS spectrum showing synthetic PLN (m/z 




   
Figure 6-13.  (a) Western blot showing the monomer and pentamer bands for PLN 
reconstituted in phospholipids (DOPC/DOPE 4:1).  Native PLN corresponds to PLN 
expressed in insect cell microsomes.  (b) CD spectrum of PLN reconstituted in 
phospholipids. 
 
6.2.3 Studies to Purify HNO-Treated PLN Monomer and Dimer 
 We have conducted preliminary studies to purify HNO-treated PLN species for 
spectroscopic characterization.  Previous research in the Toscano group as well as our 
initial studies were focused on purifying the PLN monomer and dimer from microsomal 
samples following HNO-treatment.  The strategy involved immunoprecipitation of PLN 
samples with anti-PLN monoclonal antibody (2D12), and isolation of samples by SDS-
PAGE followed by electroelution.  Although we were able to immunoprecipitate both 
monomeric and dimeric PLN species, this method was not convenient due to extremely 
low yields. 
 To increase the yield of purified PLN, we decided to eliminate immunoprecipitation 
and employ synthetic PLN as described above.  Following separation on SDS-PAGE, the 
protein was extracted from the gel by electroelution.  It should be noted that size and 
hydrophobicity precluded the passive elution of either intact PLN (6.1 kDa) or the peptide 
containing its transmembrane region (3 kDa) upon in-gel digestion.  Moreover, 
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electroelution of PLN could only be achieved upon addition of 0.02% SDS to electroelution 
and soaking buffers. 
 Since characterization techniques such as mass spectrometry (MS) require the 
removal of detergents prior to analysis, we explored feasible methods to remove SDS from 
the PLN sample.  Due to the hydrophobicity of PLN, precipitation of the sample by acetone 
was not feasible.  Moreover, washing the lyophilized PLN sample with water or 
employment of dialysis methods were not sufficient to remove protein-bound SDS as 
determined by a methylene blue assay.40  Approximately 10-fold decrease in SDS was 
achieved by two consecutive applications of a modified chloroform/methanol/water 
extraction41, but unfortunately, this was accompanied by ca. 50% loss in PLN.  
6.2.4 Preliminary Studies to Investigate PLN by Mass 
Spectrometry 
Mass spectrometry of PLN is extremely challenging due to the very low ion yields 
stemming from its hydrophobic nature.  We have attempted to solve this issue via several 
different approaches and conditions.  Since intact PLN is more soluble and easier to handle 
compared with its transmembrane region, initially we followed a top-down strategy.  
Briefly, we employed matrix-assisted laser desorption ionization mass spectrometry 
(MALDI-MS) either in linear or reflectron modes, and used several matrices and spotting 
techniques.  Moreover, we prepared various concentrations of PLN (0.005-5 mg/ml) in 
methanol or methanol/chloroform solutions containing trifluoroacetic acid (0.025-1%) or 
formic acid (1-20%).  Best results were obtained with 0.5 mg/ml PLN (in methanol 
containing 0.025% TFA), -cyanohydroxycinnamic acid and the dried-droplet method in 
linear mode.  Although we were able to detect pure, intact, full-length PLN by MALDI-
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MS, the signal to noise was not sufficient to study modifications (Figure 6-12).  It should 
be also noted that preliminary efforts to analyze PLN with reflectron in-source decay 
MALDI-MS resulted in random fragmentation of the protein rather than providing any 
useful sequence information. 
 Since we obtained promising spectra with the PLN peptide, Gln22-Leu52, we 
explored digestion of PLN using the serine proteases, Staphylococcus aureus protease V8 
(Glu-C) and trypsin.  Glu-C selectively cleaves peptide bonds C-terminal to Glu and 
remains active even in the presence of 20% methanol.  Also, it is known to cleave at Asp 
at a rate approximately 100-300 times slower than at Glu.  PLN has only one cleavage site 
(Glu19) for Glu-C, producing peptides with molecular weights 2284.6 and 3859.8 g/mol.  
Preliminary studies to digest PLN with various concentrations of Glu-C in the presence or 
absence of an MS-compatible detergent were not successful, presumably due to PLN 
aggregation during the long incubation (19 h) in 20 mM ammonium acetate buffer 
containing 20% methanol.  Similar results were obtained with trypsin.  
Although there might be other strategies and conditions to be explored, these 
studies indicate that utilization of mass spectrometry techniques for studying PLN are very 
challenging and inconvenient due to the extremely hydrophobic nature of this protein.  Not 






6.3 Effects of HNO on the Interaction of Phospholamban and 
SERCA2a  
As mentioned previously, HNO-induced of SERCA2a activation as well as the 
enhanced myocardial contractility and relaxation are PLN-dependent.  To elucidate the 
effect of HNO on SERCA2a-PLN interaction, we have employed co-immunoprecipitation 
and SDS-PAGE experiments. 
Initially we treated co-expressed SERCA2a and PLN with HNO, and analyzed the 
samples by SDS-PAGE and western blotting.  Visualization of the bands by an anti-PLN 
antibody revealed that the HNO-derived PLN dimer can be observed in the presence of 
SERCA2a.  Moreover, no bands corresponding to a SERCA-PLN heterodimer were 
detected in the presence or absence of HNO treatment, suggesting the lack of a covalent 
interaction between SERCA2a and PLN under either condition.  It should be noted that 
reported literature demonstrates the detection of this heterodimer by the anti-PLN antibody 
upon treatment of the proteins with cross-linking agents.42  
We employed co-immunoprecipitation experiments to determine if HNO 
physically dissociates PLN from SERCA2a, and consequently removes the PLN inhibition 
on SERCA2a by decreasing the amount of PLN-bound SERCA2a.  As seen in Figure 6-14 
this procedure involves precipitation of co-expressed SERCA2a and PLN microsomes with 
anti-SERCA2a antibody, which pulls down both PLN-bound and unbound SERCA2a.  
Following SDS-PAGE and western blotting, the samples are visualized with anti-PLN 









Figure 6-14.  Co-immunoprecipitation procedure for co-expressed SERCA2a and PLN. 
 
Co-immunoprecipitation of samples in the presence or absence of prior HNO 
treatment revealed that the relative fraction of PLN associated with SERCA2a is effectively 
unchanged (Figure 6-15).  These results indicate that PLN remains physically associated 
with SERCA2a upon exposure to HNO, in accordance with literature suggesting that PLN 
remains bound to SERCA even though inhibition is relieved.16, 43, 44  Moreover, analysis of 
the co-immunoprecipitated samples without boiling prior to SDS-PAGE led to the 
observation of PLN oligomers independent of HNO treatment (Figure 6-15).  Consistent 
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with a recent co-crystallization study,43 these observations point to a potential physical 
interaction between PLN oligomers and SERCA2a.  It should be noted that although we 
have also attempted to perform the co-immunoprecipitation in the reverse order (i.e., 
precipitation with anti-PLN antibody (2D12) and visualization with anti-SERCA2a), these 
efforts were unsuccessful due to the disruption of SERCA2a/PLN complex in the presence 




Figure 6-15.  Microsomes containing co-expressed SERCA2a and PLN were treated with 
0, 2.5, or 5 mM AS.  Samples were co-immunoprecipitated with monoclonal anti-
SERCA2a antibody.  The immunoprecipitates were eluted by incubating the samples at (a) 
37 oC, (b) by boiling.  The proteins were detected by monoclonal anti-PLN antibody 
(2D12).  (c) The bar graph showing the total amount of PLN associated with SERCA2a, is 
the average of triplicate experiments. 
 
The influence of HNO on the SERCA2a/PLN interaction was explored further 
using fluorescence spectroscopy in collaboration with the Mahaney group.  These studies 
have shown that HNO alleviates PLN inhibition of SERCA2a [Ca2+]-dependent 
conformational flexibility, with a concomitant increase in SERCA2a activity.46  Moreover, 
these effects were observed only in the presence of PLN.  Similarly, electron paramagnetic 
resonance (EPR) spectroscopy analyses demonstrated an increase in SERCA2a rotational 
mobility upon HNO treatment only in the presence of PLN.46  These findings are attributed 
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to the changes in the size of the rotating unit, stemming from relief of PLN inhibition on 
SERCA2a by HNO, and consequent oligomerization of the pump.  This behavior is also 
consistent with functional uncoupling of PLN from SERCA2a via PKA-induced PLN 
phosphorylation.15 
Overall, our results indicate that HNO functionally uncouples PLN from 
SERCA2a, although the physical association remains.  Moreover, the lack of PKA in the 
microsomal systems confirms that this effect is independent of PKA-induced 
phosphorylation of PLN. 
6.4 Conclusions 
  Collaborative studies have shown that HNO activates Ca2+ uptake by SERCA2a in 
a PLN-dependent manner.  The lack of HNO effect in the absence or blockage of PLN 
cysteine residues, and the reversible nature of this modification by thiol-based reducing 
agents or TCEP suggest that PLN cysteine residues are targets of HNO.  Our SDS-PAGE 
experiments indicate the formation of HNO-induced PLN oligomers in microsomal 
samples, isolated cardiomyocytes, and heart extracts.   
Based on the known chemisty of HNO,47-49 the potential modifications of PLN are 
an intermolecular disulfide, an intramolecular disulfide, and/or a sulfinamide (Figure 6-
10).  Our current data imply the formation of an intermolecular disulfide bond between 
PLN monomers, presumably formed within the PLN pentamer, resulting in a decrease in 
the amount of inhibitory PLN monomer.  However, further studies are required to 
determine the exact nature and location of HNO-derived modification(s) on PLN. 
Our co-immunoprecipitation studies indicate that PLN remains physically 
associated with SERCA2a upon HNO treatment.  Combined with kinetic and spectroscopic 
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studies investigating the effects of HNO on the SERCA2a/PLN interaction, we conclude 
that HNO functionally uncouples PLN from SERCA2a, presumably by affecting PLN 
oligomerization.  The studies conducted in isolated cardiomytes and whole hearts confirm 
the central role of PLN in HNO-induced effects on myocardial contractility and 
relaxation.46  Moreover, this effect is independent of PKA-induced phosphorylation of 
PLN, as shown by the lack of change in PLN phosphorylation status,46 and suggest that 
PLN function can be modified in a redox-dependent manner that augments cardiac 
contraction and relaxation. 
6.5 Future Directions 
 Considering the role of HNO as a potential heart failure therapeutic, it will be 
important to understand fully the mechanism responsible for HNO-induced effects on the 
SERCA2a/PLN system.  To achieve this, unambiguous characterization of HNO-derived 
modifications on PLN are needed. 
Several studies have employed solution and solid-state NMR techniques to 
investigate the structural topology and dynamics of monomeric and pentameric PLN, its 
interaction with lipids, its regulation of SERCA, and the effect of phosphorylation on PLN 
in lipid bilayer, detergent micelles and organic solvents.38, 50-56  One of the major 
approaches is to utilize 15N uniformly- or selectively-labeled PLN.  
As mentioned previously, the 15N-edited NMR method proved to be a powerful 
technique for the detection of HNO-derived sulfinamides.  Following reconstitution of 
synthetic PLN and its single cysteine variants into dodecylphosphocholine (DPC) micelles, 
which have been typically employed in the solution NMR studies of PLN,52, 54, 55 samples 
can be treated with an 15N-labeled HNO donor and analyzed using the 15N-edited NMR 
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method.  These studies would allow the detection of potential HNO-derived sulfinamides 
on PLN.  Moreover, 15N-edited 1H-1H NOESY experiments may be employed to determine 
the location of H15NO-induced sulfinamide(s) formed in PLN.  Since 1H NMR data are 
available for Cys36 and Cys46 of PLN in the literature,50 we expect the corresponding 
signals to be distinguishable.  Additionally, single cysteine PLN variants can serve as 
standards. 
To gain more insight into the sites of HNO reactivity, formation of the HNO-
induced PLN dimer can be explored in single cysteine PLN variants by SDS-PAGE 
analysis.  Reports indicate the destabilization of the PLN pentamer upon mutation of Cys41 
to Ala.57  Considering the results pointing to the generation of HNO-derived PLN dimer 
within the pentamer, the formation of this species might be affected in C36,41A-PLN and 
C41,46A-PLN.   
 The presence of a potential disulfide bond can be determined by alkylation of the 
H15NO-modified PLN sample with isotopically-labeled, cysteine-specific alkylating agents 
(e.g., iodoacetamide) with or without prior reduction.  In each case, the amount of 
alkylation can be quantified with an internal standard and compared to the amount of 
alkylation in the absence of prior H15NO treatment.  We expect all three cysteines to be 
fully alkylated in the untreated sample. 
As demonstrated in Chapter 2, in lower dielectric constant environments 
sulfinamide reduction by thiols is more facile in a peptide structure compared with a non-
peptide organic molecule.  Moreover, the time-frame for sulfinamide reduction is 
significantly longer than that for disulfide reduction under the same conditions.  The single 
cysteine variants of PLN reconstituted in DPC micelles can also be utilized to study the 
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reactivity of any potentially formed HNO-induced sulfinamide modifications in the 
presence of α-helical structure and hydrophobic environment.  For this purpose, 15N-edited 
NMR experiments can be conducted in the presence or absence of reducing agents 
analogous to our recent ESI-MS and NMR studies involving short peptides.58, 59  
 
6.6 Other Reactivity Studies with Phospholamban and 
Sarco(endo)plasmic Reticulum Ca2+-ATPase 
6.6.1 Preliminary Studies with PLN and C-Nitroso Compounds  
Thiol groups are known to react with C-nitroso compounds.60, 61  Moreover, studies 
indicate that C-nitroso compounds, nitrosobenzene (NB), 1-nitrosoadamantane (NA), 2-
methyl-2-nitrosopropane (MNP) can mimic and act as a more stable version of HNO in 
inhibiting aldehyde dehydrogenase (AlDH) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).62, 63  AlDH was shown to be inhibited by NB, NA, and 2-MNP 
with IC50 values of 2.5, 8.6, and 150 M, respectively.
63  The IC50 value for AS was 
determined to be 1.3M under anaerobic conditions.63  The inhibition of GAPDH was less 
efficient with NB compared with AS (IC50 ≈ 1 mM vs. complete inhibition with 0.1 mM 
AS).62  Although highly toxic, administration of NB has shown in vivo activity towards 
AlDH in rats. 
We have shown that HNO reacts with PLN to form the corresponding dimeric 
species.  To determine if PLN behaves similarly with the C-nitroso compounds, we have 
employed the commercially available NB and MNP.  In solution, both compounds turned 
blue, consistent with the presence of monomeric C-nitroso species.64  Treatment of PLN-
containing microsomes with 5 and 10 mM AS or NB provided similar results, indicating 
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PLN thiols are accessible to NB (Figure 6-16).  Moreover, the extent of PLN oligomer 
formation was the same following 30 min or 2 h incubation at 37 oC (Figure 6-16).  It 
should be also noted that incubation with NB corresponds to a bolus addition of HNO, 




Figure 6-16.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml 
(in 0.05 M PBS at pH 7.4) and incubated with varying concentrations of nitrosobenzene 
(NB) for (a) 30 min or (b) 2 h at 37 oC.  Loading buffer was then added and the samples 
were subjected to SDS-PAGE analysis.
   
To gain more insight into the efficiency of NB, we treated PLN with lower 
concentrations of NB (from 0.1 M to 1 mM).  As shown in Figure 6-17 among the NB 






Figure 6-17.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml 
(in 0.05 M PBS at pH 7.4) and incubated with 0-1 mM nitrosobenzene (NB) for 30 min at 
37 oC.  Loading buffer was then added and the samples were subjected to SDS-PAGE 
analysis.
 
To avoid the highly toxic nature of aromatic C-nitroso compounds, we decided to 
test 1-chloro-1-nitrosocyclohexane (CNCH) and MNP.  Attempts to employ CNCH were 
unsuccessful due to the extremely low solubility of this compound in several solvents.  
Following equilibration of MNP for 1 h under argon-saturated conditions to establish the 
monomer/dimer ratio, PLN was incubated with various concentrations of MNP for 30 min 
or 2 h at 37 oC.  Although no MNP-derived PLN dimer was observed upon 30 min 
incubation, a faint dimer band was detected following 2 h incubation with 10 mM MNP 







Figure 6-18.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml 
(in 0.05 M PBS at pH 7.4) and incubated with varying concentrations of 2-methyl-2-
nitrosopropane (MNP) for (a) 30 min or (b) 2 h at 37 oC.  Loading buffer was then added 
and the samples were subjected to SDS-PAGE analysis.
 
Since only monomeric MNP would be reactive towards thiols, we confirmed the 
monomer/dimer ratio of MNP by UV-visible spectroscopy.  Analyses in buffer and diethyl 
ether showed the percentage of monomeric species to be ca. 77 and 90, respectively.  
Moreover, longer incubation of samples resulted in a decrease in monomeric species.  
Consistent with these observations, MNP (10 mM) with PLN following an overnight 
equilibration did not lead to the formation of PLN dimer.  In accordance with previous 
studies with AlDH,65 our results point to the relatively unreactive nature of MNP towards 
PLN thiols, presumably due to steric hindrance. 
6.6.2 Reactivity of PLN with Peroxynitrite 
Peroxynitrite (ONOO-) is generated from the diffusion-controlled reaction of nitric 
oxide (NO) and superoxide (O2
•-).66, 67  It has a pKa of 6.8 and studies report that ca. 80% 
of ONOO- is in anionic form under physiological conditions.68  Moreover, ONOO- has 
been shown to cross biological membranes via an anion channel, and as ONOOH via 
passive diffusion.69  Major biological targets of ONOO- include metal centers, DNA, lipids, 
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cysteine, tryptophan, tyrosine and methionine residues.68, 70-75  It is also known to result in 
protein fragmentation and formation of protein carbonyls.75  
We have conducted preliminary studies to assess the effect of ONOO- on PLN.  For 
these experiments, we utilized both 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium 
chloride (SIN-1) (Scheme 6-1), an NO and O2
•- donor, and authentic ONOO-.76  SIN-1 has 
a half-life of ca. 40 min under physiological conditions.77, 78  
 
 
Scheme 6-1.  Decomposition of 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride 
(SIN-1) under physiological conditions to generate nitric oxide (NO) and superoxide     
(O2
•-), which react with a diffusion-controlled rate to form peroxynitrite (ONOO-).  Singh, 
R. J., Hogg, N., Joseph, J., Konorev, E., and Kalyanaraman, B. (1999) The peroxynitrite 
generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors, Arch. 
Biochem. Biophys. 361, 331-339.  
 
Treatment of microsomes containing expressed PLN with 5 or 10 mM SIN-1, 
resulted in the formation of PLN dimer (Figure 6-19).  However, it was accompanied by 
significant protein fragmentation (Figure 6-19).  Moreover, the band corresponding to the 
PLN pentamer appeared at a slightly higher molecular weight in the SIN-1-treated samples 
compared with the untreated samples.  Considering the highly reactive nature of ONOO- 
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with several amino acids,70-72, 75 the increase in the molecular weight of the pentamer could 
be attributed to the modification of different PLN residues (Figure 6-19).  It should be also 
noted that no PLN modifications were observed in the absence of SIN-1 decomposition, 
indicating that these effects are due to ONOO- and not SIN-1 or its organic byproduct.26  
As expected, bolus addition of authentic ONOO- produced the same results (Figure 6-20). 
 
 
Figure 6-19.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml 
(in 0.1 M PBS containing 100 M EDTA at pH 7.4) and incubated with varying 
concentrations of 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride (SIN-1) for 3 h 





Figure 6-20.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml 
(in 0.1 M PBS containing 100 M EDTA at pH 7.4) and incubated with varying 
concentrations of authentic peroxynitrite (ONOO-) for 30 min at 37 oC.  Loading buffer 
was then added and the samples were subjected to SDS-PAGE analysis.
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ONOO- is known to react with tyrosine residues to form a dityrosine or a 3-
nitrotyrosine.  Moreover, this reactivity becomes more prominent in the presence of carbon 
dioxide (CO2).  Since ONOO
--derived dityrosine formation could be responsible for the 
generation of PLN dimer, we tested this possibility by blocking PLN cysteines with NEM.  
The lack of PLN dimer reveals that this modification is due to modification of PLN cysteine 
residues rather than tyrosine (Figure 6-21).  Consistent with the involvement of non-
cysteine residues, ONOO--derived increase in the molecular weight of PLN pentamer was 
still observed (Figure 6-21).  Interestingly, increasing concentrations of ONOO- resulted in 
destabilization of PLN pentamer especially in the presence of NEM.  Importantly, 




Figure 6-21.  Insect cell microsomes containing expressed PLN were diluted to 1 mg/ml 
(in 0.1 M PBS containing 100 M EDTA at pH 7.4) and pretreated with 0 or 10 mM NEM 
for 1 h at room temperature.  The samples were then incubated with varying concentrations 
of authentic peroxynitrite (ONOO-) for 30 min at 37 oC.  After the incubation, loading 
buffer was added and the samples were subjected to SDS-PAGE analysis.
 
These initial findings indicate that although ONOO- results in the formation of PLN 
dimer, possibly via its reactivity towards cysteines, the overall impact of ONOO- on PLN 
is significantly different from HNO. 
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6.6.3 Preliminary Studies on the Effects of HNO on 
Sarco(endo)plasmic Reticulum Ca2+-ATPase  
Recent studies have suggested that HNO may directly stimulate SERCA2a activity 
by promoting reversible S-glutathiolation on SERCA2a at Cys674.79  However, the impact 
of this modification on myocyte and heart function, or the simultaneous changes in PLN 
were not explored.79  As mentioned previously, our activity studies indicate the vital role 
of PLN and its cysteine residues in HNO-induced SERCA2a stimulation.  
We have conducted preliminary studies to explore the effects of HNO on 
SERCA2a.  For this purpose, we utilized microsomes expressing SERCA2a.  On SDS-
PAGE gel, wild-type SERCA2a primarily migrates as a monomer.  Previous investigations 
in Toscano group have shown that treatment of SERCA2a with HNO results in a substantial 
decrease in SERCA2a monomer, presumably due to the formation of SERCA2a higher 
oligomers.26  The reactivity of SERCA2a with HNO was also seen in the presence of co-
expressed SERCA2a and PLN samples.  Moreover, this effect was not observed upon 
incubation of SERCA2a with the nitric oxide donor, DEA/NO.26  We have probed the 
decrease in SERCA2a as a function of AS concentration.  As shown in Figure 6-22 the 
amount of SERCA2a monomer diminished upon treatment with AS in a concentration-
dependent manner.  At relatively higher concentrations of AS, presumably, the loss of 




Figure 6-22.  Insect cell microsomes containing expressed SERCA2a were diluted to 1.5 
mg/ml (in immunoprecipitation buffer at pH 7.5) and centrifuged at 12 000 for 5 min.  The 
samples were then incubated with varying concentrations of AS for 30 min at 37 oC.  After 
the incubation, loading buffer was added and the samples were subjected to SDS-PAGE 
analysis.  (a) Selected region of western blot showing SERCA2a monomer incubated in 
the presence or absence of AS.  (b) Graph showing the percentage of SERCA2a monomer 
observed upon HNO treatment.      
 
Treatment of SERCA2a with ONOO- (produced from SIN-1) also resulted in the 
disappearance of the monomer, likely, attributable to the generation of SERCA2a 
oligomers.  Moreover, this behavior was not observed in the absence of SIN-1 








Figure 6-23.  Insect cell microsomes containing expressed SERCA2a were diluted to 1.5 
mg/ml (in immunoprecipitation buffer at pH 7.5) and centrifuged at 12 000 for 5 min.  The 
samples were then incubated with varying concentrations of 5-amino-3-(4-morpholinyl)-
1,2,3-oxadiazolium chloride (SIN-1) for 3 h at 37 oC.  After the incubation, loading buffer 
was added and the samples were subjected to SDS-PAGE analysis. 
 
To examine the role of SERCA2a cysteines in the HNO-derived modification of 
SERCA2a, we blocked the cysteine residues with N-ethylmaleimide (NEM).  Following 
incubation with HNO, no decrease in the amount of SERCA2a monomer was detected in 
NEM-treated samples, indicating the importance of SERCA2a cysteine residues in this 
process (Figure 6-24). 
 
 
Figure 6-24.  Insect cell microsomes containing expressed SERCA2a were diluted to 1.5 
mg/ml (in immunoprecipitation buffer at pH 7.5) and centrifuged at 12 000 for 5 min.  The 
samples were pretreated with 0 or 10 mM NEM for 1 h at room temperature.  The samples 
were then incubated in the presence or absence of 10 mM AS for 30 min at 37 oC.  After 
the incubation, loading buffer was added and the samples were subjected to SDS-PAGE 
analysis.  
 
The reversibility of the HNO-derived modifications on SERCA2a were 
investigated by employing dithiothreitol (DTT) and tris(2-carboxyethyl)phosphine 
(TCEP).  The incubation of the HNO-treated SERCA2a samples with high concentrations 
of DTT or TCEP resulted in the partial recovery of the SERCA2a monomer, consistent 
with the involvement of cysteine residues (Figure 6-25).  It should be also noted that 
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increasing the concentration of reducing agents from 50 to 250 mM did not provide 
complete recovery of the SERCA2a monomer. 
 
 
Figure 6-25. Insect cell microsomes containing expressed SERCA2a were diluted to 1.5 
mg/ml (in immunoprecipitation buffer at pH 7.5) and centrifuged at 12 000 for 5 min.  The 
samples were then incubated in the presence or absence of AS for 30 min at 37 oC.  
Following the incubation, the samples were treated with 50 mM DTT or TCEP.  Loading 
buffer was then added and the samples were subjected to SDS-PAGE analysis.  
 
 
In summary, these findings point to a potential modification(s) of SERCA2a by 
HNO.  However, the impact of these modification(s) on SERCA2a/PLN system as well as 
their physiological relevance requires further investigation.  It should be also noted that a 
major hurdle in studying SERCA2a oligomerization by electrophoresis is the smearing 
observed on the gel, a condition commonly seen with very hydrophobic, high molecular 
weight, membrane/transmembrane proteins.  Although we have been able to observe the 
SERCA2a monomer band clearly, it has not been possible to identify the oligomers due to 
extreme smearing.  Despite our attempts to obtain better resolution by the addition of 8 M 
urea to SDS sample buffer, use of gradient gels, exclusion of heating, or centrifugation of 
samples to remove insoluble materials, we were not able to solve this issue.  To obtain 
more information on SERCA2a oligomerization via electrophoresis techniques, better 





6.7 Experimental Methods 
Reagents.  N-ethylmaleimide (NEM), sodium dodecyl sulfate (SDS), octaethylene 
glycol monododecyl ether (C12E8), t-butanesulfinamide, nitrosobenzene (NB), 2-methyl-2-
nitrosopropane (MNP) dimer, tris(2-carboxyethyl)phosphine (TCEP), and dithiothreitol 
(DTT) were of the highest purity available and purchased from Sigma (St. Louis, MO).  
Bicinchoninic acid (BCA) assay kit, urea, HPLC-grade acetonitrile (ACN), HPLC-grade 
isopropanol (IPA), and trifluoroacetic acid (TFA) were of the highest purity available and 
purchased from Thermo Fisher Scientific (Rockford, IL).  HPLC-grade IPA was further 
purified via distillation.  Anti-PLN monoclonal antibody (2D12) and anti-SERCA2a 
monoclonal antibody were obtained from Affinity Bioreagents (Golden, CO).  Horseradish 
peroxidase-conjugated anti-mouse IgG secondary antibody were purchased from Upstate 
Cell Signaling Solutions (Lake Placid, NY).  Molecular weight marker and polyvinylidene 
fluoride (PVDF) membranes were obtained from Bio-Rad.  Enhanced chemiluminescence 
reagents (ECL Western Blotting Substrate) was purchased from Pierce (Rockford, IL).  
The pseudoproline dipeptide of Fmoc-Leu-Thr (Me,Me Pro)-OH was purchased from 
Novabiochem (San Diego, CA).  The phospholipids, dioleoylphosphatidylethanolamine 
(DOPE) and dioleoylphosphatidylcholine (DOPC), were obtained from Avanti Polar 
Lipids.  The peroxynitrite-donor, 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride 
(SIN-1), was obtained from Calbiochem (San Diego, CA).  The syntheses of HNO-donors, 
Angeli’s salt (Na2N2O3, AS)
73 and 2-bromo-N-hydroxybenzenesulfonamide (2-BrPA),80 
and NO-donor (DEA/NO) were carried out as previously described.  Authentic 
peroxynitrite (ONOO-) was synthesized and characterized following a literature 
procedure.81  High Five insect cell ER microsomes expressing wild-type PLN, null-cysteine 
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PLN (C36,41,46A-PLN), SERCA2a, or co-expressing SERCA2a and PLN were kindly 
provided by Dr. James E. Mahaney (Edward Via Virginia College of Osteopathic 
Medicine). 
Treatment of PLN with HNO-Donors.  High Five insect cell ER microsomes 
expressing wild-type PLN and null-cysteine PLN (C36,41,46A-PLN) were diluted to 0.25, 
0.5 or 1 mg/ml in 0.05 M phosphate-buffered saline (PBS) at pH 7.4 unless otherwise indicated.  
Stock solutions of AS were prepared in 10 mM NaOH and used within 15 minutes.  Stock 
solutions of 2-BrPA were prepared in dimethyl sulfoxide (DMSO) and used within 15 
minutes.  The samples were incubated with varying concentrations of HNO-donor at 37 oC 
for 30 min unless otherwise indicated.  The samples were then diluted with SDS sample 
buffer and analyzed by electrophoresis, western blotting and immunodetection.  For 
experiments involving prolonged exposures for visualization via chemiluminescence, 8 M 
urea was added to SDS sample buffer. 
Treatment of PLN with HNO-Donors under Anaerobic Conditions.  Stock 
solutions of AS and 2-BrPA were prepared as described above and purged with argon.  High 
Five insect cell ER microsomes expressing wild-type PLN were diluted to 1 mg/ml in 0.1 M 
phosphate-buffered saline (PBS) with 100 M EDTA at pH 7.4.  The samples were placed in 
glass vials sealed with rubber septa and purged with argon or compressed air for 4 min.  
Following the introduction of various concentrations of HNO-donor, the samples were incubated 
at 37 oC for 30 min.  After the incubation, the samples were purged with argon for an additional 
3 min to remove any nitrogen oxide species.  The samples were then diluted with SDS sample 
buffer, and analyzed by electrophoresis, western blotting and immunodetection. 
In some cases, PLN was labeled with NEM prior to purging with argon as described 
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below.  Following treatment with HNO-donors under anaerobic conditions, the samples 
were analyzed. 
Treatment of SERCA2a or Co-expressed SERCA2a and PLN with HNO-
Donors.  High Five insect cell ER microsomes expressing wild-type SERCA2a or co-
expressed SERCA2a and PLN were diluted to 1.5 mg/ml in 0.05 M PBS at pH 7.4 or in 
immunoprecipitation buffer ([in mM]: 110 sucrose, 5 Tris-HCl, 75 KCl, 20 HEPES; 150 
NaCl, 1 EDTA, 2  PMSF,  0.5%  Tween 20) at pH 7.5.  In some cases, the samples were 
centrifuged at 12000 rpm at room temperature for 5 min to remove insoluble material.  
Stock solutions of AS were prepared in 10 mM NaOH and used within 15 minutes.  The 
samples were then incubated with varying concentrations of AS at 37 oC for 30 min unless 
otherwise indicated.  The samples were then diluted with SDS sample buffer and analyzed 
by electrophoresis, western blotting and immunodetection. 
Treatment of PLN and SERCA2a with Reducing Agents.  High Five insect cell 
ER microsomes expressing wild-type PLN or SERCA2a were incubated with AS as 
described above.  Stock solutions of DTT and TCEP were freshly prepared in sterilized, 
deionized water.  The samples were incubated with various concentrations of the reducing 
agents for 30 min at room temperature or 37 oC (as indicated).  The samples were then 
diluted with SDS sample buffer and analyzed by electrophoresis, western blotting and 
immunodetection. 
Labeling of PLN and SERCA2a with NEM.  Stock solutions of NEM were 
prepared in sterilized, deionized water.  High Five insect cell ER microsomes expressing 
wild-type PLN or SERCA2a diluted in 0.05 M PBS at pH 7.4 to have a final concentration 
of 0.25, 0.5, 1, or 1.5 mg/ml.  The samples were then incubated with various concentrations 
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of NEM at room temperature prior to treatment with HNO. 
Treatment of PLN or SERCA2a with DEA/NO, SIN-1, Synthetic ONOO-, and 
C-Nitroso Compounds.  High Five insect cell ER microsomes expressing wild-type PLN 
or SERCA2a diluted in 0.05 M PBS at pH 7.4 or in immunoprecipitation buffer ([in mM]: 
110 sucrose, 5 Tris-HCl, 75 KCl, 20 HEPES; 150 NaCl, 1 EDTA, 2  PMSF,  0.5%  Tween 
20) at pH 7.5 to have a final concentration of 0.25, 0.5, 1, or 1.5 mg/ml.  Stock solutions of 
DEA/NO, SIN-1, and NB were dissolved in 0.01 M NaOH, 0.002 M HCl, and DMSO, 
respectively and used within 15 min of preparation.  Stock solutions of MNP were prepared 
in argon-saturated DMSO, and stirred at room temperature for 1 h or overnight (as indicated) 
to establish monomer/dimer equilibrium.  Solutions of ONOO- in ca. 1 M NaOH were used 
immediately following quantification by UV-visible spectroscopy.  PLN or SERCA2a 
samples were then incubated with various concentrations of DEA/NO, SIN-1, synthetic 
ONOO-, or C-nitroso compounds at room temperature or 37 oC for various time intervals 
(as indicated).  To avoid potential photolysis, the incubations with C-nitroso compounds 
were carried out strictly in the dark.  The samples were then diluted with SDS sample buffer 
and analyzed by electrophoresis, western blotting and immunodetection. 
Electrophoresis, Western Blotting and Immunodetection.  SDS-PAGE using 
15% polyacrylamide was performed using standard procedures.82  Samples were either 
loaded directly or boiled for 5 min prior to loading.  Upon separation by gel electrophoresis, 
the proteins were transferred via western blotting onto PVDF membrane.  After blocking 
the membrane with 1% non-fat dry milk for 1 h, it was incubated overnight at 4 oC 
with anti-PLN monoclonal antibody (2D12).  The membrane was washed and incubated 
for 1 h with horseradish peroxidase-conjugated anti-mouse IgG secondary antibody.  
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After washing, the chemiluminescent signals were generated by treating the membrane with 
enhanced chemiluminescence reagents and captured on film following either normal (30 
s) or prolonged (30 min) exposure.  PLN bands (monomer, dimer, pentamer) were assigned 
based on a standard molecular weight marker.  For experiments with prolonged exposure, 
a very weak PLN dimer bands is observed (along with the monomer and dimer bands) prior 
to exposure to AS; the dimer band intensity increases substantially upon exposure to AS.  
All gels and western blots were run using a Bio-Rad Mini-Protean II electrophoresis and 
western blotting system.  The results were quantified by a Bio-Rad GS-670 imaging 
densitometer.  
Synthesis and Purification of PLN.  Full-length phospholamban (PLB) in the 
presence or absence of the N-terminal acetyl cap was synthesized according to a literature 
procedure, which involves a modified Fmoc-based solid-phase method.37, 38  Starting with 
Fmoc-L-Leu-PEG-PS resin (initial loading 0.19 mmol/g), the 52 residue protein was 
assembled in 11 days.  Acidolyzable side-chain protecting groups were 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg; trityl (Trt) for Asn, Gln, His and 
Cys; tert-butyl ester (OtBu) for Glu and Asp; tert-butyloxycarbonyl (tBoc) for Lys; tert-
butyl ether for Ser, Thr and Tyr.  A double coupling protocol was used with a capping step 
following the recoupling as a part of the protocol.  Fmoc removal was achieved with 20% 
piperidine in NMP.  Couplings were performed using 10-fold excess of Fmoc-amino acids 
activated by HBTU/DIEA.  In some cases, the difficulty of the coupling of Leu7 to Thr8 
was overcome by using the pseudoproline dipeptide of Fmoc-Leu-Thr (Me,Me Pro)-OH.  
Also some couplings were achieved by extending the reaction time to 6 h.  The synthesis 
was carried out on a Symphony Quartet peptide synthesizer. 
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Crude PLN was cleaved off the resin using a cleavage cocktail containing 
TFA/thioanisole/phenol/water/1,2-ethanedithiol 82.5:5:5:5:2.5, and precipitated using 
methyl t-butyl ether.83  Synthetic PLN was dissolved in neat TFA, and purified by HPLC 
(Waters HPLC equipped with Delta 600 pump system and dual wavelength absorbance 
detector) on a Vydac C4 reverse-phase column using a linear gradient from 
water/ACN/IPA/TFA 95:2:3:0.1 to 5:38:57:0.1 over 100 min at 40 oC.83  PLN fractions 
were identified via electrophoresis and immunodetection.  Pure fractions were pooled and 
lyophilized, and the purified product was quantified by a standard BCA assay.84 
Reconstitution of PLN into Phospholipids.   The phospholipids DOPC and DOPE 
were mixed in 4:1 ratio in chloroform (CHCl3).  Synthetic PLN was added onto the 
phospholipids to have a final ratio of lipid/PLN 200:1.  The final concentrations of PLN, 
DOPC, and DOPE were approximately 0.01, 2, and 0.5 mM, respectively.  Following 
vortexing (5 min), the solvent was evaporated with N2.  The samples were then lyophilized 
for ca. 2-4 h.  The lyophilized samples were re-dissolved in either 0.05 M PBS or 10 mM 
phosphate buffer at pH 7.4 by several cycles of vortexing, and sonication to ensure liposome 
formation.  Reconstitution was completed following a freeze (-20 oC, ca. 2 d)-thaw cycle. 
Analysis of PLN by Circular Dichroism.  PLN reconstituted into phospholipids, 
diluted into 10 mM phosphate buffer at pH 7.4, and exposed to a freeze-thaw cycle was 
passed through an extruder containing polycarbonate membrane with 100 nm pore size to 
form unilamellar liposomal suspensions.  As a standard, PLN was also dissolved in a 0.3% 
solution of the nonionic detergent, C12E8, which is known to promote the -helical 
conformation of PLN,85 and analyzed following a freeze (-20 oC, ca. 2 d)-thaw cycle.  The 
presence of -helical structure was determined by circular dichroism at 20 oC in 0.2 or 1.0 
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mm pathlength, quartz cuvettes.  All the data were collected over the 190-260 nm region 
with the following settings:  50 nm/s scan rate, 4 s response time, and two accumulations 
(scans).  As controls, lipid and buffer solutions were analyzed in the absence of reconstituted 
PLN.    
Co-immunoprecipitation of SERCA2a and PLN (with different concentrations 
of AS).  Microsomes co-expressed with SERCA2a and PLN (11 mg/ml in 250 mM sucrose, 
10 mM histidine, pH 7.2) were diluted to 0.25 mg/ml in immunoprecipitation buffer ([in 
mM]: 110 sucrose, 5 Tris-HCl, 75 KCl, 20 HEPES; 150 NaCl, 1 EDTA, 2  PMSF,  0.5%  
Tween 20).  The microsomes were centrifuged for 15 min at 16,000 g to remove large 
microsomal debris. Recombinant protein G sepharose was added to the cleared solution 
and the sample was rocked at 4 °C overnight to collect all proteins bound non-specifically 
to protein G sepharose.  The supernatant was obtained by centrifugation (1 min at 4000 g).  
Then the solution was divided into equal aliquots and incubated with 0 and 5 mM AS/HNO 
for 30 min at 37 °C.  The samples were rocked overnight at 4°C with protein G sepharose 
which has been pretreated with monoclonal anti-SERCA2a antibody.  Immunoprecipitates 
were then collected by centrifugation (1 min at 4000 g) and washed three times with ice 
cold wash buffer (pH = 7.5, (in mM): 20 HEPES, 150 NaCl, 1 EDTA, 1.5 BME, 1% Tween 
20).  Non-reducing sample loading buffer was added after re-suspending the protein-bound 
beads in 0.05 M PBS (pH = 7.4).  Proteins were eluted from the beads by incubating the 
samples at 37 °C for 15 min or by boiling for 10 min.  Beads were collected by 
centrifugation (1 min at 4000 g).  Aliquots of the supernatant (containing the 
immunoprecipitates) were then loaded onto 15% polyacrylamide gels and the proteins were 
separated by using standard SDS-PAGE protocols.  Upon separation, proteins were 
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transferred onto PVDF membranes via western blotting.  After blocking open membrane 
sites in skim milk suspension for 1 h at room temperature, the membranes were incubated 
overnight at 4°C with anti-PLN monoclonal antibody (2D12) specific for the epitope 
between 2 and 25 of wt-PLN.  The membranes were washed three times for 10 min each 
with cold Tris-HCl (pH 7.5, 150 mM NaCl; Tris- buffered saline [TBS]), with 0.1% Tween 
20.  The membranes were then incubated for 1 h at room temperature with horseradish 
peroxidase-conjugated anti-mouse IgG secondary antibody and washed three times with 
cold TBS/0.1% Tween 20.  Chemiluminescent signals were generated by treating the 
membranes with enhanced chemiluminescence reagents and captured on film.  The results 
were quantified by a Bio-Rad GS-670 imaging densitometer. 
Mass Spectrometry of PLN.  For MALDI-MS analysis, synthetic PLN (0.5 mg/ml, 
0.75 l) in methanol was spotted with -cyanohydroxycinnamic acid (10 mg/ml in 
ACN/water/TFA 50:50:0.05 (v/v), 0.75 L).  A total of 5000 shots were accumulated with 
a frequency of 100 Hz.  All MALDI-MS analyses were conducted in linear mode using a 
Bruker Autoflex III MALDI-TOF/TOF instrument equipped with a 355 nm pulsed UV 
laser.   
The ESI-MS spectrum of PLN peptide, Gln22-Leu52, was obtained by dissolving 
the crude peptide in ACN with 1% TFA.  ESI-MS analysis was carried out on a Thermo 
Finnigan LCQ Deca Ion Trap Mass Spectrometer fitted with an electrospray ionization 
source, operating in the positive ion mode with an accuracy of ca. 0.1 m/z.  In all 
experiments, the samples were introduced to the instrument at a rate of 10 L/min using a 
syringe pump via a silica capillary line.  The heated capillary temperature was 250 °C and 
the spray voltage was 5 kV. 
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Electroelution of PLN.  SDS-PAGE was run using 15% polyacrylamide as 
described above.  Following electrophoresis, one lane was excised and stained with silver 
staining to locate the PLN band.  The regions of the gel corresponding to PLN bands were 
estimated and excised based on the stained gel piece.  The excised gel pieces were soaked 
in soaking buffer (25 mM Tris and 192 mM glycine containing 0.2% SDS at pH 8.3).  The 
electroelution was carried out in electroelution buffer (25 mM Tris and 192 mM glycine 
containing 0.02% SDS at pH 8.3).  The eluates were collected following 6 h electroelution 
at 200 V and an additional 12 h electroelution at 96 V.  All the experiments were carried 
out using Whatman Elutrap electroelution system, and BT1 and BT2 membranes 
recommended by the manufacturer. 
The complete electroelution of the samples was confirmed by silver staining of the 
excised gel pieces.  Also the presence of PLN in the eluate was determined electrophoresis, 
western blotting and immunodetection as described above.  
Recovery of PLN from SDS Solutions.  A modified chloroform/methanol/water 
(1:4:3 v/v) extraction procedure41 was employed to remove SDS from the eluates following 
the electroelution of PLN.  Briefly, SDS was removed by using two consecutive 
chloroform/methanol/water extractions, in which the final addition of MeOH to precipitate 
PLN from the chloroform solution was replaced with evaporation of chloroform. 
The efficiency of the method was determined by quantification of the amount of 
remaining SDS after each step by a colorimetric assay employing methylene blue 
(651=80000 M
-1cm-1).40, 41 
Treatment of t-Butanesulfinamide with Reducing Agents.  A 0.12 M solution of 
t-butanesulfinamide was prepared in 0.05 M PBS (pH 7.4).  The solution was divided into 
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two equal aliquots and DTT or TCEP was added to one of the aliquots such that the final 
concentration of DTT or TCEP were 0.5 M.  The solutions were incubated at room 
temperature overnight.  Each solution was then acidified, extracted with a total volume of 
15 mL ether, and analyzed by gas chromatography-mass spectrometry (GC-MS).  This 
analysis indicated no reaction between t-butanesulfinamide and DTT or TCEP. 
Analysis of MNP by UV-Visible Spectroscopy.  The stock solutions of MNP were 
prepared in DMSO.  The amount of MNP dimer in 0.05 M PBS at pH 7.4 or in diethyl 
ether was calculated based on the absorbances at 287 and 295 nm, respectively. (287= 8000 
M-1cm-1, 295=8000 M
-1cm-1).86 
SERCA2a Activity Studies.  All the kinetic assays and analyses were conducted by 
late Dr. Jeffrey P. Froehlich (Division of Cardiology, Johns Hopkins Medical Institutions).  
Briefly, activation of the cardiac SR Ca2+
 
pump by HNO in the presence or absence of 
wild-type or null-cysteine PLN (C36,41,46A-PLN) was investigated by measuring the 
kinetics of spontaneous dephosphorylation of SERCA2a revealed by chasing the 
phosphorylated enzyme with EGTA.87, 88  In some cases, the effects of DTT on HNO-
treated microsomes were also analyzed. 
In some cases, effect of HNO on SERCA2a ATPase activity in the presence or 
absence of PLN were examined by Mahaney group (Department of Biochemistry, Edward 
Via Virginia College of Osteopathic Medicine) using the malachite green-ammonium 
molybdate assay.46, 89 
Fluorescence Spectroscopy and EPR Analyses.  All fluroscence and EPR 
spectroscopic analyses investigating the effects of HNO on SERCA2a in the presence or 
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absence of PLN were conducted by Mahaney group (Department of Biochemistry, Edward 
Via Virginia College of Osteopathic Medicine). 
Isolated Myocyte, Whole Heart, and Animal Studies.  All the in vivo and in vitro 
studies investigating the effects of HNO on isolated myocytes, heart extracts, regular or 
PLN-/- mice were conducted by Paolocci group (Division of Cardiology, Johns Hopkins 
Medical Institutions).  
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Chapter 7 – Miscellaneous Reactivity Studies 
7.1 HNO Partitioning Preference between Aqueous and 
Hydrophobic Phases 
Studies have shown that, in biological systems, HNO can reach and modify several 
protein thiols without being trapped by cellular glutathione (GSH).1, 2  Although the 
mechanisms involved have not been established, partitioning of HNO into cellular 
membranes has been suggested as a potential pathway.3  Lancaster and co-workers have 
demonstrated that NO partitions into biological membranes by comparing the rates of NO 
autooxidation in the presence of detergent micelles and in aqueous solution.4  Unlike NO, 
HNO undergoes a rapid dimerization reaction, which results in the formation of nitrous 
oxide (N2O) and H2O (Scheme 7-1).
5-7  To learn more about HNO and its properties, we 
have investigated the HNO partitioning preference between aqueous and hydrophobic 










7.1.1 HNO Partitioning into Bovine Serum Albumin (BSA) via 
Headspace Gas Chromatography Analyses 
N2O headspace analysis via gas chromatography (GC) is a generally used method 
for the indirect detection of HNO.8-12  We intended to determine the HNO partitioning 
preference for hydrophobic versus aqueous phases by utilizing this technique.  Albumin is 
the major protein in blood plasma and known to have hydrophobic pockets.  In fact, 
albumin binds and holds numerous ligands including noble gases.13  Moreover, studies 
have suggested the partitioning of NO and O2 into the hydrophobic compartments of 
albumin, which consequently acts an N2O3 reserve in plasma.
14  We wished to employ 
bovine serum albumin (BSA) as the hydrophobic phase and test its potential as a carrier 
for HNO. 
The reaction of BSA with HNO was investigated by analyzing the amount of N2O 
in the headspace upon incubation of 0.05 mM unmodified BSA with 0.1 mM HNO-donors, 
AS or 2-BrPA.  These results indicate that 35 and 22% decrease in total N2O with respect 
to the amount of N2O obtained in the absence of traps, pointing to the scavenging of HNO 
by BSA, consistent with a reported mass spectrometry study.15  Moreover, the use of 0.5 
mM BSA results in all almost complete (91%) quenching of HNO generated from 0.1 mM 
AS.  Although the above results indicate quenching of HNO by BSA, the extent of 
quenching is lower than expected.  Since the single free thiol (Cys34) of BSA might 
partially exist in a mixed disulfide with cysteine or GSH, we reduced BSA samples with 
DTT.  Following incubation with AS, an approximately 87% decrease was observed in 
total N2O with respect to the amount of N2O obtained in the absence of traps.  Table 7-1 
shows the percent yields of N2O obtained from headspace GC analyses. 
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Table 7-1.  Percent yields of N2O obtained following decomposition of AS under different 
conditions  
 
Samplesa % N2O Yield
b 
AS 76 
AS + GSH 6 
AS + BSA 7 
AS + NEM-Treated BSA 56 
AS + BSA + GSH 5 
AS + NEM-Treated BSA + GSH 5 
 
a AS (0.1 mM) was incubated in the presence or absence of different traps in 0.1 M PBS 
containing 100 M DTPA (pH 7.4) at 37 oC for 30 min under argon.  The concentrations 
of GSH, BSA, and NEM-treated BSA were 0.1, 0.05 and 0.05 mM, respectively. 
b Percent yields were calculated based on the theoretical maximum of N2O. 
  
 
To distinguish between the reactivity of HNO with BSA Cys34 and the potential 
partitioning of HNO/N2O into BSA hydrophobic pockets, we intended to block the BSA 
free thiol with N-ethylmaleimide (NEM).  Initial control experiments conducted with AS 
(0.1 mM) and various concentrations of NEM (0-5 mM) indicated that the absolute yield 
of N2O is decreased in the presence of NEM under these conditions (Figure 7-1).  To avoid 
complications, the samples were dialyzed against PBS following NEM treatment.  No 
decrease in N2O was detected upon incubation of dialyzed control samples with AS in the 





Figure 7-1.  Percent yield of N2O upon treatment of NEM (0-5 mM) with AS (0.1 mM).  
Yields were calculated based on the theoretical maximum yield of N2O. 
 
As shown in Table 7-1, incubation of NEM-treated BSA (0.05 or 0.1 mM) with AS 
(0.1 mM) resulted in a decrease in the percent N2O yield compared with the percent N2O 
yield obtained from AS in the absence of traps.  Moreover, the decrease in percent N2O 
yield is less in the presence of NEM-treated BSA compared with unmodified BSA.  
Although HNO is known to react with Trp, making Trp134 and Trp213 of BSA potential 
targets, the presence of oxygen is required for product formation.16, 17  Overall, these results 
potentially suggest the partitioning of HNO/N2O into BSA hydrophobic pockets.   
To be able to distinguish between HNO and N2O partitioning, we have examined 
the partitioning of standard N2O between buffer and headspace.  Our initial results did not 
show any significant changes in the partitioning coefficient of N2O due to the addition of 
0.9 mM BSA or 2.5 mM NEM to buffer, indicating the partitioning preference of HNO 
rather than N2O into BSA hydrophobic pockets.  However, further experiments are needed 
to confirm these findings. 
We have also conducted preliminary experiments to investigate the potential 
protective effect of BSA on HNO against trapping by GSH.  Since GSH is an aqueous 
thiol, it will quench only the HNO that has partitioned to the aqueous phase.  The effect of 
241 
 
GSH on percent N2O yield was first determined by incubating GSH (0-0.5 mM) with AS 
(0.1 mM).  As shown in Figure 7-2, almost complete trapping was observed with 0.1 mM 
GSH.  No significant difference was observed in percent N2O yield upon treatment of AS 
with GSH in the presence or absence of NEM-treated BSA, indicating the lack of a 
protective effect of BSA on HNO (Table 7-1). 
 
 
Figure 7-2.  Percent yield of N2O upon treatment of GSH (0-0.5 mM) with AS (0.1 mM).  
Yields were calculated based on the theoretical maximum yield of N2O. 
 
7.1.2 HNO Partitioning into Detergent Micelles via High 
Pressure Liquid Chromatography Analyses 
 The partitioning preference of HNO into hydrophobic versus aqueous phases was 
also investigated by employing detergent micelles as the hydrophobic phase.  For this 
purpose, we investigated the trapping of HNO by GSH in the presence of sodium dodecyl 
sulfate (SDS) or Tween 20 micelles and analyzed the HNO-derived GSH modifications by 
high pressure liquid chromatography (HPLC).  As mentioned previously, HNO generally 
reacts with thiols to form a disulfide or a sulfinamide depending on the concentration of 
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thiol.18, 19  If HNO has a partitioning preference for hydrophobic phases, then the presence 
of detergent micelles would provide protection against the scavenging of HNO by GSH, 
resulting in a decrease in HNO-derived modifications. 
 We confirmed the formation of detergent micelles by the change in max of 
Coomassie Brilliant Blue R.20  Treatment of SDS in 0.1 M PBS containing 100 M EDTA 
(pH 7.4) with Coomassie Brilliant Blue R at room temperature and 37 oC resulted in max 
to shift from 560 to 591 nm at 0.14 and 6.4 mM SDS, respectively.  Similar experiments 
conducted with Tween 20 in buffer at room temperature demonstrated micelle generation 
at 0.08 mM Tween 20.  These results are comparable to the reported critical micelle 
concentration (cmc) values for SDS (8.9 mM at 37 oC)21 and Tween 20 (0.06 mM at room 
temperature)22.   
 The trapping of HNO by GSH was investigated by incubating GSH (0.5-2 mM) 
with AS (1 or 5 mM) at physiological pH and temperature in the presence or absence of 
SDS (10 or 700 mM) or Tween 20 (81 mM) to ensure micelle formation.  Under these 
conditions the HNO-derived modifications mainly consisted of glutathione disulfide 
(GSSG) as expected.23  In all cases, similar GSSG yields were obtained in the presence or 
absence of detergent micelles, suggesting the lack of a protective effect on HNO towards 
GSH scavenging at least at these GSH/micelle concentrations (Figure 7-3).  Incubations 
carried out under anaerobic conditions also produced similar results, confirming that GSSG 
formation is due to HNO treatment.  Consistent with these, no significant trend was 
observed in GSSG yields upon employment of varied concentrations of SDS (0-300 mM) 
or Tween 20 (0-81 mM) (Figure 7-4).  As a control, the solubility of GSH in Tween 20 was 




Figure 7-3.  Area of glutathione disulfide (GSSG) peak detected by HPLC upon treatment 
of glutathione (GSH) (0.5-2 mM) with 1 mM AS in pH 7.4 PBS in the absence (□) or 






Figure 7-4.  Area of glutathione disulfide (GSSG) peak detected by HPLC upon treatment 
of glutathione (GSH) (2 mM) with 5 mM AS in pH 7.4 PBS in the presence of Tween 20 
(0-81 mM) at room temperature for 2 h at room temperature.  
 
Since thermal decomposition of AS to form HNO has a half-life of approximately 
2.4 min under physiological conditions, we conducted preliminary studies to investigate 
the effects of rapid HNO introduction on partitioning.  Upon photolysis at 254 nm, the 
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complete decomposition of 5 mM AS was achieved in 7 min as detected by UV-visible 
spectroscopy.  No significant difference was observed in GSSG yields upon photolysis of 
AS in the presence or absence of 700 mM SDS. 
 Although the partitioning preference of HNO into hydrophobic or aqueous phases 
could not be determined unambiguously, our overall results indicate that neither BSA nor 
detergent micelles are able to protect HNO from trapping by GSH under the conditions 
examined.  However, further experiments are required to distinguish between the lack of 
HNO partitioning into hydrophobic phases and the presence of slow partitioning, which is 
outcompeted by thiol reactivity. 
7.1.3 Experimental Methods 
 Reagents.  Bovine serum albumin (BSA), glutathione (GSH), N-ethylmaleimide 
(NEM), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), sodium dodecyl sulfate (SDS), and 
dithiothreitol (DTT) were of the highest purity available and purchased from Sigma (St. 
Louis, MO).  Coomassie Brilliant Blue R was obtained from Biorad.  Nitrous oxide (45 
ppm) balanced with nitrogen was obtained from Airgas.  Bicinchoninic acid (BCA) assay 
kit, dialysis tubing, HPLC grade acetonitrile (ACN) and Tween 20 were purchased from 
Thermo Fisher Scientific (Rockford, IL). The syntheses of HNO-donors, Angeli’s salt 
(Na2N2O3, AS)
24 and 2-bromo-N-hydroxybenzenesulfonamide (2-BrPA)25 were carried out 
as previously described. 
 Preparation of BSA Samples.  BSA was dissolved in 0.1 M phosphate-buffered 
saline (PBS) containing 100 M EDTA at pH 7.4 to have a final concentration of 0.05, 0.1 
mM.  The samples were incubated with 0.5 or 1 mM NEM (as indicated) for 1 h at room 
temperature to block BSA free thiol (Cys 34) and dialyzed overnight against 0.1 M PBS 
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containing 100 M EDTA (pH 7.4) with three solution changes to remove excess NEM.  
Control experiments were also conducted in the absence of BSA or NEM.  In some cases, 
BSA samples were reduced with 2 mM DTT and dialyzed against 0.1 M PBS for 18 h prior 
to NEM treatment.  The total protein concentrations were determined at various stages of 
sample preparation by using a standard BCA assay.26   
Incubations with HNO-Donors.  Stock solutions of AS and 2-BrPA were prepared 
in 0.01 M NaOH and ACN, respectively, and used within 15 min of preparation.  For 
headspace GC analysis, the samples (5 ml) containing BSA (0.05, 0.1 or 0.5 mM), GSH 
(0-0.5 mM), or NEM (0-5 mM) in 0.1 M PBS containing 100 M EDTA at pH 7.4 were 
placed in 15 ml vials sealed with rubber septa and purged with argon as reported 
previously27.  Following the introduction of AS (0.1 mM) or 2-BrPA (0.1 mM) via a 
gastight syringe, the samples were then incubated at 37 oC and 1 atm for 1.5 h to ensure 
complete decomposition of HNO-donor and equilibration of N2O with the headspace.  The 
samples were then analyzed for N2O by headspace GC analyses.  In all cases, the final 
concentration of ACN was less than or equal to 1% (v/v).  To determine if NEM-treated 
BSA could protect HNO from GSH scavenging, for some experiments BSA samples were 
incubated with AS in the presence of 0.05 or 0.1 mM GSH (as indicated).  Side-by-side 
control experiments were also conducted in the absence of any HNO scavengers to detect 
the maximum amount of N2O that could be obtained. 
For HPLC analysis, GSH was dissolved in 0.1 M PBS containing 100 M EDTA 
in the presence of 0-700 mM SDS or 0-81 mM Tween 20 to have a final concentration of 
0.5-2 mM.  The samples were then incubated with 1 or 5 mM AS for 30 min at 37 oC or 2 
h at room temperature (as indicated).  Samples containing Tween 20 were incubated and 
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stored in the dark due to the light sensitivity of this detergent.  In some cases, incubations 
with AS were carried out under argon saturated conditions as described above.  The 
samples were then filtered through 0.45 m filters and analyzed by HPLC. 
Incubations with N2O.  To determine whether the presence of NEM or BSA 
affects the partitioning coefficient of N2O between the solution and the headspace, empty 
vials were purged with N2O (45 ppm).  Following the addition 89 M NEM-treated BSA 
in buffer in the presence of a ventilation needle to keep the pressure constant, the samples 
were incubated at 37 oC for 1.5 h.  Then the amount of N2O in the headspace was 
determined by GC analysis. 
 Headspace GC Analyses.  All headspace GC analyses were conducted on a Varian 
CP-3800 instrument equipped with 1041 manual injector, electron capture detector (ECD), 
and a 25 m 5Å molecular sieve capillary column.  The injector, column oven, and ECD 
were operated at 200, 200 and 300 oC, respectively, and ultrahigh purity nitrogen was used 
as the carrier gas.  The column flow was set to 8 ml/min.  All injections were conducted 
by using a 100 L gastight syringe equipped with a sample-lock.  Calibration curves were 
prepared by using an N2O tank and the absolute amount of N2O in the samples were 
determined by employing ideal gas law and Henry’s law constant as described previously.27  
The percent yields of N2O were calculated based on the theoretical maximum of N2O.  In 
some cases the relative percent yields were determined by normalizing the amount of N2O 
with respect to the total amount of N2O obtained from AS in the absence of HNO 
scavengers.   
Quantification of Free Thiol by DTNB Assay.  The amount of free thiol in various 
BSA or GSH samples in 0.1 M PBS with 100 M EDTA at pH 7.4 were quantified by 
247 
 
using DTNB titration.28  The concentration of free thiol was determined by utilizing the 
literature extinction coefficient (412=13600 m
-1 cm-1).28 
 Photolysis of AS.  GSH (2 mM) was dissolved in 0.1 M PBS containing 100 M 
EDTA at pH 7.4 in the presence or absence of 700 mM SDS.  Upon the addition of 5 mM 
AS, the samples were photolyzed at 254 nm for 7 min.  The samples were then analyzed 
by UV-visible spectroscopy.  Following storage of samples in the fridge overnight, the 
samples were also analyzed by HPLC.  Control samples prepared in the absence of AS 
were photolyzed and analyzed under the same conditions. 
 HPLC Analyses.  All analyses were performed on a Waters HPLC equipped with 
Delta 600 pump system, dual wavelength absorbance detector, and manual injector.  The 
samples were analyzed on an Apollo C18 reverse-phase column using a literature method.
23  
The peaks were assigned by co-injection with standards.  The peaks were integrated by 
using Waters Millenium software. 
7.2 Studies with Glutathione Reductase and Glutaredoxin 
System 
As mentioned previously, treatment of papain, a cysteine protease, with HNO 
results in the inhibition of enzyme activity due to the formation of a sulfinamide at its active 
site thiol.29, 30  In the presence of excess thiol, the sulfinamide modification of papain can 
be reduced back to free thiol, accompanied by a recovery of papain activity (Chapter 2).31  
We investigated the effect of glutathione reductase and glutaredoxin system               




Scheme 7-2.  Traditional model of glutaredoxin (Grx) catalysis.  The mechanism involves 
the reduction of S-glutathionylated proteins (P) by Grx in the presence of glutathione 
reductase (GR), GSH, and NADPH.  Gallogly, M. M., Starke, D. W., and Mieyal, J. J. 
(2009) Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by 
glutaredoxins and potential mechanisms of regulation, Antioxid. Redox Signaling 11, 1059-
1081.  
 
7.2.1 Reactivity of HNO-Treated Papain with Glutathione 
Reductase and Glutaredoxin System  
 Glutathione reductase (GR) is a homodimeric enzyme (ca. 100 kDa), which reduces 
glutathione disulfide (GSSG) to two molecules of glutathione (GSH) in an NADPH-
dependent process.33   
Since sulfinamide modification on papain can be reduced by GSH,31 we tested if the 
reduction could be facilitated in the presence of GR and NADPH.  Incubation of 
sulfinamide-modified papain with 1 or 5 mM GSH in the presence of catalytic amount of 
GR and 0.2 mM NADPH at physiological pH and temperature did not increase the 
observed gain of activity compared with the previous results (Figure 7-5).  However, this 
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ineffectiveness of GR could be due to its inhibition by physiological levels of GSH.34  
Although a slight recovery in papain activity is observed upon treatment with GR and 
NADPH in the absence of GSH, it was not significant (Figure 7-5).  Similarly no significant 
change in activity was detected upon incubation of HNO-treated papain with GR or 
NADPH in the absence of GSH.  
 
 
Figure 7-5.  Reduction of HNO-derived sulfinamide in papain under different conditions.  
Previously activated papain (0.2 mg/ml) was treated with 0.1 mM AS.  The samples were 
incubated with 1 or 5 mM GSH in the presence or absence of glutathione reductase (GR, 6 
g/ml) and NADPH (0.2 mM), or glutaredoxin (Grx) system (0.026 units/ml Grx, 6g/ml 
GR, 0.2 mM NADPH) in phosphate buffer at 37 oC.  
 
 Glutaredoxins (Grx) are 11-13 kDa enzymes, which are members of the thioredoxin 
superfamily and are involved in the deglutathionylation of glutathionylated substrates or 
protein disulfide substrates.32, 33  Studies have reported the slow deglutathionylation of 
papain mixed disulfide (papain-SSG) by Grx in the presence of GSH.35  Since the reduction 
of the sulfinamide on the papain active site cysteine back to free thiol presumably involves 
a papain-SSG intermediate (Chapter 2),31 we have conducted preliminary experiments to 
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investigate the effect of Grx system on the reduction of sulfinamide-modified papain by 
GSH. 
 The presence of 0.2 mM NADPH and catalytic amounts of Grx and GR did not 
result in a significant increase in gain of activity upon treatment of sulfinamide-modified 
papain with 1 or 5 mM GSH (Figure 7-5).  It should be also noted that possible inhibition 
of GR caused by higher concentration of GSH might have affected the overall efficiency 
of the Grx system.  Although our results indicate the lack of a significant impact of GR or 
Grx system on sulfinamide reduction in papain under these conditions, further studies at 
low GSH levels and shorter incubation times are needed to determine the exact effects of 
both enzymes. 
7.2.2 Experimental Methods 
 Reagents.  Glutathione (GSH), papain, Nα-Benzoyl-L-arginine 4-nitroanilide 
hydrochloride (L-BAPNA), glutathione reductase (GR), β-Nicotinamide adenine 
dinucleotide 2′-phosphate reduced tetrasodium salt hydrate (NADPH), bovine serum 
albumin (BSA), and dithiothreitol (DTT) were of the highest purity available and 
purchased from Sigma (St. Louis, MO).  Glutaredoxin-1 (Grx) was purchased from 
ATGen.  2-Hydroxyethyl disulfide (HED) was purchased from Thermo Fisher Scientific 
(Rockford, IL).  The synthesis of HNO-donor, Angeli’s salt (Na2N2O3, AS) was carried out 
as previously described.24  Milli Q water was used for all purifications and experiments.  
Activation of Papain. A 0.5 mg/ml papain solution was prepared by dissolving the 
lyophilized enzyme in 82 mM sodium phosphate buffer with 410 M DTPA at pH 7.4.  
The papain sample was activated by treating it with 2 mM DTT for 1.5 h at room 
temperature to reconvert its single free cysteine to the sulfhydryl form.  The activated 
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enzyme was stored at -20 °C.  Before analysis, it was thawed and desalted with Zeba spin 
desalting columns to remove excess DTT.  The papain solution was then diluted to 0.2 
mg/ml with sodium phosphate buffer.  To overcome batch to batch variation in the actual 
activity of the reduced papain preparation, all activity results are expressed as a percentage 
of the indicated control. 
Determination of Grx Activity.  Grx activity was determined by following a 
slightly modified literature procedure.36-38  Briefly, a solution of 1 mM GSH, 0.7 mM HED, 
0.01 mg/ml BSA, 0.2 mM NADPH, 6 g/ml GR, and 2 mM EDTA in 0.1 M Tris-HCl at 
pH 7.4 was incubated at 30 oC for 3 min.  The kinetic analysis was started by the addition 
of Grx in 20 mM Tris-HCl with 10% glycerol at pH 8 to have a final concentration of 0.5 
g/ml.  The reaction was followed at 340 nm for 5 min by UV-visible spectroscopy 
(ε340=6200 M
-1cm-1).39  1 unit corresponds to 1 μmole of NADPH oxidized per minute at 
30 °C per ml of Grx.  
Incubation of Papain Solutions and Activity Assay.  A solution of 0.2 mg/ml 
activated papain in 82 mM sodium phosphate buffer with 410 M DTPA at pH 7.4 was 
divided into two and the aliquots were incubated with 0 or 0.1 mM AS at 37 °C for 30 min.  
Following the addition of 1 or 5 mM GSH, 0.2 mM NADPH, 6 g/ml GR, and 0.026 
units/ml Grx were then added to both solutions to have the required concentration and the 
samples were incubated at 37 °C.  Aliquots were taken from each sample at certain time 
intervals, and immediately analyzed by a 20 min kinetic assay using L-BAPNA as the 
substrate.29  For some experiments, the samples were incubated with NADPH (0.2 mM) 
and GR (6 or 27 g/ml) GR in the presence or absence of GSH (1 or 5 mM) to investigate 
the reduction of sulfinamide-modified papain by GR.  Also HNO-treated samples were 
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separately incubated with 0.2 mM NADPH or 27 g/ml GR to test their effects.  In all 
cases, the sample incubated without AS served as the control sample to correct for the 
decrease in papain activity due to long incubations.  All the spectrophotometric analyses 
were conducted on a Hewlett-Packard 8453 Diode Array Spectrophotometer. 
7.3 Studies with Nitrite 
 One of the most common HNO-donors is Angeli’s salt, which produces nitrite 
(NO2
-) as the byproduct.  Nitrite is known to produce nitrosating species, especially under 
acidic conditions (Scheme 7-3).40  Also, recent reviews highlight the role of nitrite in NO 
production.40-42  To understand potential side reactions due to AS-produced nitrite, we 
investigated NO2
- reactivity.   
 
    
 
Scheme 7-3.  Formation of nitrosating species from nitrite under acidic conditions. 
 
7.3.1 Nitrite-Induced Complications in Sulfinamide Formation 
Thiols react with nitrosating species to form S-nitrosothiols (RSNO), which can 
react further with excess thiol to release HNO.19  To determine if NO2
- acts as a nitrosating 
agent under physiological conditions, we tested S-nitrosation of -mercaptoethanol (BME) 
in the presence of metal chelator, DTPA, by 15N NMR.  Incubation of 0.1 M 15NO2
- with 
equimolar amount of BME at physiological pH and temperature did not result in the 
detection of the corresponding nitrosothiol species (BME-S15NO).  Similarly, S-
253 
 
nitrosoglutathione (GSNO) was not observed by UV-visible spectroscopy upon treatment 
of GSH with NO2
-.  These results are consistent with previously reported kinetic studies.43 
Studies indicate that freezing nitrite-containing samples in sodium phosphate 
buffers at neutral pH results in the S-nitrosation of cysteine residues.44  Moreover, this 
process has been attributed to the formation of nitrosating species from nitrite due to the 
pH shift (from pH 7.4 to ca. 4-5) in sodium phosphate buffers during freezing.44, 45  
Consistent with these reports, we observed 15N-labeled S-nitrosoglutathione (GS15NO, 769 
ppm) by 15N NMR upon freezing 10 mM 15N-labeled nitrite (15NO2
-) with equimolar 
amounts of GSH in pH 7.4 and 8.5, but not in pH 11, sodium phosphate buffer (Figure 7-
6).  In all cases, no GS15NO could be detected prior to freezing.  
 
 
Figure 7-6.  Selected region of 15N NMR spectrum of 15NO2
- (10 mM) frozen with GSH 
(10 mM) in 0.25 M sodium phosphate buffer containing 50 M DTPA at pH 7.4.  Peaks at 
609 and 769 ppm were assigned to 15NO2
- and GS15NO, respectively. 
 
To learn more about this effect and understand the potential complications in HNO-
derived modifications, we examined thiol samples in the presence of NO2
- by NMR 
spectroscopy.  Surprisingly, freezing of equimolar amounts of NO2
- and BME in pH 7.4 
sodium phosphate buffer at -75 oC resulted in the detection of a small peak at 5.68 ppm 
(Figure 7-7), which corresponds to BME sulfinamide.30  Larger amounts of the BME 
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sulfinamide were detected in the presence of 1 mM NO2
- and 50 mM BME.  Moreover, 
upon conducting the experiment with 15NO2
- (Figure 7-7), the sulfinamide peak was 
observed by our 15N-edited NMR method for sulfinamide detection (Chapter 3).30  
Similarly, freezing of 15NO2
- with a cysteine-containing peptide, VYPCLA, produced 
small amount of the corresponding sulfinamide.  It should also be noted that this effect is 
not observed upon freezing of samples that had been previously incubated with equimolar 
or excess amounts of AS due to the complete modification of thiols by HNO.  As shown 
in Chapter 3, no unlabeled sulfinamide is observed upon prior treatment of BME with 10-
fold excess 15N-AS, which decomposes to produce 15N-labeled HNO (H15NO) and 
unlabeled NO2
-.  Freezing of 1 mM nitrate (NO3
-) and 50 mM BME under the same 







Figure 7-7.  Selected region of 1H NMR spectrum of (a) NO2
- (1 mM), (b) 15NO2
- (10 
mM), and (c) 15N-edited NMR spectrum of 15NO2
- (10 mM) frozen with BME (10 mM) in 
10 mM sodium phosphate buffer containing 50 M DTPA at pH 7.4 showing NH and 15NH 
peaks of BME sulfinamide. 
 
Since sulfinamide formation is considered to be unique to HNO among reactive 
nitrogen species, these observations could be explained by the formation of nitrosating 
species from NO2
- during the freezing process in sodium phosphate buffer, and consequent 
formation of S-nitrosothiol.  As mentioned above, reaction of S-nitrosothiols with excess 
thiol would result in the formation of HNO,19 followed by sulfinamide generation, which 
is expected to be promoted under acidic conditions. 
We have also investigated this process with sodium phosphate buffers at different 
pH values.  The BME sulfinamide was observed at pH 8.5; however, no sulfinamide 
formation was detected upon the freezing of NO2
- with BME in pH 5 or pH 11 buffer. 
256 
 
Despite the low yields of sulfinamides obtained, these results demonstrate a 
potential nitrite-induced complication in studying sulfinamide formation and emphasize 
the need for control experiments when working with AS. 
7.3.2 Experimental Methods 
Reagents.  Glutathione (GSH) and -mercaptoethanol (BME), sodium nitrite 
(NaNO2), and sodium nitrate (NaNO3) were of the highest purity available and purchased 
from Sigma (St. Louis, MO).  15N-labeled sodium nitrite (Na15NO2) and deuterated 
dimethyl sulfoxide (DMSO-d6) were obtained from Cambridge Isotope Labs (Andover, 
MA).  Synthesis and purification of VYPCLA was carried out as described in Chapters 2 
and 3.  Milli Q water was used for all purifications and experiments. 
Treatment of Thiols with Nitrite.  NaNO2 or Na
15NO2 were dissolved in 10 mM 
phosphate buffer with 50 M DTPA at various pH values to have a final concentration of 
1 mM.  -Mercaptoethanol (BME) or VYPCLA were added to the nitrite solution in buffer 
to have a final concentration of 1 or 50 mM.  The samples were frozen at -75 oC.  Following 
lyophilization, the samples were dissolved in DMSO-d6 and analyzed by 
1H NMR or 15N-
edited 1H NMR.  
 For direct 15N NMR experiments, Na15NO2 was dissolved in 0.25 M sodium 
phosphate buffer with 50 M DTPA at various pH values to have a final concentration of 
10 mM.  Following the addition of 10 mM GSH, the samples were frozen at -75 oC and 
lyophilized.  The samples were then dissolved in 10% D2O and analyzed by 
15N NMR.  In 
some cases, BME (0.1 M) was incubated with 0.1 M 15NO2
- in 0.25 M sodium phosphate 
buffer with 50 M DTPA (pH 7.4) at 37 oC and followed by 15N NMR for 45 min.  
257 
 
Treatment of Thiols with Nitrate.  NaNO3 was dissolved in 10 mM phosphate 
buffer with 50 M DTPA at various pH values to have a final concentration of 1 mM.  
BME was added to the nitrate solution in buffer to have a final concentration of 1 mM.  
The samples were frozen at -75 oC.  Following lyophilization, the samples were dissolved 
in DMSO-d6 and analyzed by 
1H NMR.  
NMR Analyses.  All 1H-NMR and 15N-edited 1H 1D-NMR analyses were carried 
out on a Bruker Avance 400 MHz FT-NMR spectrometer.  1H NMR and 15N-edited 1H 1D-
NMR analyses were carried out in DMSO-d6 at 303 K.  
15N-edited 1H 1D-NMR spectra 
were acquired using the HSQC pulse sequence for selection.  Chemical shifts are reported 
in parts per million (ppm) relative to residual DMSO (2.49 ppm for 1H) or residual H2O 
(4.7 ppm for 1H). 
UV-Visible Spectroscopy Analyses.  NaNO2 (10 mM) was dissolved in 0.25 M 
sodium phosphate buffer with 50 M DTPA (pH 7.4) and incubated at 37 oC for 45 min.  
Following the addition of GSH to have a final concentration of 10 mM, the sample was 
analyzed before and after freezing (-75 oC) by UV-visible spectroscopy at 25 oC.  All the 
spectrophotometric analyses were conducted on a Hewlett-Packard 8453 Diode Array 
Spectrophotometer.   
7.4 Studies on the Reactivity of HNO with Bovine Serum 
Albumin 
 As mentioned in section 7.1.1, bovine serum albumin (BSA) has a single free thiol 
(Cys34) which has been shown to react with HNO in a recent study.13, 15  Moreover, the 
formation of a cyclic sulfinamide involving Cys34 and a nearby Lys or Arg upon treatment 
of BSA with HNO has been proposed (Scheme 7-4).15  However, bottom-up mass 
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spectrometric approaches to identify the modification were unsuccessful.15  We have 




Scheme 7-4.  Proposed reaction of HNO with BSA.  Shen, B., and English, A. M. (2005) 
Mass spectrometric analysis of nitroxyl-mediated protein modification: Comparison of 
products formed with free and protein-based cysteines, Biochemistry 44, 14030-14044. 
 
7.4.1 Detection of BSA by Reflector In-Source Decay MALDI 
Mass Spectrometry 
 We wished to investigate the HNO-derived cysteine modification on BSA by 
utilizing mass spectrometry (MS).  Although BSA was observed by MALDI-MS and ESI-
MS techniques, the resolution was not high enough to investigate this modification.  Since 
HNO-derived modifications might not be completely stable to tryptic digestion 
conditions,46 we decided to employ a top-down mass spectrometric approach. 
Reflector in-source decay (ISD) is a MALDI-MS method used to obtain sequence 
information from pure, intact proteins.47, 48  This technique depends on the spontaneous 
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fragmentation of molecular ions within the ion source to produce mainly c-type ions from 
the N-terminus and y- or z-type of ions from the C-terminus (Scheme 7-5).47, 48  The 
reflector ISD-MALDI-MS technique is useful for m/z range of 1000-4000 (from 
approximately the 10th to the 40th residue from each terminal).  However, ion yields are 
typically poor and generally 5-20 pmol of analyte is required on the MALDI plate.47, 48 
 
 
Scheme 7-5.  Fragment ions produced by CID from protonated peptides. Biemann, K. 
(1992) Mass spectrometry of peptides and proteins, Annu. Rev. Biochem. 61, 977-1010. 
 
Initial studies with different matrices and various protein concentrations revealed 
that “super-DHB” (a mixture of 2,5-dihydroxybenzoic acid and 2-hydroxy-5-
methoxybenzoic acid) and a theoretical amount of 150 pmol of BSA gave the best results.  
BSA N-terminal amino acids up to Glu63 could be detected.  Moreover, increasing the 
number of scans allowed us to get sequence information up to Ala78 (Figure 7-8).  It should 
also be noted that the Cys34 b-ion was observed rather than the c-ion due to the cyclic 





Figure 7-8.  Selected region of reflector ISD-MALDI-MS spectrum. 
 
7.4.2 Studies to Determine HNO-Derived Cysteine Modification 
on BSA 
 Recent mass spectrometry studies indicate a mass increase of +14 Da on BSA 
following incubation with AS, which could correspond either to the formation of an 
intramolecular, cyclic sulfinamide with a nearby Lys or Arg residue (Scheme 7-4), or the 







Scheme 7-6.  Reaction of HNO with thiols showing the proposed intermediates.  Lopez, 
B. E., Rodriguez, C. E., Pribadi, M., Cook, N. M., Shinyashiki, M., and Fukuto, J. M. 
(2005) Inhibition of yeast glycolysis by nitroxyl (HNO): A mechanism of HNO toxicity 
and implications to HNO biology, Arch. Biochem. Biophys. 442, 140-148. 
  
 To gain more insight into the nature of HNO-derived cysteine modification, we 
analyzed BSA in the presence or absence of HNO treatment.  Reflector ISD-MALDI-MS 
studies demonstrated a gap in sequence readout (starting from Cys34) upon treatment of 
BSA with HNO, consistent with the presence of a cyclic structure (Figure 7-9).  Although 
some peaks with m/z values >4500 were detected in some HNO-treated BSA samples, 
unambiguous assignments were not possible due to the low resolution observed in these 
regions.  However, in some cases, a- or c-ions, which could be assigned to Val77 or Ala78 
were detected.  These observations might suggest that the cyclic structure is located within 
the Cys34-Ala78 region.  Surprisingly, the reported +14 Da increase in mass was not 
observed.  It should also be noted that a peak which could be assigned to a regular 
sulfinamide or sulfinic acid was detected in some cases, however the lack of enough 





Figure 7-9.  Selected region of reflector ISD-MALDI-MS spectrum showing BSA 
incubated (a) in the absence or (b) in the presence of 2 mM AS. 
 
We also analyzed H15NO-treated BSA with our 15N-edited NMR method for 
sulfinamide detection.30  As mentioned previously, this method detects the protons bonded 
to 15N nuclei.51  In the presence of a regular sulfinamide formed with H15NO, the 
incorporation of 15N is observed and consequently sulfinamide 15NH peaks are detected.30  
However, in the case of an intramolecular, cyclic sulfinamide formed with a nearby Lys or 
Arg, no 15N incorporation is expected.  No significant 15NH peaks were detected upon 
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treatment of BSA with excess 15N-labeled AS (15N-AS), indicating the lack of detectable 
amounts of regular sulfinamide.   
As shown in Scheme 7-6, exposure to HNO could also result in disulfide formation.  
Although not likely, the presence of an HNO-derived BSA dimer was investigated by SDS-
PAGE experiments.  As expected, no HNO-derived BSA dimer was observed upon 
incubation of BSA with AS.  Following treatment with dithiothreitol (DTT), the intensity 
of BSA monomer band remained the same, confirming the lack of HNO-derived BSA 
higher oligomers.  Notably, BSA bands appeared at a slightly higher molecular weight 
upon DTT treatment with or without prior exposure of BSA samples to HNO, presumably 
due to the formation of BSA-DTT adducts.  Overall, our results support the formation of a 
cyclic structure as the major product. 
 We have also conducted preliminary reactivity studies to examine the cyclic 
modification.  Since the +14 Da increase on BSA upon HNO treatment is attributed to the 
oxidation of HNO-derived cyclic sulfenamide to the corresponding cyclic sulfinamide 
(Scheme 7-4),15 we analyzed the samples following 2 h or overnight incubation at room 
temperature.  The ISD-MALDI-MS spectra were essentially the same before and after the 
incubation, and no mass increase was observed in any peaks with m/z values >4500.  
Similar results were obtained in the absence of chelator.  To assess the potential effect of 
buffer salts on oxidation, samples were also incubated with AS in Milli Q water containing 
0.1 mM DTPA at pH 7.4.15  As expected, only partial modification of BSA was obtained 
under these conditions, presumably due to the incomplete decomposition of AS.  These 
results indicate the lack of further oxidation in this region under our conditions.   
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 Sulfenamides are known to generate sulfonic acids (-SO3H) upon exposure to 
hydrogen peroxide (H2O2).
52  We tested this reactivity by incubating HNO-treated BSA 
samples with NEM to block any residual free thiols, and then treating them with H2O2.  
Reflector ISD-MALDI-MS analysis showed new peaks, which could be assigned to 
sulfonic acid-modified residues in the Cys34-Ala78 region.  Notably, no sulfonic acid 
modification was observed in the absence of HNO-treatment prior to incubation with NEM 
followed by H2O2.  Although these results are consistent with the reactivity of 
sulfenamides, better resolution as well as control experiments with sulfinamides are 
needed.    
 The hydrolysis of the cyclic structure was examined by reflector ISD-MALDI-MS.  
Hydrolysis of this structure is expected to result in ring opening, consequently removing 
the gap in sequence readout.  We initially attempted to hydrolyze HNO-treated BSA under 
acidic conditions (10 min at pH 1-2).  Although a peak assigned to the Pro35 a-ion was 
detected, no other peaks with higher m/z values were observed.  Upon boiling HNO-treated 
BSA at pH 7.4 for 30 min, new peaks appeared.  Despite the low intensities observed, these 
results might suggest at least a partial hydrolysis of the cyclic structure; further studies are 
required. 
 We also attempted to exploit the ring opening strategy to distinguish between a 
cyclic sulfenamide and a cyclic sulfinamide.  Compounds with amine functionality 
including N-acetyl-L-lysine methyl ester, aniline, O-methylhydroxylamine and O-
benzylhydroxylamine were incubated with HNO-treated BSA under several conditions.  
However, no change in the spectra was observed in the presence or absence of amines, 
presumably due to lack of reactivity with the cyclic structure.  
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 To learn more about the cyclic modification in HNO-treated BSA, we explored its 
reversibility in the presence of reducing agents.  Following a short (15 min) incubation at 
37 oC in the presence of excess DTT, peaks were detected in the Cys34-Ala78 region, 
indicating significant reduction of cyclic structure (Figure 7-10).  Interestingly, the peak 
that had been assigned to a regular sulfinamide or sulfinic acid was still observed (Figure 
7-10).  This peak disappeared following 26 h incubation with excess DTT.  Moreover, the 
peak intensities increased and more peaks became apparent in the Cys34-Ala78 region 
(Figure 7-10).  It should be noted that the spectrum of unmodified BSA also improved upon 
incubation with DTT, presumable due to the reduction of BSA disulfide linkages.  These 
observations demonstrate that HNO-derived cysteine modifications on BSA can be 
reduced in the presence of excess thiol, and might point to the more readily reducible nature 




Figure 7-10.  Selected region of reflector ISD-MALDI-MS spectrum showing BSA 
incubated with 2 mM AS followed by treatment with DTT at 37 oC.  The spectra correspond 
to (a) initial, (b) 15 min, and (c) 26 h after the addition of DTT. 
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7.4.3 Labeling Studies with BSA 
Labeling approaches are commonly used to investigate protein modifications.53, 54  
We conducted preliminary studies utilizing several labeling agents to explore BSA residues 
involved in the formation of the HNO-derived cyclic structure. 
 Consistent with previous studies,15 blocking cysteine with N-ethylmaleimide 
(NEM) prevented the formation of the cyclic structure.  Moreover, the putative sulfinamide 
or sulfinic acid peak was not observed, supporting our assignment.  Similarly, incubation 
of HNO-treated BSA with NEM did not show any NEM-modified peaks.  These results 
confirm the involvement of cysteine in the generation of the cyclic structure. 
To investigate the potential role of Lys residues, we attempted to employ 3-
sulfosuccinimid-1-yl acetate (Sulfo-NHS-Acetate) (Scheme 7-7).55  However, control 
experiments conducted with the VYPCGA model peptide in the presence of N-acetyl-L-
lysine methyl ester revealed the labeling of Cys with Sulfo-NHS-Acetate.  To avoid 
complications due to the lack of labeling agent specificity, we treated the samples with AS 
prior to the addition of Sulfo-NHS-Acetate.  In the case of a Lys modification by HNO, no 
labeling is expected to occur provided that the cyclic structure remains intact.  Reflector 
ISD-MALDI-MS analysis indicated the presence of Lys labeling upon incubation of HNO-
treated samples with Sulfo-NHS-Acetate.  Although these results might point to the 
inertness of Lys to HNO-induced modification, the possibility of ring opening during 
Sulfo-NHS-Acetate incubation could not be eliminated.  Efforts to probe the potential 
involvement of Arg by utilizing p-hydroxyphenylglyoxal (HPG) (Scheme 7-8)56 were 
unsuccessful due to inefficient labeling with this reagent as determined by reflector ISD-
MALDI-MS and UV-visible spectroscopy. 





Scheme 7-7.  Reaction of 3-sulfosuccinimid-1-yl acetate (Sulfo-NHS-Acetate) with 







Scheme 7-8.  Reaction of p-hydroxyphenylglyoxal (HPG) with amines. Lundblad, R. L. 
(2006) The Evolution from Protein Chemistry to Proteomics:  Basic Science to Clinical 
Application, 2 ed., CRC Press, Boca Raton.  
 
In summary, we have conducted preliminary studies to explore the HNO-derived 
cysteine modification on BSA.  Although our results agree with the formation of a cyclic 
structure as the major product, and likely point to the structure being a cyclic sulfenamide 
located in Cys34-Ala78 region, further investigations employing more efficient and 
specific labeling agents, or BSA mutants as well as more efficient detection methods are 




7.4.4 Experimental Methods 
Reagents.  Mass spectrometry-grade bovine serum albumin (BSA) was obtained 
from Protea Biosciences (Morgantown, WV).  BSA (electrophoresis-grade), N-acetyl-L-
lysine methyl ester, super-DHB (2,5-dihydroxybenzoic acid and 2-hydroxy-5-
methoxybenzoic acid 10:1 v/v), and N-ethylmaleimide (NEM) were of the highest purity 
available and purchased from Sigma (St. Louis, MO).  Dithiothreitol (DTT), 3-
sulfosuccinimid-1-yl acetate (Sulfo-NHS-Acetate), p-hydroxyphenylglyoxal (HPG) were 
obtained from Pierce (Rockford, IL).  Deuterated dimethyl sulfoxide (DMSO-d6) was 
obtained from Cambridge Isotope Labs (Andover, MA).  Aniline, O-
methylhydroxylamine, O-benzylhydroxylamine, hydrogen peroxide (H2O2), and MS-grade 
acetonitrile (ACN) were purchased from Thermo Fisher Scientific (Rockford, IL).  
Synthesis of Angeli’s salt (AS)24 and 15N-labeled AS (15N-AS)57 were carried out as 
described previously.  Synthesis and purification of VYPCGA was carried out as described 
in Chapter 2.  Milli Q water was used for all purifications and experiments. 
Preparation of BSA.  MS-grade BSA was employed for all ISD-MALDI-MS 
experiments.  Electrophoresis-grade BSA was dissolved in 10 mM phosphate buffer with 
50 M DTPA at pH 7.4 to have a final concentration of 0.2 mM.  The samples were then 
pre-incubated with 2 mM DTT for 3 h at room temperature to generate its single free thiol 
and desalted with Zeba spin columns to remove excess DTT.  
Incubation of BSA with HNO-Donor.  Stock solutions of AS were prepared in 
0.01 M NaOH and used within 15 min of preparation.  BSA (MS-grade or electrophoresis 
grade) was dissolved in 10 mM phosphate buffer with 50 M DTPA at pH 7.4 to have a 
final concentration of 0.2 mM.  BSA samples were incubated in the presence or absence of 
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1 or 2 mM AS or 15N-AS at 37 oC for 30 min.  As a control, the samples were also incubated 
with AS byproduct, NO2
- (2 mM).  In some cases, BSA samples were prepared in 0.1 mM 
DTPA at pH 7.4 and incubated with AS (1 mM) at room temperature for 1 h.  
To investigate the oxidation of HNO-treated BSA, the samples were incubated in 
the presence of absence of metal chelator at room temperature for 2 or 18 h.  In some cases, 
samples exposed to HNO followed by NEM treatment (see below) were further incubated 
with 1 mM H2O2 at room temperature for 1 h.  
For reflector ISD-MALDI-MS analyses, the samples were desalted using C4 ziptips 
and spotted on the MALDI plate using dried-droplet method.  Super-DHB was employed 
as the matrix for all reflector ISD-MALDI-MS analyses.  15N-edited NMR analyses were 
carried out in DMSO-d6 as described in Chapter 3. 
Hydrolysis of HNO-Treated BSA.  BSA samples (0.2 mM) were incubated with 
AS (2 mM) as described above.  The samples were then boiled for 30 min in pH 7.4 buffer.  
In some cases, the HNO-treated samples were adjusted to pH 1-2 with TFA and incubated 
at 37 oC for 10 min.  Following incubation, the samples were neutralized with NaOH and 
prepared for ISD-MALDI-MS analysis as described above. 
Reduction of HNO-Treated BSA.  BSA samples (0.2 mM) were incubated with 
AS (2 mM) as described above.  The samples were then treated with 50 mM DTT for 15 
min or 26 h at 37 oC and prepared for ISD-MALDI-MS analysis as described above. 
Incubations of BSA with Labeling Agents.  Stock solutions of NEM (0.1 M), 
Sulfo-NHS-Acetate (0.2 M), and HPG (0.1 M) were prepared in Milli Q water.  
Unmodified or HNO-treated BSA samples were treated with NEM (2 mM, 1 h, room 
temperature), Sulfo-NHS-Acetate (30 mM, 2.5 h, room temperature), or HPG (20 or 100 
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mM, 3-40 h, 37 oC) in 10 mM phosphate buffer with 50 M DTPA at pH 7.4 prior or 
following HNO-treatment.  To avoid pH changes during Sulfo-NHS-Acetate incubation, 
the samples were monitored by pH paper and re-adjusted to pH 7.4 when needed.   
Samples labeled with NEM or Sulfo-NHS-Acetate were desalted using C4 ziptips.  
Samples labeled with HPG were precipitated with acetone to remove the bulk of HPG prior 
to desalting with C4 ziptips. 
Incubations of BSA with Amines.  BSA samples (0.2 mM) were incubated with 
AS (2 mM) as described above.  The samples were then treated with N-acetyl-L-lysine 
methyl ester (2 or 10 mM) in 10 mM phosphate buffer with 50 M DTPA (pH 7.4) at 37 
or 55 oC for 3-14 h.  Incubations with aniline (10 mM), O-methylhydroxylamine (10 mM), 
and O-benzylhydroxylamine (10 mM) were conducted in pH 5 or 7.4 phosphate buffer at 
37, 55 or 65 oC for 3-26 h.  Following incubation, the samples were prepared for ISD-
MALDI-MS analysis as described above.   
Mass Spectrometry Analyses.  All ISD-MALDI-MS analyses were conducted in 
reflectron mode using a Bruker Autoflex III MALDI-TOF/TOF instrument equipped with 
a 355 nm pulsed UV laser.  A total of 60000 shots were accumulated for each ISD-MALDI-
MS spectrum.  The spectra were externally calibrated with unmodified BSA.  All spectra 
were analyzed by using Biotools 3.2 software.  
NMR Analyses.  All 1H-NMR and 15N-edited 1H 1D-NMR analyses were carried 
out on a Bruker Avance 400 MHz FT-NMR spectrometer.  1H NMR and 15N-edited 1H 1D-
NMR analyses were carried out in DMSO-d6 at 303 K.  
15N-edited 1H 1D-NMR spectra 
were acquired using the HSQC pulse sequence for selection.  Chemical shifts are reported 
in parts per million (ppm) relative to residual DMSO (2.49 ppm for 1H). 
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Electrophoresis.  BSA samples (0.2 mM) were incubated with AS (2 mM) as 
described above.  The samples were then incubated in the presence or absence of 50 mM 
DTT for 1 h at room temperature.  Following 1:53 dilution into a mixture of SDS sample 
buffer and pH 7.4 phosphate buffer, the samples were loaded onto gel.  SDS-PAGE using 
10% polyacrylamide was performed employing standard procedures.58  Following 
electrophoresis, the bands were visualized by Ag staining. 
UV-Visible Spectroscopy Analyses.  HPG-labeled BSA samples were diluted into 
82 mM phosphate buffer with 450 M DTPA at pH 9 and analyzed at 340 nm (340 = 1.83 
x 104 M-1 cm-1).59  All the spectrophotometric analyses were conducted on a Hewlett-
Packard 8453 Diode Array Spectrophotometer. 
7.5 Preliminary Studies on the Reactivity of VYPCLA with 
Acyloxy Nitroso Compounds 
 Recent studies have employed acyloxy nitroso compounds as a new class of HNO-
donors.60, 61  These compounds exist as blue, monomeric C-nitroso compounds, which 
release HNO upon hydrolysis.60, 61  We have conducted preliminary studies to investigate 
the reactivity of VYPCLA with the acyloxy nitroso compounds, 1-nitrosocyclohexyl 
trifluoroacetate (NCTFA) and 1-nitrosocyclohexyl pivalate (NCP), in collaboration with 
the King group (Wake Forest University).                        
                             
Figure 7-11. Chemical structures of the acyloxy nitroso compounds 
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7.5.1 Reactivity of VYPCLA with NCTFA and NCP 
 Studies have shown that the hydrolysis rate of acyloxy nitroso compounds to 
produce HNO depends on pH and the structure of the ester portion of the molecule.60, 61  In 
MeOH/pH 7.4 buffer 50:50 (v/v) at room temperature, NCTFA was reported to decompose 
immediately, whereas NCP has a half-life of 37.8 h.61  Although these compounds release 
HNO in the absence of traps, their reactivity with thiols is more complicated due to the 
possibility of a direct reaction between the thiol and acyloxy nitroso precursor.61  
Moreover, the competing pathways (hydrolysis vs. direct reaction) would ultimately 




Scheme 7-9.  Hydrolysis and direct reaction pathways for the reaction of acyloxy nitroso 
compounds with thiols.  Shoman, M. E.; DuMond, J. F.; Isbell, T. S.; Crawford, J. H.; 
Brandon, A.; Honovar, J.; Vitturi, D. A.; White, C. R.; Patel, R. P.; King, S. B. (2011) J. 
Med. Chem. 54, 1059-1070.  
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To gain more insight about the reactivity of acyloxy nitroso compounds with thiols, 
we treated the hexapeptide, VYPCLA, with NCTFA or NCP.  As shown in Chapter 2, high 
sulfinamide yields are obtained upon incubation of VYPCLA (0.1 mM) with various 
concentrations of Angeli’s salt (AS).  Since sulfinamide formation is unique to HNO, 
detection of sulfinamide would point to the intermediacy of HNO via the hydrolysis 
pathway.  Due to solubility issues, these reactivity studies were carried out in MeOH/pH 
7.4 buffer 50:50 (v/v).  Treatment of VYPCLA (0.1 mM) with 0.1, 0.3, 1 and 5 mM 
NCTFA resulted in the detection of 0, 10, 7 and 3% sulfinamide, respectively.  Similarly 
the amount of disulfide formation (ca. 33%) stayed the same from 0.3 to 5 mM.  Assuming 
the MeOH/buffer system has no effect on the reaction, the trend for sulfinamide formation 
seems to be different than that of the other HNO-donors we have investigated.  For 
comparison, as shown in Figure 2-1, the corresponding sulfinamide yields were 73, 81, 86, 
97 and 95% upon employment of AS in pH 7.4 buffer. 
The samples were analyzed with NCP following two different incubation times (2 
h and 6 days).  Upon 2 h incubation with NCP, both the unmodified peptide and the 
disulfide were detected.  Approximately 40, 38, and 48% of the peptide (0.1 mM) was 
modified to the corresponding disulfide in the presence of 0.1, 0.3, and 5 mM NCP.  
Considering the half-life of the compound, the disulfide seems to have originated from the 
direct reaction of NCP with the peptide (rather than from HNO formation). 
Incubation of VYPCLA (0.1 mM) in the presence or absence of NCP (0.1 or 0.3 
mM) for 6 days resulted in the formation of disulfide.  Several other peaks were observed 
upon incubating the peptide with 5 mM NCP for 6 days (not observed upon 2 h incubation).  
Importantly, no sulfinamide was detected following 2 h- or 6 day-incubation of VYPCLA 
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with NCP.  Overall, these results point to the involvement of a non-HNO producing 
pathway under these conditions. 
7.5.2 Experimental Methods 
Reagents.  The acyloxy nitroso compounds, 1-nitrosocyclohexyl trifluoroacetate 
(NCTFA) and 1-nitrosocyclohexyl pivalate (NCP) were a generous gift from Dr. S. Bruce 
King.  MS-grade acetonitrile (ACN) was purchased from Thermo Fisher Scientific 
(Rockford, IL).  Synthesis and purification of VYPCLA was carried out as described in 
Chapters 2 and 3.  Milli Q water was used for all purifications and experiments. 
Incubation of acyloxy nitroso compounds with VYPCLA.  VYPCLA was 
dissolved in MeOH/pH 7.4 phosphate buffer 50:50 (v/v) to have a final concentration of 
0.1 mM.  In all cases, 10 mM phosphate buffer with 50 M DTPA at pH 7.4 was employed.  
Stock solutions of NCTFA (0.5 M) and NCP (0.5 M) were prepared in ACN.  Samples 
were incubated with 0-5 mM NCTFA at room temperature for 2 h.  Incubations of 
VYPCLA (0.1 mM) with 0-5 mM NCP were carried out at room temperature for 2 h or 6 
days.  The samples were then frozen and lyophilized.  Following lyophilization, the 
samples were dissolved in Milli Q water and desalted with C18 PepClean spin columns.  
The samples were then diluted into 70% ACN with 0.1% TFA for immediate ESI-MS 
analysis.   
Mass Spectrometric Analyses.  ESI-MS analysis was carried out on a Thermo 
Finnigan LCQ Deca Ion Trap Mass Spectrometer fitted with an electrospray ionization 
source, operating in the positive ion mode with an accuracy of ca. 0.1 m/z.  In all 
experiments, the samples were introduced to the instrument at a rate of 10 L/min using a 
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syringe pump via a silica capillary line. The heated capillary temperature was 250 °C and 
the spray voltage was 5 kV. 
Analysis of the Data.  For ESI-MS experiments, the quantification was done by 
calculating the percentage of sulfinamide in the total thiol-containing peptide species 
(mainly free thiol, disulfide, and sulfinamide) based on their relative peak intensities in the 
averaged spectrum.  
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Chapter 8 – Post-Study Caffeine 
Administration Enhances Memory 
Consolidation in Humans 
8.1 Introduction 
Studies indicate caffeine is one of the most frequently used psychoactive 
stimulants.1  The effects of caffeine are increased arousal, vigilance, attention, and 
processing speed.  Despite the known cognitive enhancing properties of caffeine,2 its 
effects on long-term memory have not been investigated in detail.  Previous studies have 
involved the administration of caffeine before learning.2  Since caffeine was present at the 
time of the learning or memory task, it was not possible to distinguish the effect of caffeine 
on memory from its other effects such as increased alertness and attention. 
In a post-study design, the subjects, who were randomly assigned to an 
experimental or control group, are tested following a treatment (e.g., caffeine 
administration after the subjects had a chance to study the material).3  Animal studies 
conducted following these procedures have reported enhancement of memory 
consolidation.4-6  In a collaborative project, we assisted the studies of the Yassa group 
(Department of Psychological and Brain Sciences, Johns Hopkins University) in 
investigating the effect of caffeine administered post-training on the consolidation or 
storage of memories for later recall.   This double-blind study involved a memory test and 
an HPLC assay to quantify caffeine and paraxanthine levels in the samples collected from 
participants.    
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8.2 Results and Discussion 
8.2.1 Detection of Caffeine Metabolites by HPLC 
High pressure liquid chromatography (HPLC) is a commonly used technique to 
analyze drug and metabolite concentrations in biological samples.7-9  Moreover, several 
HPLC assays have been reported to quantify caffeine and its major metabolite, 
paraxanthine, (Figure 8-1) in plasma, saliva or urine samples.10-14  Due to its easily 
obtainable and non-invasive nature, we decided to employ saliva as the matrix.  Notably, 
recent literature indicates the consistent and reproducible correlations obtained between 
saliva and plasma paraxanthine/caffeine ratios as well as plasma caffeine              
clearance.11, 13, 15, 16 
To detect caffeine and paraxanthine levels in saliva, we employed a modified 
literature procedure.14  The sample extraction and HPLC conditions were optimized using 
paraxanthine and caffeine standards prepared in Milli Q water or caffeine-free saliva.  
Elimination of a centrifugation step and increasing the organic content of the mobile phase 
from 10 to 12% acetonitrile allowed us to shorten the overall analysis time significantly 
(ca. 60 min versus ca. 40 min for each sample).  As seen in Figure 8-1, the retention times 
of paraxanthine, caffeine, and the internal standard (benzotriazole) were ca. 5.1, 9.5 and 




Figure 8-1.  Representative HPLC trace collected at 280 nm showing distinct peaks for 
paraxanthine (5.1 min), caffeine (9.5 min) and the internal standard, benzotriazole (12.0 
min).  The compounds were extracted from salivary samples following caffeine 
administration.  
 
Using standard caffeine or paraxanthine samples under our conditions, the 
sensitivity limits in Milli Q water and saliva were determined to be ca. 0.03 mg/ml (0.15 
M) and ca. 0.05 mg/ml (ca. 0.26 M), respectively (Figure 8-2 and 8-3).  The extraction 
efficiencies of caffeine, paraxanthine, and benzotriazole from saliva were also found to be 
similar (ca. 72, 63 and 73%, respectively).  Moreover, the assay was highly reproducible 





Figure 8-2.  Linearity and sensitivity of HPLC detection for caffeine, paraxanthine, and 






      
 
Figure 8-3.  Linearity and sensitivity of HPLC detection for caffeine and paraxanthine 
standards dissolved in caffeine-free saliva.  The peak areas were normalized with respect 





8.2.2 Memory Tests and Analyses of Caffeine Metabolites from 
Subjects 
Memory consolidation is a neurological process involving the transfer of 
information from short-term memory to long-term memory.17, 18  To investigate the effect 
of caffeine on memory consolidation, a randomized, double-blind, placebo-controlled trial 
was conducted in caffeine-naive participants.  In these investigations, the participants 
incidentally studied images of objects, then received either 200 mg caffeine or placebo.  
Twenty-four hours after the study session, the participants were subjected to a memory 
test, in which they were shown some items they saw the previous day (targets), some new 
items (foils), and some items that were similar, but not identical, to the ones they saw before 
(lures) (Figure 8-4).  The participants were asked to identify these items as “old”, “new”, 
or “similar”.  Salivary samples were also collected at baseline and 1 h, 3 h and 24 h after 
the administration of caffeine or placebo to quantify caffeine metabolites (Figure 8-4).  
These studies have shown that the participants who received caffeine were more likely to 





Figure 8-4.  Outline of study design. 
 
The caffeine absorption and metabolism of participants through the twenty-four 
hour time period were determined by HPLC analysis of the collected salivary samples.  As 
shown in Figure 8-5, we observed a significant increase in the sum of caffeine and 
paraxanthine levels after 1 and 3 h of caffeine administration, followed by a return to the 
baseline level after 24 h.  These observations are consistent with the caffeine metabolism 
in humans.19  As expected, the sum of caffeine and paraxanthine levels remained 




Figure 8-5.  Group averages of the sum of caffeine and paraxanthine concentrations 
(g/ml) detected by HPLC analysis.  Both the caffeine and placebo group had negligible 
amounts of caffeine and paraxanthine in saliva at baseline.  The caffeine group had a 
significant increase in caffeine and paraxanthine concentrations at 1 h and 3 h, then 
declined to baseline at 24 hours (SEM ± 1).  The placebo group had no such increase in 
caffeine or paraxanthine. 
 
Since caffeine might also affect retrieval (the process of obtaining memory 
information from wherever it has been stored)20, a delayed manipulation experiment, in 
which caffeine was administered 1 h before the memory test (24 h after the initial study 
session) was conducted.  No significant improvement in memory was observed compared 
with placebo, indicating that caffeine does not affect retrieval.  To follow the sum of 
caffeine and paraxanthine levels, we tested the salivary samples collected prior to the initial 
study session and at the time of the memory test.  Similar to the above results, the increase 
in caffeine and paraxanthine levels were observed only in participants who received 
caffeine. 
The effect of different caffeine doses was also explored by administration of 100, 
200 and 300 mg of caffeine.  In all cases, HPLC analysis of the salivary samples obtained 
at baseline, 1 h and 24 h after caffeine administration was consistent with the administered 
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dose of caffeine.  Participants who received 200 or 300 mg caffeine had similar 
performances on the memory test.  This was significantly higher compared to participants 
who received 100 mg caffeine or placebo.  These results suggest that a dose of at least 200 
mg is required to observe the enhancing effect of caffeine on consolidation of memory.  
8.3 Conclusions 
 A post-study design was employed to examine the effects of caffeine consumption 
on human long-term memory.  Moreover, the levels of caffeine and its primary metabolite, 
paraxanthine, in salivary samples were quantified at various time intervals by using an 
HPLC assay.  Overall, these studies demonstrate that caffeine enhances consolidation of 
long-term memory in humans.  Further investigations are required to understand the 
mechanisms by which caffeine can potentiate memory. 
8.4 Experimental Methods 
Reagents.  Caffeine, paraxanthine and benzotriazole were of the highest purity 
available and purchased from Sigma (St. Louis, MO).  HPLC grade acetonitrile (ACN) was 
obtained from Thermo Fisher Scientific (Rockford, IL).  Milli Q water was used for all 
purifications and experiments. 
Subjects.  160 healthy, caffeine-naïve subjects between the ages of 18 and 30 
participated in the study.  Participants were excluded because of compromised saliva 
samples (5 participants), caffeine content in baseline salivary samples (18 participants) or 
in 1 h sample (1 participant) or in 24 h sample (9 participants), at chance discrimination 




Saliva Collection.  Subjects provided 1 ml samples of saliva following a 
standardized saliva collection protocol (Salimetrics kit) in 2 ml cryovial test tubes, which 
were refrigerated at -80 oC within 24 h of collection.   
Determination of Caffeine and Paraxanthine Levels in Saliva.  Saliva samples 
collected from the subjects at various time intervals were analyzed based on a modified 
literature procedure.14  Briefly, benzotriazole (50 µL of 5.0 µg/mL solution) was added to 
100 µL of each saliva sample as an internal standard.  The samples were then extracted 
with 4 mL ethyl acetate.  The organic layer which contained caffeine, paraxanthine, and 
benzotriazole was transferred to a separate test tube and the solvent was evaporated with 
condensed air at 55 oC.  The dried samples were stored at -20 oC until HPLC analysis.  On 
the day of the analysis, the samples were re-dissolved in 200 µL Milli Q water, filtered (0.2 
µm pore size), and analyzed by HPLC.  All the analyses were performed on an Apollo C18 
reverse-phase column connected to an Agilent 1200 HPLC system equipped with a 
quaternary pump, diode array detector and a standard autosampler.  The mobile phase 
consisted of 12% acetonitrile with 0.1% trifluoroacetic acid at room temperature and the 
compounds were followed at 280 nm for 15 minutes.  The amounts of caffeine and 
paraxanthine were normalized with respect to the internal standard and quantified based on 
calibration curves constructed from standards that were prepared in Milli Q water and 
exposed to the same sample preparation procedures. 
Memory Test and Statistical Analysis.  All memory tests and statistical analyses 
were performed by Yassa group.  Briefly, a hippocampal memory-dependent task 
particularly taxing pattern separation was employed.21  Group comparisons were conducted 
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